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(A) GENERAL 
The kidney is a vital organ, which plays an essential role in health, diseases and 
overall development and growth. The main function of the kidney is to maintain total 
body fluid volume, its composition and thus plays a major role in the maintenance and 
regulation of acid-base balance of the body fluids including the blood. This is 
accomplished collectively by the presence of several millions of fimctional units of the 
kidney known as "nephron". A nephron consists of a glomerulus with an extended 
tubular structure. The renal functions are mainly characterized by the reabsorption 
abilities of the tubules which run through several anatomically distinct parts of the 
kidney. 
The structure of the mammahan kidney apparently looks very homogenous, 
however, it can be viewed as a composite of several organs/segments, geometrically, 
functionally and metabolically [1]. Thus each nephron consists of a group of 
organs/segments arranged in series coursing through four concentric tissue planes 
namely, the cortex, outer and inner zones of the outer medulla and the inner medulla 
[1]. Each concentric tissue plane from cortex to inner medulla also possesses 
individual "organ" characteristics with respect to their ionic contents and 
characteristics of metabolism (metabolic rates) among the above tissue zones [1]. The 
renal tubular structure documented to be the site of whole kidney fimctions can be 
characterized by transport processes which occur in the mammalian kidney. It has 
been demonstrated that these transport processes, mostly of ions and solutes, are 
somehow driven by metabolic energy yielding reactions [2]. The transport of sodium 
ions (Na^ is considered to be the major work function in mammalian kidney, as in 
the absence of any Na"" transport, the transport of other solutes such as amino acids 
and hexoses approaches zero [3,4,5]. Fromter et al. [6] suggested that one third of 
the net transepithelial sodium flux is transported actively. Atleast 80% of this active 
transport depends on adenosine triphosphate (ATP) [7] indicating a linkage between 
transport processes and energy producing metabolic reactions [8,9,10,11], The active 
transport performed by the kidney has been shown to be associated with oxygen 
consumption rate which is usually involved in producing energy for such transport 
systems. Earlier studies demonstrated a linear relationship between sodium transport 
and oxygen consumption [12,13], however, a direct relationship with the energy 
production or utilization could not be confirmed. 
Fatty acids, glucose and their metabolites e.g. intermediates of citric acid cycle, 
amino acids, lactate etc. are known to contribute to the energy supply of the kidney 
in various mammals including man [8]. The rate of metabolism of the above 
substrates by one or the other pathways seems to be dependent on the availability of 
oxygen in any particular zone of the kidney [8,14-18]. There appears to be a reverse 
cortico-medullary gradient for tissue oxygen tension (PO2) i.e. PO2 in inner medulla is 
far lower then cortical tissue [19-22]. Available evidences so far indicate that aerobic 
metabolism is more prevalent in renal cortex while anaerobic metabolism in renal 
outer and inner medulla [14]. 
Nephron which consists of various subsegments shows distinct structural and 
functional differences. Thus nephron heterogeneity also adds to the variation in the 
function of kidney as a whole. Both inter- and intra-nephronal heterogeneity exist in 
the mammalian kidney that depends on the origin and location of the nephrons in 
cortical region of kidney [23,24]. The nephrons which originate from the glomeruli 
located in the superficial cortex are known as "superficial nephrons" while the 
nephrons originating from the deep cortical region are known as "deep" or 
"juxtamedullary nephrons". These populations of nephrons have been found to be 
distinct structurally and fiinctionally [23]. 
Inter- and intra-renal heterogeneity of proximal tubules (PT) 
Structural and/or functional differences between proximal convoluted tubules 
(PCT) of superficial cortex and juxtamedullary cortex represent inter-nephron 
heterogeneity, whereas, differences between early segment and late segment of 
proximal tubule of a single nephron represent intra-nephron or axial heterogeneity. 
The nephron classification system fundamentally is based on the cortical location of 
their glomeruli and/or on the length of their loops of Henle. According to the recent 
view, nephrons are classified into three groups: Superficial cortical nephrons wliich 
have glomeruli located approximately 0.5 to 1mm below the capsular surface, 
Midcortical nephrons with glomeruli situated in the midcortex deep to the superficial 
nephrons but above the juxtamedullary nephrons, and Juxtamedullary nephrons with 
glomeruli located immediately above the corticomedullary jxmction. Generally, the 
most superficial nephrons have "short loops" (or even cortical loops) and deep 
nephrons have long loops. Besides the differences in glomerular diameter, proximal 
tubular length, filtration rate, epithelial permeability and transport characteristics, 
transepithelial voltage differences and distribution of various enzyme activities are 
other factors that contribute to distinguish different nephron populations [25,26]. In 
inter-nephron heterogeneity, proximal convoluted tubules of superficial nephrons 
always touch the surface of the kidney, while convolutions fi-om midcortical nephrons 
do so infi-equently [27] and then tend to run perpendicular to the cortical surface, 
whereas proximal convolutions fi'om juxtameduUary nephron run perpendicular to 
and intertwine with medullary rays. In most mammals juxtameduUary nephrons have 
longer proximal tubules (pars recta included) than superficial nephrons [28-31]. 
Juxtamedullary-proximal convolutions are approximately 25% longer and have a 
significantly greater diameter than superficial convolutions [27]. 
In intra-nephron or axial heterogeneity, the proximal tubules have been divided 
into three distinct morphological subsegments namely. Si, Sa and S3. The early PCT 
both in superficial and juxtameduUary nephrons is defined as Si-segment and can be 
identified by its attachment with glomeruli on one side. The cells are tall (10-12 i^ m) 
having a long (~3 \xm) brush border and extensive interdigitations between lateral cell 
and margin of adjacent cells [27,32]. S2 is defined as the late superficial proximal 
convoluted tubule, early superficial proximal straight tubule and late juxtameduUary 
proximal convoluted tubule. Thus it includes rest of the convolutions and entire pars 
recta (straight portion) in cortical portion of the kidney. Cells of 82 segments are 
shorter, with shorter brush border and less extensive lateral and basal infoldings than 
Si ceUs [27,32]. In contrast, S3 is located principaUy in the outer stripe of outer 
meduUa and terminal superficial proximal straight tubule and entire juxtameduUary 
proximal straight tubule. S3 is identified by its meduUary location and by its 
connection with thin Umbs on distal part. Superficial pars recta is long and contains 
S2 and S3 ceU types whereas juxtameduUary-pars recta is short and made of 
predominantly S3 subsegments [27]. All Ss-subsegments (pars recta), as they descend 
from cortex into the outer stripe of the outer medulla, change from the S2 to S3 cell 
type. Thus the outer stripe of the outer medulla contains proximal tubular cells but 
only the S3 type [27]. S3 cells are cuboidal and have the longest brush border, fewest 
mitochondria, least basolateral invaginations and least developed endocytic apparatus 
of all three proximal tubular cell types [33]. Peroxisomes are most numerous in S3 
cells [33].' 
Besides morphologic differences, the functional inter- and intra-nephronal 
differences have also been observed in proximal tubule. Functional differences mostly 
coincide with the morphological subdivisions. In early PCT (S\- segment) oxidative 
metabolism, Na '^-K^ATPase activity and active transport are relatively high, allowing 
very efficient Na-coupled net reabsorption of glucose, amino acids, phosphate and 
net secretion of hydrogen ions [23]. In S2 cells, glucose. Pi and H^ trarisport 
capacities are still noticeable and progressively decrease along proximal convolution 
[23]. Finally, in S3, Na^-K '^ATPase activity, NSL' transport is found to be relatively 
low however the transport of organic acids and bases is main concern of the S3 
segments. Proximal heterogeneity also exists in regard to hormonal action and some 
other adaptive changes [34]. In the proximal tubule, the apical cell border is well 
developed and closely packed microvilli form the brush border. The luminal 
membrane contains a number of specific carrier systems for the reabsorption or 
transport of ions and solutes [35]. It is well established that in proximal tubule, brush 
border membrane is the major site by which most of the solutes are reabsorbed [36-
39]. It is also the site for the regulation of the reabsorptive properties by the adaptive 
changes and by various stimuli [36]. 
Acute Renal Failure (ARF) 
The term "Acute renal failure" denotes a dramatic clinical situation in which both 
the kidneys stop their function within a short period of time or immediately 
depending on the severity of ARF. Since, the major function of the kidney is to 
maintain the composition of extracellular body fluids by filtration and reabsorption 
processes, the loss of renal function is reflected by oligonuria and a steady rise in the 
concentration of urea and creatinine in plasma [40,41]. The major causes of ARF are 
either ischemia or toxic insult to the kidneys [42-51]. 
Acute renal failure is a process rather than a state. It begins with cellular damage 
initiated by primary toxic insult or ischemia and it continues until renal fijnction and 
structure have essentially recovered due to reperfusion of blood or by the 
administration of various drugs and hormones [41,52-74]. Although, the time course 
of injury and recovery overlap and are variable due to degree of damage, 
nevertheless, ARF can be grossly divided into three phases; pathogenic phase, 
manifestation phase and recovery phase. In the first phase, a progressive 
disintegration and necrosis especially of tubular epithelial cells has been observed, 
leading to the functional loss of the kidney which is manifested by the reduction of 
inulin clearance [40]. In the second phase, long lasting effects are observed that 
severely affect the clearance of both creatinine and inulin and which can continue for 
several days after recovery begins, depending on the degree of renal damage. Other 
additional adverse effects are not observed and the recovery processes are not being 
initiated in this phase. In the recovery phase there is an increase in concentrating 
ability of the kidney with eventual normalization of kidney function. 
A variety of experimental models have been used to study ARF. In experimental 
animals, toxic ARF can be induced by various agents such as heavy metals [42,43], 
chemicals [75-82] and drugs [44,83]. Generally ARF caused by drugs and chemicals 
is much more severe and irreversible and the recovery sometimes is not possible [40]. 
The pathophysiologic mechanism of ARF has been investigated extensively in the last 
few decades [52]. Although a number of structural and functional changes involved in 
ARF were observed, but due to the varying experimental conditions in which they 
were observed, no single possible pathogenic mechanism to explain ARF could be 
concluded [52]. Four major possible causes of ARF have been generalized which 
include renal vasoconstriction, glomerular permeability, tubular obstruction and 
tubular leakage [52]. Several preventive measures have also been utilized [41,52-74] 
but a definite answer for the pathogenesis and its control however remains the topic 
of future studies. 
The physiological role of the kidney in the production of urine involves the 
selective reabsorption and secretion of solutes and fluids [36,37,84,85]. Tubular 
reabsorption of sodium, the major work function of the kidney, is dependent on 
active ion transport, an energy dependent process which in the kidney is primarily 
dependent on ATP supplied by oxidative metabolism [7-11]. In fact, most of the 
metabolic work of the renal cell is directed towards the production of ATP for the 
support of active reabsorption of ions and solutes [12,13]. A close relationship has 
been observed between ion transport and cell metabolism in extension with the O2 
consumption in the kidney [12,13]. The oxygen tension or consumption in the kidney 
has been demonstrated to be different in the nephron subsegments distributed in 
metabolically different kidney tissues such as the cortex and meduUa 
[1,8,11,14,17,18]. ARF doe to toxic insult or ischemia, results in the depressed 
metabolic activity because of limited O2 supply through the blood, curtailing energy 
production and leading to the loss of active reabsorption and secretion processes in 
the kidney [49-51,76-78,86]. 
Pathophysiology of ARF 
Toxic agents are known to cause acute or chronic renal failure leading to the 
partial or total loss of normal excretory functions of the kidney. Acute renal failure is 
accompanied by a simultaneous but steady rise in plasma creatinine and urea 
concentrations [40,41]. Classical concepts regarding the cause of the loss of renal 
functions in ARF include tubular leakage across the damaged epithelium, tubular 
obstruction by cast formation or interstitial compression, a decrease in renal blood 
flow (RBF) and glomerular membrane permeability [52]. However, due to lack of 
support for a satisfactory explanation for the loss of renal function following toxic 
insult, some of the above factors were considered as not the only basis for initiating 
the damage caused by toxic insult or ischemia. Raised intratubular pressure indicative 
of tubular obstruction was not consistently present [87]. A decrease in RBF was 
frequently observed, but was often lacking [88]. A reduction in glomerular 
permeability was able to explain only a depression in filtration rate but not the 
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decrease in tubular function [89-91]. Thus the extensive research of the past 40 years 
using morphology, clearance and micropuncture techniques were unable to provide a 
universal view regarding the mechanism for the pathogenesis of ARF. The other 
reason for not reaching a consensus could be due to the fact that most of the 
evidences are based on structural alterations rather than on functional ones. Some 
recent experimental evidence shows that ARF induced by ischemia or administration 
of toxic agents is characterized by a progression of well-defined events [40,92-94]. 
Initially, the epithelial cells lining the proximal tubule (the principal site of damage 
along the nephron) exhibit varying degree of sublethal cell injury that can ultimately 
culminate in cellular necrosis. 
(B) AMINOGLYCOSroE NEPHROTOXICITY 
Renal dysfunction or disease may resuh from the clinical use of antibacterial 
agents. The clinical and morphological expression of antibiotic nephrotoxicity 
represents a spectrum of alterations ranging from acute renal failure and 
tubulointerstitial nephrotoxicity to selected renal tubular disorders. 
Molecular and pharmacologic aspects of Aminoglycoside Nephrotoxicity 
Aminoglycosides are highly polar cations (average pKa 8.0 or greater) composed 
of various sugar molecules in glycosidic linkage with amino-group containing side 
chains. Aminoglycosides act by inhibiting the synthesis of bacterial proteins via 
interference with the activity of ribosomes. Aminoglycosides have low lipid solubility 
and a low capacity for penetrating membranes; all aminoglycosides are poorly 
absorbed from gut, when given intramuscularly or intravenously, aminoglycosides are 
rapidly distributed tiiroughout the extracellular fluid. Because of their polar nature 
(Fig. 1), these are largely excluded from most cells. 
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Fig. 1; Structure of gentamicin 
The potential for aminoglycoside nephrotoxicity seems to depend on the number 
of ionizable amino groups (NH2O contained on their molecule and on the derived 
cationicity. The cationic charge of the aminoglycoside is correlated with the degree of 
aminoglycoside and membrane interaction and interference with mitochondrial 
function [95]. Although a good correlation exists between the cationicity and specific 
(renal, oto or neurotoxicities) or whole animal toxicity [96,97] but aminoglycosides 
with similar cationic charges may exhibit different clinical or experimental toxicities 
[98]. Soberon et al. [99] showed that aminoglycosides containing equal number of 
aminogroups (five NH2^ groups) exhibit different nephrotoxicities. Therefore factors 
other than the molecular cationic charge are of importance. These may include charge 
orientation or position and an inherent propensity of the aminoglycoside molecular 
structure for causing toxic injury to intracellular organelles [99,100]. 
10 
Renal transport of aminoglycosides 
Aminoglycosides do not undergo metabolism in the body and are rapidly excreted 
by the kidney in experimental animals and/or in humans. The excretion being faster in 
rats than humans. The kidney is the major route by which aminoglycosides are 
eliminated from the body [101,102]. Binding of aminoglycosides to plasma protein 
plays only a minor role in restricting ultrafiUration, however, the degree of protein 
binding may give conflicting results regarding net tubular transport of aminoglycoside 
[103,104], Following a single injection, 60 to 80% of the drug is recovered in the 
urine unchanged over the subsequent 24 h period [105]. Once in the tubular lumen, 
aminoglycosides undergo cellular uptake by the proximal convoluted tubule and pars 
recta. Uptake of GM has been demonstrated by means of microinjection and 
micropuncture techniques [104,106-108], autoradiograph experiments [109-111], 
isolated renal cortical slices [104,112,113], tubule suspensions [111,114] and in 
profosed kidneys [115] in either rats or rabbits. Overwhelming evidence supports the 
net reabsorption of GM along the proximal tubule. Due to small but substantial 
aminoglycoside uptake, the concentration of aminoglycosides in renal cortex was 
several folds higher than plasma in humans [116-118] and in experimental animals 
[118-121]. However, the accumulation in renal medulla and papilla is considerably 
less. In one study, urinary fractional excretion of GM exceeded delivery of the drug 
to the superficial distal tubule, suggesting secretion beyond this segment of the 
nephron [106]. Sheth et al. [107] suggests this heterogeneity for GM transport by 
demonstrating secretion of GM in the deep nephrons. In the superficial nephj"ons, 
reabsorption is the predominant direction of net transport, whereas, net secretion 
predominates in the juxtamedullary nephron [107]. Although the overall transport 
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favours net luminal reabsoiption, there is possibility that tubular secretion may be 
important under certain circumstances. Pastoriza-Munoz et al. [108] showed that in 
Sprague-Dawley rats, netilmicin undergoes both net secretion along the early 
proximal convoluted tubule and net reabsorption along the pars recta. However GM 
has higher absorptive flux and lower secretory flux along proximal tubule. I'hese 
differences in transport explain the higher accumulation of GM in renal cortex. The 
steps leading to cellular uptake and accumulation of GM in the proximal tubule have 
been elucidated by means of autoradiographic studies [109-111]. They are 
schematically depicted in Fig. 2 and can be summarized as follows: The first step is 
binding of the cationic aminoglycoside to anionic sites on the brush border 
membranes of the proximal tubular cells [104,110,122,123]. The binding of 
aminoglycoside to the BBM is mediated in part by electrostatic interaction with 
acidic phospholipid, predominantly to phosphotidylinositol (PI) [123-125]. However, 
recently it has been suggested that uptake may also involve the protein receptor gp"° 
[126], also called megalin [127]. Megalin is a member of the low density lipoprotein 
(LDL) receptor super family that includes the LDL receptor, the very low-density 
lipoprotein receptor etc. The membrane bound aminoglycosides are then engulfed by 
absorptive endocytosis (pinocytosis) into small vesicles that fuse with lysosomes. 
These transfer the aminoglycosides to secondary lysosomes, where storage occurs. 
The uptake and intracellular accumulation of aminoglycosides in lysosomes has been 
demonstrated by Tulkens et al. [128-130] in cultured rat fibroblasts and renal tubular 
cells. Uptake via the basolateral membrane of the proximal tubular cells, although, 
generally considered to be minor route of aminoglycoside cellular penetration, may 
contribute to the overall renal cortical accumulation of these drugs and to their 
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Fig. 2 : Possible pathways of aminoglycoside transport and mechanisms of aminoglycoside 
cellular injury. After binding on brushborder, aminoglycosides (AG) are taken up 
in pinocytotic vesicles (PV), which separate from the luminal membraine. These 
vesicles fijse wdth primary lysosomes (PL), and AG are subsequently transferred 
to secondary lysosomes (SL). The AG may interfere with lysosomal digestion of 
phospholipids and proteins, inducing formation of myeloid bodies (MB). Later 
AG labilize lysosomes that may release their lytic content into cytosol or may 
discharge lysosomal residues outside of the cell via exocytosis. In addition to 
endocytosis, the existence of other uptake mechanisms at the luminal and 
contraluminal membrane {dashed arrows) may contribute to direct alterations in 
structure and function of cellular organelles, such as mitochondria (M). In the 
upper right comer, both a schema of the binding of cationic AG with anionic 
receptors (phosphatidylinositol, PI) of the brush border membrane and 
subsequent internalization of the AG-membrane receptor complex is shown. On 
the lower right corner, the assumed effect of gentamicin in blocking 
phospho lipase C and in altering the turnover of the membrane-bound receptor is 
also shown. 
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toxicity [106-108,113,118]. Once in the renal tubular cell, it appears that 
aminoglycosides are in a tightly bound and non-exchangeable pool, which is the cause 
for their long half-life in the renal cortex [117,120,131]. Since these compounds do 
not undergo metabolism in the tubular cells, their elimination is accompanied by 
exocytosis into the tubular lumen. 
Morphologic patterns of Aminoglycoside Nephrotoxicity 
Aminoglycosides produce acute tubular cell necrosis, largely of the proximal 
convoluted tubules and pars recta (Si and S2 segments) [117,132-135]. Although the 
morphologic changes have been extensively studied in animals, findings in human 
kidney show the same general pattern. An increase in the number and size of 
secondary lysosomes: cytosegrosomes or phagosomes constitute the earliest 
morphologic evidence of toxicity [132]. In the rat, these changes are seen 48 h after 
GM administration and may extend in late toxicity to the distal tubule [132]. 
However, they have been shown in humans just 4 h after the GM administration with 
normal renal function [136]. These cytosegrosomes are primary lysosomes that have 
fiised with endocytic or autophagic vacuoles. Many of these secondary lysosomes 
contain myeloid bodies [136]. Myeloid bodies probably represent autophagic 
vacuoles that result from sequestration of membrane and organelle fragments 
damaged during cellular handling of potential toxins including aminoglycosides 
undergoing lysosomal processing and digestion [137]. However, the lysosomal 
alterations, including the formation of myeloid bodies, do not necessarily imply that 
the person or animal under study has been exposed to these compounds. 
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Furthermore, they are not specific, since many other toxins are capable of inducing 
their formation [137]. 
Following the initial lysosomal morphologic alterations of the proximal tubular 
cells, a decrease in the number and height of the microvilli of brush border membrane, 
cytoplasmic vacuolation, and dilation of the ER appear [134]. Depending on the 
intensity of the lesions, various cellular debris begin to appear in the tubular lumen. 
Simuhaneously mitochondrial swelling also becomes prominent and as cellular injury 
evolves, initially patchy and later extensive tubular cell necrosis with tubular 
obstruction becomes apparent. 
Since vascular endothelial cells contain negatively charged binding sites and are 
capable of endocytosis, it is conceivable that glomerular cells may incorporate 
aminoglycosides [105]. Scanning electron microscope shows that structural 
alterations of the glomerular endothelial cells may play a causative role in the 
development of renal dysfunction in ischemia and nephrotoxic acute renal failure 
(ARF) in humans and animals [90,138,139], Other studies have revealed both 
decrease in the size and area of endothelial fenestrae and swelling of endothelial cells 
following experimental aminoglycoside nephrotoxicity [140-142]. However, more 
recent quantitative investigations cast some doubt on these earlier findings [143]. 
Thus presumptive role of the glomerular endothelium in the early pathogenesis of 
GM-induced acute renal failure remains unsolved. 
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Cellular Mechanisms of Aminoglycoside Toxicity 
The final pathways by which aminoglycosides cause tubular cell necrosis remains 
to be established, but major cellular targets for their action are the plasma 
membranes, lysosomes and mitochondria. GM exerts a direct inhibitory effect on 
renal cortical mitochondrial oxidative phosphorylation [95,144]. Mitochondrial 
dysfunction also occurs during GM nephrotoxicity in vivo before functional or 
morphologic evidence of severe renal damage appears [145]. GM is also a 
competitive inhibitor of mitochondrial Ca^ uptake [146]. This indicates the potential 
for aminoglycosides to alter membrane function and thereby, to contribute to toxic 
cell injury through its interaction with divalent cations. Renal cortex ion composition 
in dogs treated with GM showed an early cellular depletion of potassium, magnesium 
and phosphorous [147] which probably explain the potassium and magnesium 
wasting seen in GM-treated animals [148]. Decrease in sodium and calcium content 
and decrease in activity of Na^-K'^ ATPase may occur in later phase of GM toxicity 
[147]. 
Changes in both the integrity and function of cellular structures have been 
described as associated with aminoglycoside treatment and they undoubtedly are key 
factors in the pathophysiologic events leading to cellular toxicity. It is possible that 
the tubular cells die because of the simultaneous occurrence of multiple changes. In 
addition to luminal binding and transport of GM, an increase in total phospholipid 
content and selected phosphoinositides, particularly phosphatidylinositol (PI) have 
been reported in rat renal cortex after GM treatment [123,124,149]. Similar results 
were obtained in cultured rat fibroblasts and in rat and human renal tubular cells 
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[128-130,136,149]. Subcellular fractionation studies of rat renal cortex have shown 
that the increase in phosphatidylinositol (PI) induced by GM involved multiple cell 
membranes, including mitochondria, brush border, endoplasmic reticulum and 
lysosomes in proximal tubular cells [150]. The mechanism of the increase in PI levels 
is not entirely elucidated, but it is attributed to aminoglycoside-induced inhibition of 
phospholipases A and C [151,152]. Hostetler and Hall [152] demonstrated 
aminoglycoside inhibition of lysosomal phospholipases A and C isolated from the rat 
kidney cortex. Comparative inhibition of these phospholipases by other 
aminoglycosides approximated their known toxicities [151,153]. 
Aminoglycosides are typical "lysosomotropic agents" [154]; that is agents taken 
up in lysosome either by pinocytosis or by any other mechanism. These agents may 
stay within the lysosomes and may act either by altering the lysosomal content or the 
lysosomal ability to degrade engulfed substances, thus inducing lysosomal storage 
disorders. They may also aher the properties of the lysosomal membrane, thus 
inducing either an increase or decrease in its permeability towards exogenous 
substances or even to lysosomal enzymes, which may cause cell injury by escaping 
the organelle. GM inhibits lysosomal enzymes sphingomylinase and phospholipases A 
and C, which are responsible for the early steps in the catabolism of phospholipids 
and thus lead to accumulation of all major phosphoinositides [128-130,149,151-153] 
leading to the formation of myeloid bodies. Thus the GM toxicity has evolved as a 
lysosomal phospholipidosis or lysosomal overloading phenomena, which is an early 
manifestation of aminoglycoside-induced cellular damage [124,128-130]. As per 
Feldman et al. [124] (Fig. 2), it appears that within the lysosomes, aminoglycosides 
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might interfere with catabolism of the membrane receptor by directly inhibiting 
phospholipase C, by modifying substrate-enzyme affinity or by increasing the 
intralysosomal pH above the range of the enzyme. The relation of the 
aminoglycoside-induced renal phospholipidosis to cellular dysfunction and necrosis 
remains unsolved. It is possible that rupture of the lipid-overloaded lysosomes, with 
release of potent lysosomal hydrolases into the cytosol, or depletion of critical 
substrates due to suppressed lysosomal catabolism may be responsible for ultimate 
cellular damage and death [124]. Other mechanisms of cellular injury have also been 
suggested since membrane phospholipids are involved in regulating membrane 
permeability to calcium [155,156]. 
As hypothesized earlier that phosphoinositides function as luminal membrane 
receptors for aminoglycosides in an animal model that was characterized by 
resistance to GM nephrotoxicity [157]. Teixeira et al. [158] demonstrated that the 
Sprague-Dawley rats with imtreated streptozotocin-induced diabetes mellitus are 
functionally and morphologically protected from GM-induced acute renal failure 
[159]. This resistance was associated with a decreased accumulation of GM by the 
renal cortex [158] and it was present as early as five days after the induction of 
experimental diabetes [160]. Other investigators have also recently confirmed that the 
untreated diabetic rats injected with GM had renal cortical PI levels significantly 
lower than those of equally injected nondiabetic animals [157]. Moreover, the renal 
cortex PI content in diabetic animals was lowered even before GM administration 
[157] which was due to abnormalities of inositol metabolism [161]. Non-diabetic 
glycosuric animals and the insulin-treated diabetic rats [162] exhibited normal PI 
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renal cortical levels and so were unprotected from the GM-induced nephrotoxic 
effects. Thus the lowered content of phosphoinositides, particularly PI, limits the 
apical membrane binding and subsequent intracellular transport of GM. This results in 
lower renal cortical accumulation and prevention of aminoglycosides-induced 
nephrotoxicity. The intriguing observation that recovery from GM-induced 
nephrotoxicity occurs with continued drug administration remains unexplained 
[163,164], but it may be related to the resistance displayed by newly regenerated 
tubular cells to GM toxic effects. 
(C) PATHOPHYSIOLOGY OF URANYL NITRATE-INDUCED ARF 
Uranyl Nitrate (UN)-induced acute renal failure (ARF) best approximates the 
basic criterion for an acceptable experimental nephrotoxic model [165], These criteria 
are: ease of induction of acute renal failure; reproducible alterations in renal function 
which were predictable at any given time point in the course of acute renal failure; 
and parallels in the pathophysiologic manifestations of the model of experimental 
acute renal failure with those observed in clinical acute renal failure [165-169]. 
In common with other ARF models, the most frequent pathological lesion 
observed in the kidney as a result of UN administration is acute necrosis affecting the 
S3 segment of the proximal tubule. Functional changes reported following single 
acute nephrotoxic doses of UN include a decrease in the glomerular filtration rate 
(GFR) [170] and renal blood flow (RBF) [167] and increase in urine osmolality 
[169], electrolyte excretion [171] together with diuresis [172]. UN also causes an 
increased level of plasma renin activity [173] elevated blood urea nitrogen (BUN) 
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and increased plasma creatinine concentration [174]. A combination of 
pathophysiological mechanisms, including haemodynamic alterations, alteration in 
glomerular capillary permeability, tubular obstruction and tubular backpressure are 
believed to contribute to the pathogenesis of ARF [167,175]. However despite 
extensive study by conventional bioanalytical procedures, the mechanism of UN-
induced renal dysfunction and biochemical sequelae of UN exposure remains poorly 
understood. 
The administration of UN to rats causes morphologic changes detectable as early 
as Ih following injection that become progressively more severe during the next 5 
days. Initially, the entire epithelium of cortical proximal tubules shows subtle 
changes. Subsequently, severe lesions and necrosis occurs in a predictable pattern 
along the tubule in the following order: P3C (Cortical P3)>P2C> P3M (Medullary P3) 
[176], The renal corpuscle and portions of the nephron distal to the proximal tubule 
develops abnormalities by the end of day 5 after treatment. 
The systemic distribution of uranium after its administration may accovmt for 
several of its characteristic effects on renal structure and function. After injection 
uranium complexes with bicarbonate in the blood [177] this complex filters fi-eely at 
the glomerulus, and as much as 50 percent of the dosage given is excreted in urine in 
the first 24 hours [178]. Uranium deposited in bone has a half-life of 50 to 60 days 
[179] and is held in reversible equilibrium with that in blood [177]. Once filtered, 
uranyl ligands become progressively more concentrated and interact with the luminal 
plasma membrane of lateral segments of the proximal tubule, resulting in the 
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inhibition of active transport of sodium, chloride, amino acids and hexoses [177]. The 
general morphologic changes associated with sublethal cell injury induced by uranium 
compounds are not well known inspite of the fact that uranium-induced ARF is the 
major experimental model. However, it has been shown that the earliest site to 
become necrotic is the portion of the proximal tubule at the corticomedullary 
junction, and injury progresses proximally and distally from this site [180]. Necrosis 
of the pars recta [169,180-182] and change in the glomerular epithelial cells 
[139,165,183] within days after injection of UN has also been well documented. 
It has been suggested that the tubular injury escalates progressively for at least 5 
days following injection of UN. Thus, the pattern of injury caused by uranium more 
closely resembles that of cisplatin rather than mercury as has long been assumed. In 
the cisplatin model of ARF, proximal tubular necrosis is widespread five days after 
administration of the agent [184]. Mercury, in contrast, causes peak necrosis 24 h 
later, with epithelial regeneration well under way within 5 days of treatment. Only 
minimal evidence of repair is seen within 5 days after UN administration. The 
progressive degeneration of the nephron might be attributed to the fact that bone acts 
as a reservoir from which uranium is continually released [183], resulting in the slow, 
prolonged exposure of the kidney to the nephrotoxin. 
Within a few hours of injection of UN, the P3C segment begins to show its unique 
sensitivity to the metal [180]. Diane [176] documented that necrosis extends 
proximally up to pars recta, and that P3M region was the last to undergo necrosis. 
The particular susceptibility of the P3C segment is poorly understood. Inner cortical 
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ischemia as a factor is doubtflil since the cortical distribution of blood remains 
constant following administration of UN [167]. There is evidence that uranium 
selectively attacks the adluminal surface of the epithelium of this segment [185]. 
Moreover it has been emphasized that the metabolic activities within the P3C 
segment is heterogeneous in its distribution. It is possible that either uranium is 
secreted at the P3C segment or that some aspect of the metabolism of the cells at this 
site, reflected at the basal or luminal plasma membrane as perhaps an increase in 
electronegativity, preferentially attracts uranium. Cast formation in thin limbs of 
loops of Henle at the day 5-time interval is also reported by Diane [176]. The extent 
of the casts alone would preclude normal flow of filtrate and can be expected to 
cause considerable obstruction. Tubular obstruction must, therefore, be considered as 
a possible factor contributing to functional deficits during the later maintenance phase 
of UN-induced ARF. This cast formation due to uranium probably causes proteinuria 
in both the initiation [186] as well as maintenance [180,186-188] phase of UN-
induced ARF, 
In summary, UN causes widespread changes throughout the kidney. These 
changes begin to manifest themselves shortly after exposure of the animal to uranium 
and become progressively more severe for the subsequent 5 to 6 days. Uranium has a 
predilection for the pars recta of the proximal tubule but most of the nephron 
eventually becomes involved in pathologic changes. 
(D) PROTECTION AND PREVENTION OF ARF 
It appears fi-om the above discussion that the pathophysiology and/or 
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biochemistry of ARF is not yet fully clear. A potential repair, prevention and/or 
protection would also be a more rational approach for better understanding the 
pathogenesis as well as for the treatment of ARF. Reperfusion of blood and certain 
chemicals, drug or hormones have been used in recent past demonstrating a partial 
recovery from toxic shock or ischemia [41,53-74]. Some attempts have been made in 
the past to reverse the drug or ischemia-induced alterations by using glucose, 
essential and non-essential amino acids and their a-keto derivatives which could 
increase the survival rate after the ARF episode [189]. Solez et al [190] reported a 
beneficial effect of propranolol and chloridine. Also, mannitol, furosemide, dopamine, 
prostaglandins and bradykinin have been shown to prevent the functional defect in 
some models of ARF. Recently, calcium channel blockers like verapamil have been 
included in the above group [191-193]. 
Various other agents like epidermal growth factor, EGF [57-59,72,194], 
endothelin [41,60], atrial natriuretic factor [61,62], defibrotide [64,65], glycine and 
glutathione [81], insulin like growth factorl IGFl [53,71], platelet-activating factor 
[195], platelet-activating factor antagonist BN52021 [196], fasting [197], 
pentoxifylline analogue HWA448 [198], fleroxacin [199] and fish oil [200] have been 
shown to control renal failure induced due to toxic insult and/or ischemia. Various 
hydroxyl radicals scavengers like superoxide dismutase [67], dimethylthiourea 
(DMTU) and allopurinol [69,70,73], carvidol [201] or iron chelators [202], when 
administered just prior to the ischemic event or toxic insult, have also been reported 
to ameliorate renal function. 
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Above attempts which were made to ameliorate the function of ARF kidney, 
generally resulted in the improvement of GFR and RBF, decreased serum creatinine 
and BUN with increased inulin as well as creatinine clearance and in the enhancement 
of cellular regeneration [34-74,203]. The above efforts, however, failed to provide 
any generalized mechanism for the damage or repair of the ARF kidney in particular. 
Protection and/or prevention against GM and UN nephrotoxicity 
Due to their broad spectrum of activity against aerobic gram-negative and gram-
positive organisms, their chemical stability, and their rapid bactericidal action, 
aminoglycoside antibiotics remain of considerable value for the treatment of variety 
of life-threatening infections. However, nephrotoxicity frequently occurs as an 
adverse effect of aminoglycoside dosing especially GM [204], which is most 
commonly used. The reduction of the toxicity of these drugs remains a concern 
among clinicians and efforts have been made towards a better assessment of potential 
risk factors. An alternative strategy is the pre- or coadministration of inhibitors, but 
the clinical use of these is still questionable. Poly-L-aspartic acid has recently been 
shown to protect against aminoglycoside nephrotoxicity without reducing the cortical 
accumulation of aminoglycosides [205-210]. A series of studies by Kisore et al. 
[205,211,212] demonstrate that poly-L-asp and not poly-L-glu is an effective 
protectant against all measurable acute and sub-acute signs of aminoglycoside-
induced alterations in rats but these studies also point out to the possibility of mild 
lysosomal thesaurismosis to develop under these conditions. The latter would 
necessitate further toxicological evaluation. With respect to poly-L-glu, these studies 
also demonstrate that not all polyanionic peptides can be used for the purpose of 
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nephroprotection in vivo and thereby clearly show the limits of the in vitro 
investigations (where poly-L-glu behaved similar to poly-L-asp in binding the drug 
and displacing it from anionic phospholipids or renal membrane vesicles), for the 
design and screening of this type of nephroprotectants [205]. 
Recent studies have shown that daptomycin, a lipopeptide antibiotic active 
against methicillin resistant staphylococci and other clinically important aerobic, 
facultative, and anaerobic gram-positive bacteria, protected proximal tubular cells 
against GM-induced renal toxicity in the presence of a similar or even an increased 
accumulation of the aminoglycosides in the renal cortex [213-215]. The mechanism 
of this inhibition of toxicity is still unknown [216]. Adnan et al. [217] showed that 
methimazole, a sulfiir-containing drug commonly used to treat hyperthyroidism 
protects against kidney damage induced in rats, mice, and dogs by cisplatin, an 
antitumor drug. Furthermore, methimazole has been shown to protect rats against 
nephrotoxicity elicited by cephaloridine, S-(l-2 dichlorovinyl)-L-cysteine and 2-
bromohydroquinone, the metabolites of trichloroethylene and bromobenzene, 
respectively, and GM [217-219]. 
Investigations into thyroid-induced nephrotic effect lately have acquired growing 
interest owing to the demonstration of a positive influence of thyroid hormone upon 
various renal partial functions, occurring not only in normal or hypothyroid individual 
but also in the individual suffering from kidney disease [220]. The theory upon which 
these studies are based is that there is a thyroxine-mediated effect on tubular cells, 
resulting in an increase in Na* reabsorption in the proximal tubule and loop of Henle, 
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this will then signal the juxtaglomerular apparatus to release preglomerular or 
vasoconstriction and thereby increase RBF and GFR [220]. The protective effect of 
thyroxine (T3) on GM- and uranyl nitrate-induced ARF, two dissimilar nephrotoxic 
models of ARF, indicates that protection is likely to be nonspecific [43]. Further, the 
finding suggests that the following plasma membrane changes may be important in 
thyroid hormone protection: (1) a stimulation of Na^-K^ATPase activity, (2) an 
alteration in the brush border membrane structure and (3) accelerated repair and/or 
regeneration of injured membranes [221-222]. 
The precise cellular mechanisms responsible for the beneficial effect of thyroxine 
cannot be determined ft-om the earlier studies. However, this hormone has been 
shown to stimulate gluconeogenesis [223] and Na'^-K'ATPase activity in the renal 
cortex [224]. In fact, T3 can influence protein synthesis in the renal cortex so as to 
account for an increase in both the number and activity of Na^-K'^ ATPase units and 
to promote glucose and amino acid uptake [225] by epithelial cells. Each of these 
effects would be expected to aid the repair and regeneration of injured tubular 
epithelial cells. It is tempting to speculate that thyroxine and the adenine nucleotides 
may share a common molecular mechanism, such as repletion of cellular nucleotides, 
or repair of ceU membranes by restoration of Na'"-K"'ATPase pumps. Both of these 
effects would augment cell volume regulation and enhance recovery fi*om acute renal 
injury. However, Whittem et al. suggest that thyroid hormone does not protect 
against GM-induced proximal tubule epithelial injury at a cellular level despite a 
reduction of cellular GM uptake [226]. 
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Since nephrotoxins or ischemia consequently cause depletion of tissue level of 
ATP, ADP and AMP [54], it has been proposed that restoration of ATP synthesis by 
the damaged kidney can have a beneficial effect. Seigel et al. [55,56] showed that 
administration of adenine nucleotides (ATP, ADP and AMP) combined with 
magnesium chloride, ameliorates the renal ftinction after the initiation of acute renal 
failure. One of the reason for the decrease in ATP, ADP or AMP in renal tissue can 
be depleted Pi level due to reduced Pi reabsorption across the apical membrane, the 
primary site of action for most of the nephrotoxins. The Na-Pi co-transport across 
luminal brush border membrane is the rate-limiting step in proximal tubular Pi 
reabsorption [38]. Thus the studies of Na-Pi co-transport and its modulation by 
various stimuli is considered to be useful for the protection against ARF. The long-
term dietary phosphate deprivation [37,38] in response to feeding by low phosphate 
diet (LPD) and the administration of thyroid hormones [227] are the two 
experimental maneuvers known to elicit the most pronounced long term adaptive 
increase [37] in the capacity of renal BBM for Na"^  gradient-energized Na''-Pi 
CO transport. As the adaptive modulation of Pi transport is virtually always manifested 
as an increase or decrease in Vnv« of Na"^  gradient-dependent transport of Pi across 
BBM without change in apparent Km for Pi (KmPi), it has been proposed that in a 
more restricted biochemical sense the long term adaptive changes are due to an 
increase or decrease in number of Na-Pi symporters, also called carriers. Yet, it 
should be considered that the increase in V a^x may also be due to an enhanced rate of 
translocation of Pi, together with Na '^ by Na-Pi symporters already existing in BBM, 
with or without an increase in their number. Yusufi et al. [228] showed that in 
response to treatment with T3 the greater number of Na-Pi symporters with normal 
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affinity (KmPi) are inserted into BBM. The T3 evoked increase in Na^ gradient-
dependent ^^ Pi uptake by BBMV, which was blocked by Act and CHK; thus 
indicating that Na-Pi symporters newly inserted into BBM are probably de novo 
synthesized in response to T3. In contrast, in adaptation to LPD, the increase in Na"^  
gradient-dependent Pi transport kinetically similar to the increase in response to T3, is 
due to a faster rate of Pi plus Na^ translocation [228] across BBM by Na-Pi 
symporters that exist in BBM in the same number and have same afiSnity for Pi as in 
the control state. 
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SCOPE OF THE THESIS 
Aminoglycosides are potent, water-soluble antibiotics with peak concentration 
dependent bactericidal activity against many pathogenic gram-negative bacilli. Being 
highly water soluble, they do not cross biological membranes readily. For systemic 
therapy, they must therefore be given by intravenous, intraperitonial or intramuscular 
injection. For the same reason, once in the body, they are largely confined to 
extracellular spaces, have correspondingly small volumes of distribution (Vd) and are 
mainly eliminated unchanged in urine. Their penetration into cerebrospinal fluid, 
bronchial secretions and vitreous humour is very meager. Thus ordinarily, their 
efficacy does not extend to these tissues or to the intracellular pathogens. 
GM is the usual all purpose agent of choice which exhibits enduring antibacterial 
activity (especially against gram-negative bacilli) even many hours after tissue 
concentrations become negligible. However, like other aminoglycosides, GM is also 
endowed with a concentration-dependent liability to produce (i) ototoxicity (that 
commonly becomes irreversible) [229-231] and (ii) reversible nephrotoxicity [232]. 
Both of these toxic manifestations show a positive correlation with conventionally 
determined high trough concentration. GM concentration dependent efficacy and 
toxicity confer a narrow therapeutic index (range). 
To account for the nephrotoxicity following GM course and recovery on long-
term treatment, it should be appreciated that in reality, GM pharmakinetics and 
pharmacodynamics are very complex. Due to this complexity, the reverence and 
mystique conferred on so-called 'toxic' trough concentrations or concentration-
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dependent toxicity seems justified in some aspects while illogical in others [204,233], 
The ambiguity still persists in the relationship between GM toxicity and/or efficacy 
and its peak or trough values. This ambiguity casts shadow on the efficacy and safety 
of single dose vs. multiple dose in GM treatment. 
GM or other nephrotoxins cause structural tubular changes accompanying the 
development of acute renal failure (ARF) in experimental animals. Loss of microvilli, 
increased apical vacuolization, mitochondrial swelling and eventual cell necrosis 
occur at specific sites within the proximal tubule during experimental ARF both in the 
ischemic model [234] and in nephrotoxic models induced by mercuric chloride, 
cisplatin and some antibiotics [235-237]. While the morphology associated with each 
of these models of ARF has been described in detail, the changes associated with 
sublethal cell injury induced by uranium compounds are unknown inspite of the fact 
that uranium-induced ARF is a major experimental model [170]. The present 
investigation was designed to more carefully characterize renal structural changes 
produced by UN and GM throughout both the initiation and maintenance phase of 
ARF. Single or multiple doses of GM or UN treatment resuh in profound alterations 
in tubular cell functions, metabolism and structural integrity. Studies involving toxic 
and/or ischemic ARF have shown that renal proximal tubular cells are severely 
affected [46,234] and undergo dynamic transformations [234]. The damage that 
occurred to proximal tubular cells, the main functional site where most of the fluid, 
ions and molecules are reabsorbed, is poorly understood [238,239]. Both the early 
damage due to GM administration or recovery during long course of treatment are 
difficult to follow. However, their knowledge is very much essential for better 
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imderstanding of the pathophysiology of ARF. It has been suggested that the 
proximal tubular brush border membrane (BBM) is badly affected by toxic or 
ischemic insult and is mainly responsible for the loss of excretory functions of kidney. 
The effect of nephrotoxins has been manifested in rats mainly by the disappearance of 
brush border microvilli [240,241] or by occasional irreversible interiorization of 
microvilli and subsequent loss into the lumen leading to cellular necrosis and ARF 
[47]. The proximal tubular cell membrane has been found to be histologically 
regenerated after long-term treatment of GM or UN. Physiologic alterations of BBM 
due to toxic insult implicating surface membrane dysfunction include, loss of polarity, 
changes in the fluidity, loss of selective permeability, reductions in the activity of 
BBM associated enzymes and decrease in proximal tubular fluid, sodium, glucose and 
cation reabsorption. Some studies demonstrated that the loss of activities of BBM-
enzymes: AlkPase, GGtase and LAP show direct relationship with enzymuria. Studies 
by Herminghuysen ei al. [242] and Desmonliere & Camber [243] showed an increase 
in urinary GGtase activity in ischemia or intoxicated rats indicating the alterations in 
the BBM and the sloughing of the enzyme components to accumulate in the urine. 
Increased fractional sodium excretion together with reduced renal oxygen 
consumption was also observed [242]. 
Heterogeneity of the proximal tubule in terms of both structure and function is 
well known [243,244]. It has been shown that proximal tubule which consists of Si 
(pars convoluta), S2 and S3 (pars recta) subsegments, differ in the distribution of 
marker enzyme [245,246], reabsorptive properties of various solutes and differential 
response to various drug, hormones and dietary stresses [247-254]. Cronin et al [43] 
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has reported that these nephron subsegments were also differentially affected by GM 
and/or UN. While the surface nephron (SI-subsegments) showed susceptibility to 
GM, the deeper nephrons (S3-subsegments) were severely damaged by UN. It has 
been further reported that nephron functions, after early intoxication, were markedly 
suppressed in surface nephron by GM, the suppression was to a smaller extent in 
middle nephrons by both GM and UN and severely depressed in the deep ones by UN 
administration. GM and other aminoglycoside antibiotics-induced toxic insult showed 
specific effects in proximal convoluted tubular (PCT) segments [237,255] while 
proximal straight tubule (PST-pars recta) segment was shown to be more sensitive to 
oxygen deprivation, ischemia or toxic insuh due to UN. Molitoris el al. [49,50] have 
implicated variations in lipid contents or fluidity of the membrane as one of the major 
reasons for toxic and ischemic ARF [256,257]. 
Studies of transport functions showed reduction in the Na-dependent glucose 
[49,50] and organic cations [51] in nephrotoxic or ischemic ARF. The transport of 
Pi, which involves in the maintenance of energy for many renal fiinctions [85,86] has 
not been studied so far in nephrotoxic ARF. The transport of Pi in renal proximal 
tubule is known to be regulated at the brush border membrane site [38]. The feeding 
of low Pi diet (LPD) and the treatment of thyroid hormone resulted in the increased 
transport of Pi by differential mechanisms [228]. Thyroxine has been demonstrated to 
be beneficial in drug-induced as well as ischemic ARF [43,63]. 
It can be suggested that the study of known nephrotoxins like UN in parallel with 
clinically relevant nephrotoxins such as GM in the laboratory can provide clues to the 
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pathogenesis of toxic nephropathy as well as to renal injuries produced by other 
etiologic agents. In view of this, the present work was carefully designed and 
undertaken to study the damage caused by nephrotoxins to the structure and 
functions of the renal cortical proximal tubules. For better understanding of the 
mechanism of the pathogenesis of GM- and UN-induced ARF and its possible 
reversal, the following studies were performed: 
(1) The natural history war> studied during the course of GM and UN administration. 
The serum and urine parameters viz. creatinine, phospholipid, cholesterol, ionic 
concentrations (Na"^ , Mg^ ,^ K"^ ) along with proteinuria, enzymuria and glycosuria 
were carefully monitored during the GM and UN administration. 
(2) The activities of some marker enzymes considered to be of structural and 
flinctional importance of the proximal tubular BBM eg. AlkPase, Maltase, LAP 
and GGtase were determined in BBMVs isolated from WC or SC and JMC 
tissues of GM- or UN-treated and control rats. The activities of enzymes 
belonging to other organelles were also determined after GM or UN 
administration. 
(3) The activities of various enzymes of metabolic importance especially related to 
energy metabolism (in particular, of glucose metabolism) were determined in 
different tissue zones of the kidney eg, whole cortex, superficial cortex, 
juxtamedullary cortex and medulla isolated from GM- or UN-treated rats. 
(4) Transport of Pi was determined and further characterized in the BBMVs isolated 
from GM- or UN-treated rats under different conditions. 
(5) The protective/preventive effect of thyroid hormone (T3) and LPD were explored 
on BBM Pi transport affected by GM or UN. 
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The present studies showed specific alterations due to GM and UN treatment on 
the above parameters. These studies would be helpful in further understanding the 
pathogenesis of GM- and UN-induced toxic ARF and its possible prevention or 
protection. 
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MATERIALS 
Animals: 
Adult Albino rats (Wistar strain) were purchased from Experimental Animal 
Facility Centre, AIIMS, New Delhi and Jamia Hamdard University, New Delhi, India. 
Substrates of carbohydrate metabolism enzymes: 
D-glucose-6-phosphate for glucose-6-phosphate dehydrogenase and glucose-6-
phosphatase. Pyruvate-Na for lactate dehydrogenase, oxaloacetate for malate 
dehydrogenase, L-malic acid for malic enzyme, fructose 1,6 diphosphate for fructose 
diphosphatase, p-nitrophenyl phosphate for acid phosphatase were purchased from 
SRL, India. ATP for Na'^ -K'^ ATPase was purchased from Sigma Chemical Co., USA. 
Substrates of marker BBM enzymes: 
p-Nitrophenyl phosphate for alkaline phosphatase, y -glutamyl p-nitroanilide for 
y-glutamyl transpeptidase, maltose for maltase and L-leucine-p-nitroaniline for 
leucine amino peptidase were purchased from Sigma Chemical Co., USA. 
Radio Chemicals: 
Radioactive phosphate (^ ^Pi) was purchased from BARC, India. 
Miscellaneous: 
The chemicals used were of finest quality commercially available and their 
sources are indicated against them. Glass double distilled water was used in all 
experiments. 
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CHEMICAL SOURCE 
Acetic acid 
Ammonium Molybdate 
Bovine Serum Albumin 
Calcium Carbonate 
Casein 
Cholesterol 
Choline Chloride 
Cocktail-T (Scintillation Liquid) 
Copper Sulphate (CUSO4) 
Creatinine 
Cysteine Hydrochloride 
o-Dianisidine 
Di-potassium hydrogen orthophosphate 
Di-sodium hydrogen orthophosphate 
Ferric Chloride (FeCls) 
Ferrous Sulphate (FeS04) 
Folin's Phenol Reagent 
Gentamicin 
Glucose 
Glucose oxidase 
Glycine 
Glycyl-glycine 
Hydrochloric acid (HCl) 
E. Merck, India 
Glaxo, India 
Sisco, India 
Qualigens, India 
CDH, India 
SRL, India 
Loba, India 
Sisco, India 
BDH, India 
BDH, India 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Qualigens, India 
Qualigens, India 
Ranbaxy Lab., India 
Ranbaxy Lab., India 
Loba Chem. Co., India 
Fluka A.G., Switzerland 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
E. Merck, India 
Loba Chem. Co., India 
E. Merck, India 
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Magnesium Chloride (MgCl2) 
Magnesium Sulphate (MgS04) 
N-2-Hydroxyethyl-piperazine-N-2-ethane 
sulphonic acid (HEPES) 
Nicotinamide Adenine Dinucleotide Phosphate (NADP) 
Nicotinamide Adenine Dinucleotide Reduced (NADH) 
p-Nitroanilide 
p-Nitrophenol 
Ouabain 
Pentobarbital Sodium 
Perchloric acid 
Peroxidase 
Picric acid 
Potassium Chloride 
Potassium dihydrogen orthophosphate 
Sodium Acetate 
Sodium Carbonate (Na2C03) 
Sodium Chloride (NaCl) 
Sodium dihydrogen orthophosphate 
Sodium Hydroxide (NaOH) 
Sodium Lauryl Sulphate (SDS) 
Sodium Potassium Tartarate 
Sucrose 
Suliuric acid (H2SO4) 
QuaUgens, India 
Sarabhai Chem., India 
Sigma Chem, Co., USA 
SRL, India 
SRL, India 
Sigma Chem. Co., USA 
Loba Chem. Co., India 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Qualigens, India 
Sigma Chem. Co., USA 
Qualigens, India 
Glaxo, India 
Qualigens, India 
Glaxo, India 
Qualigens, India 
E. Merck, India 
Qualigens, India 
Qualigens, India 
CDH, India 
Qualigens, India 
CDH, India 
Qualigens, India 
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Trichloroacetic acid (TCA) 
Tri-iodo thyronine (T3) 
Tris-(Hydroxymethyl)amino-methane(Tris-base) 
Uranyl Nitrite 
Vegetable Oil 
Vitamin Mixture 
Loba Chem. Co., India 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
BDH, India 
Anand Milk Producers 
Union Ltd., India 
Glaxo, India 
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1. Animal Protocol 
Adult male wistar rats weighing 180-200g were used in all studies. Animals were 
stabilized for 10 days prior to the experiment on standard pellet rat diet (Amrut 
Laboratories, Pune, India) and allowed free access to water (Fig. 3). Gentamicin 
sulfate in dose 80mg per kg body weight per day (80mg/kg b.wt./day) was injected 
intraperitonially (i.p.) in one daily dose in a volume adjusted to 1ml with 0.9% saline. 
The following experiment groups were studied. For whole cortex studies; Group I 
received GM for 5 days. Group II received GM for 8 days, Group III received GM 
for 10 days, Group IV received GM for 12 days. Group V received GM for 15 days 
and control group received concurrent injection of 0.9% saline. For SC and JMC 
studies; GM-treated rats were injected i.p. with a solution of gentamicin sulfate 
(80mg/kg b.wt./day) in normal saline for 10 days. This time point had previously been 
showed to allow least recovery and/or desensitization of PT cells. Control rats were 
injected with appropriate volumes of saline in the same manner. On the day of 
sacrifice the animals were anesthetized with anesthetic ether. Blood was withdrawn 
from left jugular vein for analysis of serum parameters before harvesting the kidneys 
for fiuther analysis. Urine was collected at the start of GM treatment and prior to 
sacrifice. In another series of experiments (Fig. 3), UN was injected as a single bolus 
i.p. in a dose of 0.5 mg/kg body weight. UN was prepared at a concentration of 0.2 
mg/ml in normal saline. From preliminary studies using doses ranging from 0.05 to 10 
mg/kg body weight, a 0.5 mg /kg body weight dose was chosen since it produced a 
-75% reduction in glomerular filtration rate (GFR) by day 5 or 6, which 
spontaneously recovered to near normal value within 10 to 12 days. Control rats 
were treated with an equivalent volume of normal saline. On day 0 (i.e. 1 day prior to 
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Standard pellet diet 
10 days 
^K ^K ^K ^N ^t ^K ^p ^K ^K ^N ^p ^K ^N p^ S ^N 
15 day GM/saline treatment 
^K ^S ^K ^K ^N ^p ^p ^K ^N ^N ^K ^N 
12 day GM/saline treatment 
10 day (jM/salinc treatment 
salme treatment 
5 day GM/saline treatment 
Single UN/saMne injection 
Fig. 3 : Schematic representation of GM and UN treatment. 
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UN administration) and day 6 (i.e. 5 days after UN administration), the rats were 
weighed, blood and 24 hours urine specimens were collected. Five days (120 h) after 
UN and /or saline administration, the rats were anesthetized and sacrificed. Kidneys 
were harvested and tissue was separated for BBMV/homogenate preparation. 
2. Analysis of Serum Parameters 
The servun samples were deproteinated with 3% TCA in the ratio of 1:3. After 
incubation for 10 min. at room temperature, the samples were centrifiiged at 
4000rpm (Remi Centrifiige, India) for 10 min. The protein fi-ee supernatant was used 
to quantitate serum creatinine (Cr) and inorganic phosphate (Pi) and the precipitate 
was saved to quantitate total phospholipids. Cholesterol was determined directly in 
the serum samples. 
(i) Quantitative determination of Creatinine: Creatinine was determined by the 
method of Levinson and MacFate [258]. To 0.5ml of the deproteinated serum 
supernatant, 250|il of 10% NaOH and 0.5ml of saturated picric acid were added 
and incubated for exactly 20 min. at room temperature. A calibration curve was 
simultaneously prepared using a known concentration of creatinine solution 
ranging between 2.0-5.O^g. The samples and the standards were read at 520run in 
DU-40 spectrophotometer (Beckman, USA) against a reagent blank. 
(ii) Determination of Inorganic Phosphate: The inorganic phosphate (Pi) was 
measured in protein fi-ee (TCA precipitated) serum supernatant by the method of 
Tausky and Shorr [259]. The serum supernatant (1ml) was diluted to 3ml with 
glass distilled water and 2 ml of FeS04 reagent (5 gm FeS04 was dissolved in 
10ml 10% w/v ammonium molybdate in ION H2SO4 and was diluted to lOOml 
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with glass distilled water) was added. A calibration curve was prepared 
simultaneously with test samples using the known concentration of KH2PO4 
(0.018 |j,moles to 0.28 |imoles). The blue colour obtained was read at 820nm 
after 20min. incubation at room temperature in DU 40 spectrophotometer 
(Beckman) against a reagent blank. 
(iii) Quantitative determination of phospholipids: Phospholipids are determined 
in the serum TCA-precipitates by the method of Bartlet [260] as modified by 
Marinetti [261]. The precipitates were digested with 1ml 70% perchloric acid on 
an electric digestion unit. On cooling to room temperature 3ml of glass distilled 
water was added. The phosphate (inorganic) released was estimated by adding 
2ml of FeS04 reagent by the method of Tausky and Shorr [259] as described 
above in Pi estimation. The phospholipid values were obtained after multiplying 
the phospholipid phosphorus by a factor of 25. 
(iv) Quantitative Determination of Cholesterol: Cholesterol was determined by 
the method of Zlatkis et al. [262]. To 3ml acetic acid, 30 |j,l serum sample was 
added. To this, 2ml of FeCb reagent (prepared by diluting 1ml of 10% FeCls w/v 
in glacial acetic acid to 100ml of concentrated H2SO4) was added careftilly fi-om 
the side to allow the formation of a brown ring. The samples were shaken 
thoroughly, cooled and colour density was read in a DU 40 spectrophotometer 
(Beckman) at 560nm against a reagent blank. A calibration curve was 
simultaneously prepared using known concentration (0.02 to 0.2mg) of 
cholesterol. 
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(v) Determination of Urea nitrogen and Glucose: Levels of urea and glucose 
were assayed by standard colorimetric procedures, urea by reaction with diacetyl 
monoxime and glucose by reaction with glucose oxidase using Sigma kits. 
(vi) Determination of Na% IC^ , Ca^ * and Mg^*: Na^ and K^ levels were measured 
with a flame fluorimeter (FLM-3, Denmark), and Ca^ "" and Mg^ "" were determined 
by using atomic absorbance spectrophotometer (Hitachi Z-7000, Japan) as 
described previously by Zhong et al. [263]. 
(vii) Determination of Urinary enzymes: Urinary enzymes were determined by 
standard colorimetric methods as described previously by Whiting et al. [264]. 
3. Preparation of Kidney Homogenates for the Determination of Metabolic 
Enzymes 
After completion of GM or UN treatment, the kidneys were removed, 
decapsulated and kept in ice-cold buffered saline (154 mM NaCl, 5mM Tris-HEPES, 
pH 7.4). The cortical (WC or SC and JMC) and medullary regions were carefully 
separated as described below (Fig. 4) [247], and homogenized in 0.1 M Tris-HCl 
buffer pH 7.5 by a glass-teflon homogenizer at 4°C to make a 15% homogenate. The 
homogenate was centrifuged at 800xg at 4°C for lOmin. in Beckman J2-M1 high-
speed refrigerated centrifuge to remove the cell debris. The supernatant was used for 
enzyme analysis. 
4. Brush Border Membrane (BBM) preparation 
After the completion of GM or UN treatment, the kidneys were removed, 
decapsulated and kept in ice-cold buffered saline (154 mM NaCl, 5 mM Tris-HEPES, 
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BBMV-SC 
BBMV-JM 
CORTEX 
MEDULLA 
PAPILLA 
Fig. 4 : Anatomical parts of the Kidney-A longitudinal view. 
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pH 7.5). the cortical tissues were carefully separated for BBM preparation as WC, 
SC and JMC as described by Yusufi et al. [247]. In brief, the cortical part of the 
kidney was cut into two halves and the whole cortex (WC) was separated form 
medullary and papillary portions. For the preparation of BBMV-SC and BBMV-
JMC, the cortical portion was cut in the middle of the cortical thickness (Fig. 4) 
between the kidney surface and corticomedullary junction. The juxtamedullary part of 
the cortex was carefully separated from superficial cortex. The outer cortical zone, 
superficial cortical tissue (SC) "SC-tissue" was used as a starting material for 
BBMV-SC preparation. Since, in rat kidney, straight portions of the proximal tubules 
dip beyond the cortico-meduUary junction, the outermost layer of adjacent medulla 
(outer stripe of outer medulla) was also included to juxtamedullary cortical tissue i.e. 
"JMC-tissue". 
The BBM vesicles (BBMV) were prepared by the method of Schimtz et al. [265] 
using MgCl2 for precipitation of membranes other than BBM as described by Yusufi 
and Dousa [85] and as outlined in the schematic diagram (Fig. 5). In each 
experiment, tissues from three to sbc animals (control and experimental) were pooled 
to obtain a sufficient amount of starting material. All the steps involved were strictly 
carried out at 0-4°C unless otherwise specified. 
a) The cortical tissue for the preparation of BBMV was homogenized in a buffered 
solution containing 50mM mannitol, 5mM Tris base/HEPES, pH 7.0 (5ml/g 
tissue) with four complete passes by Potter-Elvejhem homogenizer. 
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RAT RENAL CORTEX 
CORTICAL HOMOGENATE SOmMMANMTOL 
5mMTRIS-HEPES, pH7.0 
lUGHSl'EED 
HOMCXJENIZAI'ION 
(Ultra-Turrex) 
BBMV IN I-rOMOGENAIE 
I 
PELLET 
DISCARDED 
Mg2* PRECIPITATION 
AND CENTRIFUGATIONAT 
2000xgFOR lOmin 
r 
BBMV IN 
SUPERNATANT 
BBMV PURIFICATION 
BYCENTRIFUGAnON 
AT 35000 xg FOR 
30MIN 
BBMV 
SUSPENDED IN 
300mMMANNITOL 
5mMTRIS-HEPES 
pH7.4 
Fig. 5 : Schematic representation of BBMV preparation from rat renal cortex. 
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b) The homogenate was diluted with the above solution (20ml/g tissue) followed by 
high speed homogenization (Ultra-Turrex T25, IKA-Laportechnik) with three 
pulses of 30s each with 30s interval in between each pulse. Aliquots of cortical 
homogenates were saved and quickly frozen for further analysis. 
c) IM MgCb was added to the homogenate (final cone. lOmM) and was kept for 
20min. with intermittent shaking. 
d) The homogenate was then centrifuged at 2000xg (4000rpm) for lOmin. in a 
Beckman J2-M1 refrigerated centrifuge using JA-17 rotor. 
e) The pellet was discarded and the supernatant was recentrifuged at 35000xg 
(17000 rpm) for 30 min. 
f) The pellet thus obtaired was resuspended in a solution containing 300mM 
mannitol, 5mM Tris base/HEPES pH 7.5 with four passes by a loose fitting 
Dounce homogenizer (Wheaton, USA) and centrifuged at 35000xg (17000 rpm) 
for 20 min. in 15 ml corex glass tube using JA-20 rotor. 
g) The white outer portion of the fluffy pellet was resuspended carefully in a small 
volume of buffered 300mM mannitol, leaving the dark brown centre of the pellet 
undisturbed (mitochondrial contamination). 
h) The steps f and g were repeated twice and the final pellet was resuspended in 
buffered 300mM mannitol. 
The suspension thus obtained was homogenized by hand held Douncer or passed 
through a needle no.21. The membrane suspension was quickly frozen in small 
aliquots and used for enzyme analysis while aliquots of freshly prepared membranes 
were used for transport studies. 
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5. Enzyme Assay 
All enzymes were assayed at zero order kinetics unless otherwise specified. The 
activities of each enzyme from various comparing groups were determined 
simultaneously under similar conditions by using same solutions to avoid day to day 
experimental variations. One unit of the enzyme activity is defined as the amount of 
enzyme required to catalyze the formation of 1 i^ mole of product per min. or h under 
the specified experimental conditions. Specific activity is defined as the enzyme unit 
per mg of enzyme protein. 
(a) Assay of carbohydrate metabolism enzymes: The assays were carried out 
measuring the extinction changes in Calbiometer (Calbiochem, USA) fixed for 340nm 
in a final volume of 3,0 ml at room temperature (28-30'^C). The net reaction rate was 
measured by difference of the extinction values obtained from addition of the 
substrates and for actual enzymatic reaction following the addition of substrate. 
(i) Lactate dehydrogenase (L-Lactate : NAD oxidoreductase ; LDH; E.C. 
1.1.1.27): The activity of LDH was measured by the method of Komberg [266]. 
The reaction mixture in a total volume of 3 ml contained Tris-HCl buffer pH 7.4, 
150 iimoles; MgCl2 10 nmoles; sodium pyruvate 5 |j,moles; NADH 0.24 jamoles 
and 4.0-6.0 ng protein. The activity was measured pyruvate dependent NADH 
oxidation to NAD"" for 5 min at 340 nm (s = 6.22 mM"'cm'') in Calbiometer 
(Calbiochem, USA), 
(ii) Malate dehydrogenase (L-Malate : NAD oxidoreductase; MDH; E.C. 
1.1.1.37): The activity of MDH was measured according to the method of Meyer 
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et al. [267]. The reaction mixture in a total volume of 3 ml contained Tris-HCl 
buffer pH 7.4, 100 [imoles; oxaloacetate (OAA, pH neutralized to 7.4) 2.5 
Hmoles, NADH 0.24 jamoles and 2.0-3.0 |ig protein. The activity was measured 
as OAA dependent NADH oxidation to NAD"^  for 5 min at 340 nm (e = 6.22 
mM''cm-l) in Calbiometer (Calbiochem, USA). 
(iii) Malic enzyme (L-Malate : NADP oxidoreductase; ME; E.C. 1.1.1.40): It 
was assayed according to the method of Ochoa et al. [268]. The reaction mbcture 
in a total volume of 3 ml contained Tris-HCl buffer, pH 7.4, 100 i^moles; MnCl2 
10 |j,moles; L-malic acid (pH neutralized to 7.4) 5 lamoles; NADP"^  0.24 nmoles; 
and 0.6-1.2 mg protein. The activity was measured by monitoring the malic acid 
dependent reduction of NADP"^  to NADPH for 5 min at 340nm (8=6.22 nm''cm"') 
in Calbiometer (Calbiochem, USA). 
(iv) GIucose-6-phosphate dehydrogenase (D-Glucose-6-phosphate NADP 
oxidoreductase; G6PDH; E.C. 1.1.1.49): G6PDH was assayed according to the 
method of Shonk and Boxer [269]. The reaction mixture in a total volume of 3 ml 
contained Tris-HCl buffer pH 7.4, 150 i^moles; MgCt 10 |imoles; Glucose-6-
phosphate 5 nmoles; NADP^ 0.24 pimoles; and 0.6-1.2 mg protein. The activity 
was measured by monitoring the G-6-P dependent reduction of NADP^ to 
NADPH for 5 min. at 340 nm (8= 6.22 mM"'cm"') in Calbiometer (Calbiochem, 
USA). 
(v) Glucose>6-phosphatase (D-glucose-6-phosphate phosphohydrolase; G6Pase; 
E.C. 3.1.3.9): It was assayed according to the method of Shull et al. [270]. The 
reaction mixture in a total volume of 1.5ml contained Tris-HCl buffer pH 7.4, 
SOtimoles; MgCli 10 ^imoles; Glucose-6-phQsphate 10 jjimoles and 2-3 mg 
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protein. The reaction was carried out at ST^ C and stopped with Iml of 10% 
TCA after 60 min. the samples were centrifuged at 4000rpm (Remi Centrifiige, 
India) and phosphorus was estimated in the protein free supernatant by the 
method of Tausky and Shorr [259]. 
(vi)Fructose-l,6-bisphosphatase(D-fructose-l-6-dlphosphate-l-phosphohydro-
lase; FBPase; E.C. 3.1.3.11): It was assayed according to the method of 
Freedland and Harper [271]. The reaction mixture in a total mixture of 1.5ml 
contained Tris-HCl buffer pH 8.4, 50 ^imoles; MgCl2 10 nmoles; Cysteine-HCl 
12 lamoles; F-1,6-DP 10 [imoles; 0.6-0.8 mg protein. The reaction was carried 
out at 3TC and was stopped with 1.0ml of 10% TCA after 60 min. The samples 
were centrifiiged at 4000 rpm (Remi Centrifiige, India) and the phosphate 
released was estimated in protein free supernatant by the method of Tausky and 
Shorr [259]. 
(vii) Isocitrate dehydrogenase (ICDH; LS-isocitrate; NADP oxidoreductase 
decarboxylate; E.C. 1.1.1.42): It was assayed according to the procedure of 
Ochoa [272], Reaction mbcture contained Tris-HCl buffer, pH 7.4, 200nmoles; 
MgCl2, 110|imoles; MnCk, lOjimoles; isocitrate, 10|xmoles; NADP 0.24 |.imoles 
and 1-2 mg enzyme protein. Increase In absorbance at 340nm was followed for 5 
min. 
(viii) Succinate dehydrogenase (SDH; E.C. 1.3.99.1): The enzyme was assayed by 
the method of Pennington [273] as described by Konkel et al. [21 A]. The reaction 
was started by the addition of 100|j,l enzyme (80-100|ig enzyme protein) to 900|j,l 
assay buffer containing K2HPO4, SOmM; INT, 0.1%; Na-succinate, 50mM; 
Sucrose, 25mM, pH 7.5 (final volume 1.0ml). After incubation at 37°C for 15 
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min., the reaction was stopped by the addition of 1ml of 10% TCA. The colour 
developed was extracted with 2.5nil ethyl acetate and read at 490nm in DU 40 
spectrophotometer (Beckman). The results were expressed as m.E.U./mg 
protein/h. (lm.E.U.=1.0 OD change). 
(b) Assay of Basolateral membrane (BLM) and lysosomal marker enzymes: 
(i) Na^-K^ATPase (E.C. 3.6.1.3): The activity of Na'^ K"' ATPase was assayed as 
described by Konkel el al. [275]. Enzyme preparations were incubated for 15 
min. at 37°C in a medium containing in a final volume 1.5ml (final concentration) 
4.8 mM ATP; 120 mM NaCl; 24 mM KCl, 7.2 mM MgS04 and 48mM Tris-HCl 
pH 7.6. The ATPase activity without the addition of Ouabain is referred to as 
"Mg-ATPase". The difference in Mg-ATPase activity assayed without or with 1.2 
mM Ouabain is taken as a measure of Na^ -K"^  ATPase [276]. The reaction was 
terminated by the addition of 0.3ml of 30% TCA and the Pi released was 
determined by the method of Tausky and Shorr [259]. 
(ii) Acid phosphatase (AcidPase, E.C. 3.1.3.2): The activity of acid phosphatase 
(AcidPase) was determined in CH and BBM by the method of Verjee [277]. The 
reaction mixture contained 2.4 ml acetate buffer (0.05 M sodium acetate, pH 4.5) 
and 100|al enzyme (35-40 |j,g both in CH and BBM). The reaction was started by 
the addition of 0.5 ml p-nitrophenyl phosphate (final concentration 0.8 mM in 
3 ml) and incubated for 15 min. at 30^C. The reaction was stopped by adding 2 ml 
2N NaOH. A calibration curve of known concentrations (0.05-0.4 |j,moles) of p-
nitrophenol was prepared simultaneously. The yellow colour developed was read 
at 405 nm in DU 40 spectrophotometer (Beckman) against a reagent blank. 
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(c) Assay of marker enzymes of brush border membrane: The enzymes were 
assayed simultaneously in CH and BBMV under similar conditions by using same 
solutions to avoid day-to-day experimental variations. Aliquots of CH and BBMV 
were diluted with lOmM Tris-HCl buffer, pH 7.5 to obtain suitable enzyme protein 
concentration. 
(i) Alkaline phosphate (AlkPase, E.C. 3.1.3.1): The activity of AlkPase in CH and 
BBM was determined according to the method of Shah et al. [278] as described 
by Kempson et al. [279]. The reaction mixture contained 1.4 ml assay buflFer (55 
mM glycine; 36 mM NaCl and 45 mM NaOH, pH 10.5) and 100 ]\.\ enzyme 
protein (10-25 |ig for CH and 4-8 |ig for BBM). The reaction was started by 
adding 15 [A1 p-nitrophenyl phosphate (final concentration 5.8 mM in 1.5 ml) and 
incubated at 30"C for the required time (5-20 min.). The reaction was stopped by 
adding 50 i^l of 5N NaOH. A calibration curve was prepared simultaneously by 
using known concentrations of p-nitrophenol (0.01-0. 2 |imoles). The colour was 
read at 405 nm in DU 40 spectrophotometer (Beckman) against a reagent blank, 
(ii) Y-GIutamyl transferase (GGtase, E.C. 2.3.2.2): The activity of y-Glutamyl 
(GGtase) in CH and BBM was determined according to the method of 
Glossmann and Neville [280] as described by Kempson et al. [281]. The reaction 
was started by adding 100 \i\ enzyme protein (15-20 |ig for CH; 2-5 ng for 
BBM) to 1.9 ml substrate buffer (20mM MgCl2, 2mM y-glutamyl p-nitroanilide, 
4mM glycylglycine, 100 mM Tris-base pH 8.2) and incubated in a shaking water 
bath maintained at 37°C for the required time (3-15 min.). The reaction was 
stopped by adding 100 i^l of 15M acetic acid. A calibration curve of known 
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concentration of standard p-nitroaniline (0.025-0.2 nmoles) was prepared 
simultaneously. The yellow colour developed was read at 405 nm in DU 40 
spectrophotometer (Beckman) against a reagent blank. 
(iii) Maltase (Mtase, E.C. 3.2.1.20): The enzyme was assayed by the method of 
Dahlqvist [282]. This is a two step method which consists of (i) incubating the 
BBMV or CH with maltose to generate glucose and (ii) measuring glucose. The 
reaction was started by addition of 100^1 enzyme (15-20|ig for CH, 3-5ng for 
BBMV protein) to 100^1 substrate buffer (Maleic acid, O.IM; NaOH, 0.15N; 
Maltose, 56mM; pH 6.0). The reaction mixture was incubated at SV^ 'C at room 
temperature for 15 min. To this, 3.0 ml TGO reagent (Tris, 0.5M, pH 7.0; 
Peroxidase, 0.1%, Triton X-100, 25% in 95% ethanol; dianisidine, 0.4% in 50% 
ethanol) was added and incubated at 37°C for 60 min. A calibration curve of 
standard glucose (0.1|j.mole-l)j,mole) was also prepared simultaneously. The 
colour obtained was read at 420nm in DU 40 spectrophotometer (Beckman). 
(iv) ly-Leucine aminopeptidase (LAP E.C. 3.4.11.2): This enzyme was assayed by 
the method of Goldman et al. [283]. The reaction was started by the addition of 
lOOul enzyme (940-60|^g for CH, 10-15)ig for BBMV protein) to 1.9 ml 
substrate buffer (NaH2P04.H20/ Na2HP04.7H20, 50mM; L-leucine p-
nitroanilide, 0.33mM; pH 7.2) and incubated at 25^C for the required time (15-30 
min.). The reaction was stopped with \QQ\x\ of 15M acetic acid. A calibration 
curve of standard p-nitroaniline (0.025-0.20|j,moles) was also prepared 
simTiItaneously. The yellow color obtained at 405 nm against a reagent blank in 
DU 40 spectrophotometer (Beckman). 
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6. Protein Estimation 
Protein was measured by the method of Lowry et al. [284] with minor 
modification as described previously by Yusufi et al. [285]. The sample was made to 
0.8ml with 0.5% SDS. In timed sequence 2.0 ml alkaline copper reagent was added 
and exactly after 10 min. of incubation at room temperature (RT) 0.2 ml Folin's 
reagent (IN) was added with brisk shaking and incubated for 30 min. at RT. A 
calibration curve of standard BSA (5-8 |ag) was prepared simultaneously. The blue 
colour obtained was read at 660 nm in DU 40 spectrophotometer (Beckman). 
7. Transport 
Measurement of phosphate (^ ^Pi) (BARC, India) uptake in brush border 
membrane vessicles was carried at 25''C by rapid filtration technique as described by 
Yusufi et al. [lAl} either in the presence or absence of Na-gradient. Uptake was 
initiated by addition of 30 ^1 incubation medium (NaCl/KCl 100 mM, 5 mM Tris-
HEPES, pH 7.5, 5mM K2HPO4 and radioactive substrate ^^ Pi to 15 \x\ BBM 
suspension (50-100 \i% protein) and incubated for desired time intervals (see 
"Results"). At the end of incubation period the uptake was stopped by rapid addition 
of 3 ml ice cold stop solution (delivered by a Cornwall Syringe type pipette) 
containing 135 mM NaCl, 5 mM Tris-HEPES with 10 mM sodium arsenate, pH 7.5 
and filtered immediately through 0.45 )im DAWP millipore filters and washed 3 times 
with the same ice-cold stop solution. Correction for non-specific binding to filters 
was made by subtracting fi-om all data the value of the corresponding blank obtained 
by filtration of the incubation medium without vesicles. The radioactivity of the dried 
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filters was measured by liquid scintillation counting (Pharmacia, Sweden) with 10 ml 
scintillation fluid ("Cocktail-T", SRL, India). 
8. Preparation of Low Thosphorus Diet (LPD) 
The LPD containing 0.07% phosphates was prepared in the laboratory, the 
composition of which is similar to the commercially available low phosphate diet of 
ICN Pharmaceuticals Inc., Cleveland, Ohio. The LPD contained (in g%) sucrose 66, 
casein 20, salt mix (1.02% NaCl; 0.53% KCl; 0.305% MgS04; 0.103% iron citrate; 
1.02% CaCOs and 0.014% cupric sulfate) 4, vitamin mixture (Glaxo, India) 0.4 and 
vegetable oil 10. The normal phosphorus diet (NPD) was prepared by supplementing 
with a mixture of sodium and potassium phosphate (ratio of monobasic: dibasic sah 
was 1:4) to a final content of 0.7% (w/w) phosphorus, as described by Kempson et 
al. [286]. 
9. Preparation of Thyroxine (T3) 
4.37 mg T3 was dissolved in 10 ml NaOH (10 mM). 10 ml Tris (5mM) in 1.8% 
NaCl was added to the T3 solution. The pH was slowly adjusted to 9.4 ± 0.1 with 
O.IN HCl. The solution was diluted to 25ml with a mixture of above solution (lOml 
lOmM NaOH, lOml 5mM Tris in 1.8% NaCl pH 9.4 ±0.1) whjcivwas-used as vehicle 
for control rats. f J^ "^^'' \ 
''-k( > \\ 
( Ace. No )^" 
\ -v. v.. ,-.•' •<•// 10. Animal protocol for LPD and T3 Treatment X -^v. ^  v^ ^ ^ ^ 1 "'^ 
The animals were placed simultaneously on similar dietary regimens~and throughout 
the experiment all groups were studied in parallel. The animals were fii"st stabilized on 
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standard pellet rat diet for ten days. The protocol for this study is shown in Fig. 6. 
On day 0, T4 was administered in a dose of 100(ig/100g body wt. and continued daily 
as an intraparitoneal injection for the next 14 days. Crystalline T3 was prepared as 
described above (preparation of T3) and all T3 injections were freshly prepared 
immediately before administration. From day 5, GM was injected daily 
intraperitonially in a dose of 80mg/kg b.wt. On day 10, UN was injected as a single 
bolus intraperitonially in a dose of 0.5mg/kg body wt. From preliminary studies using 
UN, doses ranging from 0.05 to 10 mg/kg body wt., a 0.5 mg/kg body wt dose was 
chosen since it produced -75% reduction in glomerular filtration rate (GFR) by day 5 
or 6 that spontaneously recovered to near normal values within 10-12 day. Similarly 
the rats treated with GM doses ranging from 20-lOOmg/kg b.wt, 80mg/kg b.wt. 
showed max. decrease in GFR after 10 days treatment as long term treatment (day 
12, day 15) showed recovery. 
On day 16 i.e. 24 h after the last dose of T4 and/or GM and 120h after the 
administration of UN, the animals were anesthetized with ether, the kidneys were 
quickly removed and placed in an ice cold buffer solution. The following 
experimental groups were studied. Group V+GM rats received GM (80mg/kg b.wt.) 
for 10 days and vehicle for 15 day. Group V+UN rats received UN (0.5mg/kg b.wt.) 
single bolus dose and vehicle for 15 days. Group T+S rats (the control T4 group) 
received 15 day course of T4 and saline. Group T+GM rats received T4 for 5 days 
prior to and 10 days along with the administration of GM. Group T+UN rats 
received T4 for 10 days prior to and 4 days following the administration of UN. 
Group V+S (control) received concurrent injection of vehicle (used for T4 
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preparation) and saline (used for GM or UN preparation). The allocation of animals 
was adjusted so that at the start of treatment the groups did not differ in body wt., 
food intake or urinary Pi. 
Separate groups of animals were placed simultaneously on different dietary 
regimens. The animals were first stabilized on NPD for 10 days. After the lO"* day, 
the animals were divided into sbc groups with no intragroup or intergroup difference 
in food intake, body wt. or Pi excretion. The rats were fed with specified diets for 15 
days. Group NPD+V received NPD+vehicle for 15 day. Group NPD+GM received 
NPD for 5 day prior to and along with GM administration for the 10 days. Group 
NPD+UN received NPD for 10 day prior to and 4 days following UN treatment. 
Group LPD+S received LPD and saline for 15 days. Group LPD+GM received LPD 
for 5 days prior to and 10 days along with the GM administration. Group LPD+UN 
received LPD for 10 day prior to and 4 days following UN administration. The doses 
for GM and UN were same as used in earlier experiments (see animal protocol). On 
day 16, the rats were anaesthetized by ainesthetic ether, sacrificed, and the kidneys 
were harvested for BBMV preparation. BBMVs fi"om whole cortex or superficial and 
deep cortex were prepared as described earlier. Transport of ^^ Pi was studied by 
rapid filtration technique as described earlier. 
Statistical Analysis: 
Unless specified, all experiments were repeated atleast four or five times to 
document reproducibility. All data are expressed as Mean±SEM. When appropriate, 
statistical evaluation was used and conducted employing group t-test. 
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Natural History: 
To study the time course of GM nephrotoxicity and compare it with concurrent 
changes in body weight, food intake, and renal electrolyte excretion, animals were 
studied 5, 8, 10, 12 and 15 days after GM injection. Table 1, shows the changes in 
body weight, food intake, urine flow rate, glucosuria and proteinuria that occurred in 
GM-treated groups as compared to their respective saline-treated control groups. 
Body weight of animals treated with GM did not change significantly compared with 
their respective controls. The tendency for weight to rise in all groups following the 
GM administration remained same compared to saline-treated rats. There was no 
significant change in food intake at any time point during the course of treatment. 
Changes in urine flow rate and glucose excretion are shown in Table 1. Urine flow in 
GM-treated animals rose nearly three fold at all time points during the course of 
treatment. Glucose excretion increased significantly at all time points during the 
course of GM treatment. The maximum enhancement in glucose level in urine was 
observed after 10 days of GM treatment. Both GM and UN caused significant non-
specific proteinuria (Table 1 and 2). The effect of GM on urinary electrolyte 
excretion is shown in Table 3. Small but significant increase in urinary excretion of 
Na, K, Mg, Pi and Ca occurred at all time points during GM treatment as compared 
to saline-treated rats. However, the maximum increase in electrolyte excretion was 
observed after 10 days GM treatment. Urinary electrolyte excretion was unchanged 
in saline-treated controls. 
Table 2 and 4 depict the effect of UN on body weight, food intake, urine flow 
rate, electrolyte excretion and glucose excretion. On day 6 (120 h' after UN 
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Table 1 : EflFect of GM treatment on body weight, food intake, ixrine flow rate (UFR), 
urinary glucose and protein in intact animals. 
Duration of 
Treatment (days) ^ 
BodyWt(g) 
Control 20atl0 
OVI 195±10 
Food Intake (g/day) 
Control 20tbl 
OVI 20.5±0.9 
Urine Flow rate (ml/day) 
Control 15.4±0.6 
GM 15.6t0.7 
5 
205±10 
20at9 
21±1 
2at0.9 
15.5±0.6 
24.4±0.8*t 
Protein (mg/mmole creatinine) 
Control 22&t0.10 
GM 235±0.16 
231±0.15 
11.3±l.l*f 
Glucose (mg/mg creatinine) 
Control 15.0±2 
GM 15.5±1.5 
14.&tl.2 
28.6±2.5*t 
8 
210±9 
205±8 
21±1 
20.5±0.7 
15.61:0.9 
28.4±0.8*t 
23±0.16 
15.Q±1.5*^ 
16.2±1.9 
46.8±4*t 
10 
21ttt8 
210±10 
21±0.8 
20.6±1.0 
15.2±0.7 
32.0±1.0*t 
231±0.17 
20±1.9*T 
15.&tl.8 
56.0±5*t 
12 
217±7 
215t7 
21.4±0.9 
21.4±=0.9 
15.5±0.55 
27.4±0.9*t 
224=b0.14 
16.0±1.8*t 
15.4tl3 
41.7±3*^ 
15 
220ttl0 
218±11 
2U1 
20.8±1.1 
15.2±0.7 
25.1±1.0*f 
2.3±0.15*f 
15.0±1.4*t 
16.0tfcl.3 
30.0tt2*» 
Results are mean± SEM of five different experiments. 
* significantly different at p<0.01 as compared to day 0. 
^ significantly different at p<0.01 as compared to saline-treated control. 
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Table 2 : Effect of UN treatment on body weight, food intake, urine flow rate (UFR), 
urinary glucose and protein in intact animals. 
Duration of 
Treatment (days) 
BodyWL(g) 
Control 
UN 
Food Intake (g/day) 
Control 
I N 
Urine Flow Rate (ml/day) 
Control 
UN 
Protein (mg/mmole creatinine) 
Control 
UN 
Glucose (mg/mg creatinine) 
Control 
GM 
200tbIO 
203±10 
20ttl 
20ttl 
15.4±0.6 
15.5±0.7 
22&b0.10 
23±0.16 
15d£2.0 
15.5±:1.5 
205±10 
205±9 
21±1 
2ati 
15.5±0.6 
32.5±0.8*^ 
230±0.15 
16.3±1.1*^ 
14.8±1.2 
47.5±2.5*t 
Results are mean± SEM of five different experiments. 
* significantly different at p<0.01 as compared to day 0. 
^ significantly different at p<0.01 as compared to saline-treated control. 
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Tab le s : Effect of GM treatment on ion excretion in intact animals. 
Duration of 
Treatment (days) 0 8 10 12 15 
Sodium (meq/Ug body wt/day) 
Control 3.01±0.01 3.14t0.012 32±0.02 
GM 32±0.01 4.4±0.019*^ 4.ftt0.04*t 
Potassium (meq/kg body wt/day) 
Control 6.1±0.18 62±021 6.05±0.2 
CM 62^024 6.9H).22*^ 7.2±023*^ 
Calcium (meq/kg body wt/day) 
Control 3.0i0.1 32±0.09 2.SW).09 
GM 2.9&±0.05 4.at0.08*f 4.6±0.06*f 
Magnesium (meq/kg body wt/day) 
Control 12i0.01 121±0.02 1.19±0.0101 
GM 124±0.01 1.3±0.014*t 1.41±0.009*t 
Inorganic Phosphate (fxmoles/kg body wt/day) 
Control 1.64±0.04 1.62±a03 1.63±0.02 
CM 1.65±0.03 2.0tb0.08 * 2.15±0.09*t 
3.15±0.015 3.06±0.011 3.15i0.012 
5.&t0.013*t 4.7±0.009*t 4.6±0.01*t 
5.98±().22 6.1±0.19 6.(iti)2 
7.4&±0.25*t 7.6t0277*^ 7.2±024*t 
3.1±0.11 3.(>t0.08 32±0.09 
4.9i0.12*f 4.4±0.13*^ 4.2±0.11*t 
121±0.011 12±0.008 122±0.01 
1.52±0.012*^ 1.49t0.014*t 1.42±0.011 
1.64±0.01 1.61±0..04 1.65±0.02 
2.3±0.1*^ 2.18±0.09*^ 2.1±0.08* 
Results are mean± SEM of five different experiments. 
* significantly different at p<0.01 as compared to day 0. 
^ significantly different at p<0.01 as compared to saline-treated control. 
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Table 4 : Effect of UN treatment on ion excretion in intact animals. 
Duration of 
Treatment (days) 
Sodium (mcq/kg body wt/day) 
Control 
USf 
Potassium (mcq/kg body wt/day) 
Control 
UN 
Calcium (mcq/kg body wt/day) 
Control 
IJN 
Magnesium (meq/kg body wt/day) 
Control 
UN 
0 
3.01i0.01 
32±0.01 
6.1±0.18 
6.1±024 
S.ObO.l 
3.0tfc0.05 
12H).01 
122±0.01 
Inorganic Phosphate ((xmoles/ kg body wt/day) 
Control 1.6H).03 
UN 1.61i0.02 
5 
3.14:H).012 
5.2±0.019*^ 
6.2±021 
8.8±0.22*^ 
32±0.09 
4.2±0.08*^ 
121±0.02 
1.54±0.014*t 
1.62±0.03 
2.19±0.06*^ 
Results are mean± SEM of five different experiments. 
* significantly different at p<0.01 as compared to day 0. 
^ significantly different at p<0.01 as compared to saline-treated control. 
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administration), the food intake and tendency to gain weight remained unchanged 
compared to control rats. Urine flow rate in UN-treated rats rose nearly two fold thus 
indicating polyuria. Five days after UN treatment glucosuria was also enhanced 
alongwith ion wasting. 
Serum creatinine and creatinine clearance: 
Preliminary studies showed that the changes in serum creatinine (resuhs not 
shown) in UN-induced ARF were reversible, with recovery to near normal serum 
creatinine value within 10-12 days. However, 5 days after UN treatment serum 
creatinine had risen two fold (fi-om 0.41mg/dl on day 0 to 0.9mg/dl on day 6, 
p<0.05). Serum creatinine in saline-treated control group was almost unchanged (0.4 
on day 0 to 0.42 mg/dl on day 6). Serum creatinine in groups treated with GM for 5 
to 15 day increased significantly compared to base line or control groups. Serum 
creatinine in group GI, treated with GM for five days rose significantly (fi*om 
0.4mg/dl on day 0 to 0.66mg/dl on day 5). The increase in serum creatinine showed 
direct relation with duration of treatmerit upto day 10 (Table 5). However, the 
magnitude of increase was less in groups treated with GM for 12 and 15 days. 
Intergroup comparison of GM-treated rats showed the maximum rise in serum 
creatinine after 10 days of GM administration. Intergroup comparison of saline-
treated control groups did not show any significant difference in serum creatinine 
level (Table 5). GFR as estimated by clearance of endogenous creatinine fell in UN-
treated group (0.34ml/min/100g body weight on day 0 to 0.14 ml/min/100 g body 
weight on day 5). In control rats GFR remained unaltered (Table 6). In GM-treated 
animals GFR was inversely related to duration of treatment atleast upto 10 days. 
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Table 5 : EflFect of GM treatment on serum parameters in intact animals. 
Duration of 
Treatment (days) 0 8 10 12 15 
22i:l.l 20db0.95 
35±2.0*^ 42i:1.9*^ 
Serum Creatinine (mg/dl) 
Control 0.4±.01 0.45±.011 0.44db.016 
GM 0.42±.01 0.66t07*T 0.&b.06*T 
Creatinine clearance (ml/min/lOOgm body wt) 
Control 034±.01 032±.011 032±.013 
CM 035±.01 0.16±.01*f 0.14±.009*t 
Bl]N(mg/dI) 
Control 20tbl 
CM 22tl.2 
Cholesterol (mg/dl) 
Control 54.52±3.0 56.4±4.0 
CM 53.9i4.0 67i3.8* 
Phospholipid (mg/dl) 
Control 0.5=b0.02 0.505±0.015 0.51±0.02 
avi 0.50&±0.02 0.76±0.01*f 0.84i0.02*f 
Phosphate (umole/ml) 
Control 2.4±0.12 2.45±0.11 235±0.9 
GM 2.44±0.12 1.7iJ0.6 1.6i0.5 
5Si3.5 
77.1±4.2* 
039i.015 0.41±.014 0.42±.012 
0.88±.09*t 0.85±.07*t 0.&t.065*t 
035±.015 036t.014 033±.012 
0.12±.(X)85*t 0.13±.009*t 0.14±.01*t 
18±1 18.3±0.87 19.8±0.92 
5012.05*^ 47±1.7*t 43±1.5*^ 
52i2.9 53±3.0 53.5±3.5 
82±4.4* 72±4.0* 68±3.9* 
0.514±0.018 0.52A0.013 0.51±0.02 
0.92iO.03*t 0.87±0.03*^ 0.83±0.02*^ 
239ii).l2 2.43±0.11 2.45=b0.10 
1.5i025 1.6±J020 1.82±0.11 
Results are mean± SEM of five different experiments. 
* significantly different at p<0.01 as compared to day 0. 
^ significantly different at p<0.01 as compared to saline-treated control. 
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Table 6 : Effect of UN treatment on serum parameters in intact animals, 
Duration of 
Treatment (days) 
Serum Creatinine (mg/dl) 
Control 
UN 
0 
0.4=t0.01 
0.41i{).01 
Creatinine clearance (ml/min/lOOgm body wt) 
Control 
UN 
BUN (mg/dl) 
Control 
CM 
Cholesterol (mg/dl) 
Control 
UN 
Phospholipid (mg/dl) 
Control 
UN 
Phosphate(umole/ml) 
Control 
UN 
034b0.01 
0.33±0.01 
2Qtl.O 
22tl.2 
54.52i3.0 
54b4.0 
0.61=0.02 
0.59tfc0.03 
2.40tb0.12 
2.3ftfc0.11 
5 
O.45±0.011 
0.89±0.07*f 
0.32H).011 
0.13±0.01*f 
22tl.l 
45±2.0*t 
56.4±4.0 
70bfc3.8*f 
0.61±0.02 
1.2±0.04*T 
2.41±0.11 
1.65±0.10 
Results are mean± SEM of five different experiments. 
* significantly different at p<0.01 as compared to day 0. 
^ significantly different at p<0.01 as compared to saline-treated control. 
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Intergroup comparison of GM-treated animals showed that GFR was maximally 
decreased in animals treated with GM for 10 days (0.34 on day 0 to 0.12 on day 10). 
However, no ilirther decrease in GFR was observed in animals treated upto 12 or 15 
days compared to 10 days treatment (Table 5). The change in GFR in saline-treated 
control rats was insignificant. 
Effect of GM or UN on urinary enzymes: 
No significant changes in urinary GGtase, AlkPase, LDH and AcidPase activities 
were observed in control animals at any time point tested (Table 7). In GM-treated 
animals urinary GGtase, LDH and AcidPase progressively increased over the time 
course of the experiment compared to both saline-treated control values and 
pretreatment values. However, the increase in activities in 12 day and 15 day treated 
rats were less compared to 10 day treatment (Table 7). A different pattern of urinary 
excretion of AlkPase was, however, noted. The AUcPase activity increased maximally 
on day 5 and showed lesser enhancement on prolonged treatment/exposure till day 10 
with slight fall in the percent increase being noted on day 12 and 15 (Table 7). 
UN-treated rats also showed significant increase in urinary activity of LDH, 
GGtase and AcidPase (200%, 250% and 300% respectively) compared to saline-
treated control and/or pretreatment values. The urinary AlkPase activity in UN-
treated rats increased by 50%, however, the rise in AlkPase activity was significantly 
less compared to that noted for LDH, GGtase and AcidPase (Table 8). 
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Table? : Effect of GM treatment on urinary enzymes in intact animals. 
Duration of 
Treatment (days) 0 5 8 10 12 15 
GGtase (units/nunole creatinine) 
Conlrol 22.3±1.0 23.08±1.6 2Z76tl.9 23.23^2.0 22.15±1.7 22.3±2.1 
OVI 22.15±1.90 52.6±3.8*^ 66.7±4.8*t 96.(>±6.1*t 75.0i:5.7*t 65.3±5.1*T 
AlkPase (units/mmole creatinine) 
Control 9.5±1.0 9.85±1.2 923±0.9 9.5±1.5 9.&fcl.0 iatl.2 
GM 9.2tl.O 18.86±2.2*^ 23.33±2.8*f 28.&±3.2*t 24.64^2.7*^ 22.3±1.1*^ 
AcidPase (units/mmole creatinine) 
Control 3.2rf).2 3.54i0.4 3.07±0.35 3.3di0.4 3.07±0.39 3.54±0.4 
CM 3.4t0.3 7.1±0.6*T 10.33±0.9*t 13.6±1.0*t 13.6±12*t 7.63±l.l*t 
LDH (units/mmole creatinine) 
Control 1.5±0.08 1.4±0.07 1.5±0.05 1.54di0.07 1.4±0.065 1.54±0.05 
OVI 1.4ct0.03 3.71±0.2*^ 5.0tt0.3*^ 7.2±0.5*T 5.71±0.6*t 4.6±0.5*t 
Results are mean± SEM of five different experiments. 
* significantly different at p<0.01 as compared to day 0, 
^ significantly different at p<0.01 as compared to saline-treated control. 
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Table 8 : Effect of UN treatment on urinary enzymes in intact animals, 
Duration of 
Treatment (days) 
GGtase (units/mmole creatinine) 
Control 
UN 
AlkPase (units/mmole creatinine) 
Control 
UN 
AcidPase (units/mmole creatinine) 
Control 
UN 
LDH (units/mmole creatinine) 
Control 
UN 
0 
22.3±1.0 
22.2±1.90 
9.Stl.0 
9.3±1.0 
3.2t0.2 
3.3±0.3 
1.5±0.08 
1.49iO.03 
5 
23.0&tl.6 
80.0±3.8*T 
9.85il.2 
14.7±1.2*^ 
3.54±0.4 
14.1i0.6*t 
1.4±0.07 
4.2±0.2*^ 
Results are mean± SEM of five different experiments. 
* significantly different at p<0.01 as compared to day 0. 
^ significantly different at p<0.01 as compared to saline-treated control. 
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Blood Chemistry: 
In addition to serum creatinine, renal function was also evaluated by BUN levels. 
No significant difference in BUN level was observed in saline-treated group at any 
time compared to pretreatment (base line) value. Compared to values obtained from 
saline-treated control groups and/or pretreatment value, GM-treated groups showed 
an elevated BUN level, A significant increase in BUN level was noted on day 6, 9, 
11,13 and 16 (Table 5), with maximum increase on the 11"^  day i.e. after 10 days of 
CM treatment. UN-treated rats had also a 3 fold higher BUN level compared to 
control or pretreatment level. Saline-treated control animals demonstrated relatively 
constant values for Inorganic Phosphate (Pi), Phospholipid (PL) and total Cholesterol 
(CL) over the experimental period (Table 5). The effect of GM and UN on CL, Pi 
and PL are shown in Table 5 and 6. In GM-treated rats, a significant increase 
occurred in CL, Pi and PL levels at all time periods during the course of GM 
treatment. However, the magnitude of change was greater on ll"' day i.e. after 10 
days of GM administration. UN treatment also significantly enhanced the CL, Pi and 
PL levels compared to control group (Table 6). 
Effect of GM or UN on the activities of BBM-marker enzymes: 
The kidneys were harvested from the animals and brush border membranes were 
isolated from whole cortex. The effect of GM and UN was determined on BBM-
marker enzymes and enzymes of other organelles/membranes. Relative enrichment of 
the BBM preparation was documented enzymatically, using the apical membrane 
markers AlkPase, GGtase, LAP and the basolateral membrane marker Na^-
K^ATPase. The results indicate that the membrane preparation was several fold 
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purified as the activities of Na -^K''ATPase was not enriched in BBMV as compared 
to cortical homogenate (CH), while BBM marker en2ymes showed marked 
enrichment (9-11 fold enrichment). BBM marker enzyme activities especially those of 
AlkPase and GGtase were about 10 fold enriched in BBMV compared to CH 
(Table 9 and 13). Only minor contamination was observed when two marker enzymes 
of intracellular organelles; AcidPase for lysosome and SDH for mitochondria were 
assayed. 
The specific activities of AlkPase, GGtase, Mtase and LAP were significantly but 
differentially decreased in BBMV from GM-treated rats (day 5 group) compared to 
control rats (Table 9 and 10). Further decline in the activities was observed when GM 
administration was continued for 8 days or 10 days (Fig. 7 and 8). The activities of 
marker enzymes noted after 12 and 15 days of GM administration were also 
significantly lower than the respective saline-treated controls, however, the extent of 
decrease was less as compared to 10 day treatment. The maximum decrease in 
enzyme activities was observed after 10 days of GM administration (AlkPase -56%, 
GGtase -45%, Mtase -52% and LAP -41%) indicating a greater damage to the 
proximal tubular membrane (Table 9 and 10). Fig. 9 and 10 depict the effect of UN 
intoxication on the activities of AlkPase, GGtase, Mtase and LAP. The specific 
activities of BBMV markers were significantly but differently decreased in UN-
treated rats compared to control rats (Table 11 and 12). However, in CH the 
activities of the marker enzymes were not changed significantly by GM or UN 
administration (Table 13 and 14) as compared to control. 
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Table 9 : Effect of GM treatment on the activities of (A) alkaline phosphatase (AlkPase) 
and (B) y-glutamyl transferase (GGtase) in BBMVs isolated from whole cortex 
(BBMV-WC). 
(A) 
Duration of 
Treatment (days) 
Control 
GM 
5 
148±8 
88.27±3* 
(40%) 
8 
145±6 
76.82±4* 
(47%) 
10 
150±5 
65.5±3* 
(56%) 
12 
147±5 
72±4* 
(50%) 
15 
146±6 
77.65±4* 
(47%) 
(B) 
Duration of 
Treatment (days) 
Control 
GM 
5 
355±8 
233±9* 
(34%) 
8 
350±9 
210±8* 
(40%) 
10 
365±7 
200±8* 
(45%) 
12 
360±10 
210±9* 
(40%) 
15 
363±11 
225±7* 
(38%) 
Results (specific activity expressed as pimoles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 from respective controls. 
Values in parenthesis represent percent decrease from respective controls. 
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Table 10 : Effect of GM treatment on the activities of (A) Maltase (Mtase) and 
(B) Leucineaminopeptidase (LAP) in BBMVs isolated from whole cortex 
(BBMV-WC). 
(A) 
Duration of 
Treatment (days) 
Control 
GM 
5 
260±10 
161±8* 
(38%) 
8 
255±9 
140±9* 
(45%) 
10 
257±12 
123.4±5* 
(52%) 
12 
262±10 
140.1 ±6* 
(46.5%) 
15 
264±11 
147.2±5* 
(44%) 
(B) 
Duration of 
Treatment (days) -5 8 10 12 15 
Control 
GM 
18±1.2 
12.52±0.9* 
(30%) 
17.2±1.2 17.4±1.3 18.2±1.2 18.4±1 
11.04±0.8* 10.28±0.5* 11.5±0.9* 12.1±1* 
(36%) (41%) (37%) (34%) 
Results (specific activity expressed as ^moles/mg protein/h) are Mean ± SEM of five 
dififerent preparations. 
* significantly different at p<0.01 from respective controls. 
Values in parenthesis represent percent decrease from respective controls. 
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Fig 7 : Specific activities of (A) Alkaline phosphatase (AlkPase) and (B) y-glutaniyl 
transferase (GGtase) in BBMVs isolated from whole cortex of GM-treated and 
saline-treated control rats. 
Each bar represents results (Mean ± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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300-, 
(A) 
Control 
Gentamicin 
(B) Control 
Gentamicin 
FigJ: Specific activities of (A) Maltase (Mtase) and (B) Leucineaminopeptidase(LAP) in 
BBMVs isolated from whole cortex of GM-treated and saline-treated control rats. 
Each bar represents results (Mean± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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BBMV-WC BBMV-SC BBMV-JMC 
BBM\'-WC BBMV-SC BBM\'-JMC 
Fig 9 : Specific activities of (A) Alkaline phosphatase (AlkPase) and (B) y-glutamyl 
transferase (GGtase) in BBMVs from whole cortex (WC), superficial cortex, (SC) 
and juxtameduilary cortex (JMC) of UN-treated and saline-treated control rats, 
Each bar represents results (Mean± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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BBM '^-WC BBMV-SC BBMV-JMC 
BBNr/-WC BBMV-SC BBM\'-]MC 
Fig 10 : Specific activities of (A) Maltase (Mtase) and (B) Leucineaminopeptidase (LAP) 
in BBMVs isolated from whole cortex (WC), superficial cortex (SC) and 
juxtamedullary cortex (JMC) of UN-treated and saline-treated control rats. 
Each bar represents results (Mean ± SEM) of five different preparations. 
* Significantly different fi"om saline-treated control at p<0.05 or higher degree by 
group t-test. 
I i Ace. No ) 
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Table 11: Effect of UN treatment on the activities of (A) alkaline phosphatase (AlkPase) 
and (B) y-glutamyl transferase (GGTase) in BBMVs isolated from whole cortex 
(BBMV-WC), superficial cortex (BBMV-SC) and juxtamedullary cortex 
(BBMV-JMC). 
(A) 
(B) 
Control 
UN 
1 
Control 
UN 
BBMV-WC 
145.8±3.0 
89.38±2.0* 
(38%) 
BBMV-WC 
350±11 
190.8±12* 
(45%) 
BBMV-SC 
151.51±5.0 
104.33±4.0* 
(31%) 
BBMV-SC 
300.3±18 
186.3±11* 
(38%) 
BBMV-JMC 
126.33±3.0 
53.33±2.0* 
(58%) 
BBMV-JMC 
600.5±22 
125.16±10* 
(79%) 
Results (specific activity expressed as (xmoles/mg protein/h) are Mean ± SEM of five 
different preparations, 
* significantly different at p<0.01 from respective controls. 
Values in parenthesis represent percent decrease from respective controls. 
78 
Table 12 : Effect of UN treatment on the activities of (A) Maltase (Mtase) and 
(B) Leucineaminopeptidase (LAP) in BBMVs isolated from whole cortex 
(BBMV-WC), superficial cortex (BBMV-SC) and juxtamedullary cortex 
(BBMV-JMC;. 
(A) 
Control 
UN 
0 
Control 
UN 
BBMV-WC 
256.3±12 
161.3±10* 
(37%) 
BBMV-WC 
18.3±1.2 
10.89±1.0* 
(40%) 
BBMV-SC 
300±18 
204±8* 
(32%) 
BBMV-SC 
14.5±1.0 
10.15±0.9* 
(30%) 
BBMV- JMC 
201.5±12 
100.6±7* 
(50%) 
BBMV-JMC 
37.0±3.0 
14.65±1.4* 
(65%) 
Results (specific activity expressed as |imoles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 from respective controls. 
Values in parenthesis represent percent decrease from respective controls. 
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Table 13; Effect of GM treatment on the activities of Alkpase, GGtase, Maltase and 
LAP in cortical homogenate (CH), 
Alkpase 
Duration of 
Treatment (days) 
Control 
GM 
5 
15.4±1.0 
14.4±0.5 
8 
16.0±0.9 
14.2±0.8 
10 
15.8±0.8 
13.6±0.7 
12 
15.5±1.0 
13.4±0.7 
15 
15.7±0.9 
13.6±0.7 
GGtase 
Duration of 
Treatment (days) 
Control 
GM 
5 
30.5±2.0 
25".2±2.0 
8 
32.4±1.9 
24.6±1.8 
10 
29.6±1.8 
23.7±1.7 
12 
30.9±2.0 
24.6±1.6 
15 
32.8±2.0 
24.4±1.5 
Maltase 
Duration of 
Treatment (days) 
Control 
GM 
5 
25.0±2.0 
20.1±1.5 
8 
26.5±2.0 
19.8±1.6 
10 
25.8±1.9 
20.1±1.5 
12 
24.4±1.8 
18.9±1.4 
15 
26.4±2.0 
19.2±1.3 
LAP 
Duration of 
Treatment (days) 
Control 
GM 
5 8 10 
1.60±0.095 1.70±0.098 1.64±0.091 
1.28±0.054 1.30±0.051 1.29±0.051 
12 15 
1.71±0.010 1.61±0.092 
1.31±0.054 1.38±0.053 
Results (specific activity expressed as |amole/mg protein/hr) are Mean ± SEM for five 
different preparations. 
Each preparation includes kidneys fi"om 5-6 rats in each group. 
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Table 14; Effect of UN treatment on the activities of AlkPase, GGtase, Maltase and 
LAP in the homogenates of whole cortex (WC), superficial cortex (SC) 
and juxtameduUary cortex (JMC). 
AlkPase 
Control 
GM 
WC SC JMC 
14.1±1.0 15.U1.1 12.3±1.1 
11.9±1.1 13.1±1.1 9.6±0.9 
GGtase 
Control 
GM 
WC SC JMC 
30.1±2.0 29.8±2.0 56.2±3.0 
24.3±2.0 25.2±1.6 44.4±1.7 
Maltase 
Control 
GM 
WC SC JMC 
25.4±2.0 29.4±2.1 20.1±1.4 
20.1±1.6 25.6±2.0 15.8±1.2 
LAP 
Control 
GM 
WC SC JMC 
1,90±0.09 1,40±0.08 3.80±0.22 
1.53±0.05 1.10±0.09 3.04±0.21 
Results (specific activity expressed as lamole/mg protein/hr) are Mean ± SEM for five 
different preparations. 
Each preparation includes kidneys fi-om 5-6 rats in each group. 
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Since the activities of BBM marker enzymes in CH were not significantly 
different in control, GM-treated and UN-treated groups, the activities (expressed as 
total enzyme units) of the enzyme were further analyzed. Total activities of the 
membrane-bound enzymes were found to decline, while the activities in the 
supernatant (free enzymes/ enzymes released due to GM toxicity) were found to 
increase in proportion to the duration of GM treatment upto day 10 (Fig. 11 and 12). 
On day 13 and 16 (12 and 15 days after GM administration), the activities of the free-
supernatant enzymes were still significantly high as compared to the respective 
control values, however, the magnitude of increase was less compared to 10 day 
GM-treated groups. The UN administration also caused significant increase in the 
free-supernatant enzymes with concomitant decrease in membrane bound enzymes as 
compared to the control groups (Fig. 13 and 14). 
The preliminary studies showed that 10 day GM administration caused maximum 
damage to kidney as evaluated by GFR, BUN level and BBM marker enzyme 
activities. The results also indicate that long term GM treatment after 10 days showed 
attenuation with no fiarther change being observed even with continued GM 
administration. Thus for further studies the animals were injected intraperitonially 
with a solution of GM sulfate (80mg/Kg b. wt./day) for 10 days. The animal protocol 
for UN treatment (see "Methods" for details) was same as used for previous 
experiments. 
As observed in our preceding results (Fig. 7-10, Table 9-12), the activities of 
BBM marker enzymes were markedly lowered in GM- as well as UN-treated rats 
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F'g 11: Total enzyme activity (|j,mole/h) of (A) AlkPase and (B) GGtase in thehomogenate of 
renal cortex from saline-treated control (fH) and GM-treated (@) rats 
Values are represented as Mean ± SEM for three diflferent preparations 
* significantly different from control at p<0 05 or higher degree by group t-test 
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Fig 12 : Total enzyme activity (|a.mole/h) of (A) Mtase and (B) LAP in the homogenate of 
renal cortex from saline-treated control ( B ) and GM-treated ( 0 ) rats. 
Values are represented as Mean ± SEM for three different preparations. 
* significantly different from control at p<0,05 or higher degree by group t-test. 
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Fig. 13 : Total enzyme activities of (A) Alkpase and (B) GGtase in the homogenates of 
whole cortex (WC), superficial cortex (SC) and juxtameduUary cortex (JMC) 
from GM (10 day treatment), UN (5 day after treatment) and saline-treated 
control rats. (Q)-bound, (•)-free. 
Values are represented as Mean ± SEM of five different BBMV preparations. 
* significantly different from control at p<0.01 or higher degree by group t-test. 
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Fig. 14: Total en2yme activities of (A) Maltase and (B) LAP in the homogenates of whole 
cortex (WC), superficial cortex (SC) and juxtamedullary cortex (JMC) from GM 
(10 day treatment), UN (5 day after treatment) and saline-treated control rats. 
(•)-bound, (•)-free. 
Values are represented as Mean ± SEM of five different BBMV preparations. 
* significantly different fi-om control at p<0.01 or higher degree by group t-test. 
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compared to control rats. The decrease in the activities of AlkPase, GGtase, Mtase 
and LAP in BBMV from GM- and UN-treated rats relative to controls was 
manifested by kinetic features of enzymes. Apparent Km and Vmax values were 
determined graphically from double-reciprocal plots (Fig. 15-18). BBM preparations 
from control and treated rats were always tested in one experimental day under 
identical conditions. Our data show that Vmax values (expressed as )xmoles/mg 
protein/h) of the BBM enzymes were significantly lowered both in GM- and UN-
treated rats as compared to respective control rats. The apparent Km values for GM-
and UN-treated groups showed insignificant change compared to controls (Table 15-
18). 
As morphologic and other studies indicated that the nephrons from the superficial 
cortex are greatly damaged by the GM while the nephrons from the deep cortex or 
the pars recta are greatly damaged by UN [43], BBM-vesicles were isolated from 
superficial cortex (BBMV-SC) and juxtamedullary cortex (BBMV-JMC) from GM-
or UN-treated rats as well as control rats and the damage caused by GM or UN was 
extensively studied in subsequent experiments. The activities of BBM marker 
enzymes were decreased both in BBMV-SC and BBMV-JMC by UN and/or GM 
administration when compared to control rats. In GM-treated rats the decrease in the 
activities of all the BBM marker enzymes studied was greater in BBMV-SC than 
BBMV-JMC (Fig. 19 and 20, Table 19 and 20). However, in UN-treated rats the 
decline in activities was greater in BBMV-JMC than BBMV-SC (Fig. 9 and 10, 
Table 11 and 12). The results further indicate that the decrease in the enzyme 
activities was mainly due to decrease in apparent Vmax values as Km remained 
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Fig. 15 : Kinetics of Alkpase in BBMV-WC from GM (10 day treatment), UN (5 day 
after treatment) and saline-treated control rats. (•)-control, (C))-GM, (A)-UN. 
Lines are drawn with the mean value of three separate experiments. 
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Fig. 16: Kinetics of GGtase in BBMV-WC fromGM (10 day treatment), UN (5 day after 
treatment) and saline-treated control rats. (•)-control, (O)-GM, (A)-UN. 
Lines are drawn with the mean value of three separate experiments. 
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Fig. 17 : Kinetics of Maltase in BBMV-WC from GM (10 day treatment), UN (5 day 
after treatment) and saline-treated control rats. (•)-control, (CD)-GM, (A)-UN. 
Lines are drawn with the mean value of three separate experiments. 
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Fig. 18 : Kinetics of LAP in BBMV-WC from GM (10 day treatment), UN (5 day after 
treatment) and saline-treated control rats. (•)-control, (O)-GM, (A)-UN. 
Lines are drawn with the mean value of three separate experiments. 
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Table 15: Effect of (A) GM (10 days treatment) and (B) UN (5 days after treatment) on 
kinetic parameters of BBM-Allcaline Phosphatase (AlkPase) isolated from whole 
cortex (BBMV-WC), superficial cortex (BBMV-SC) and juxtamedullary 
cortex (BBMV-JMC). 
(A) 
(B) 
BBMV-WC 
BBMV-SC 
BBMV-JMC 
BBMV-WC 
i3BMV-SC 
BBMV-JMC 
Control 
GM 
Control 
GM 
Control 
GM 
Control 
UN 
Coiilml 
UN 
Control 
UN 
V 
max 
(lomoles/mg protcin/h) 
150.00±7 
88.23±4* 
250.00±10 
136.36±6* 
156.25±8 
117.00±7* 
V 
max 
(|imoles/mg protein/h) 
150.00±7 
107.00±6* 
250.00-1-10 
166.66±6* 
156.25±8 
93.75±5* 
K_^(x 10-^M) 
0.114±0.005 
0.119±0.006 
0.190±0.009 
0.200±0.010 
0.200±0.009 
0.200±0.010 
K_^(x IG-^M) 
0.114±0.005 
0.117±0.007 
0.190J-0.009 
0.200±0.010 
0.200±0.009 
0.200±0.010 
Values are Mean± SEM of five difierent preparations. 
Values are calculated from Lineweaver-Burlc plots (Fig 15,21 and 22). 
* significantly different at p<0.01 from respective controls. 
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Table 16; Effect of (A) GM (10 days treatment) and (B) UN (5 days after treatment) on 
kinetic parameters of BBM-y-glutamyl transferase (GGtase) isolated from whole 
cortex (BBMV-WC), superficial cortex (BBMV-SC) and juxtamedullary 
cortex (BBMV-JMC). 
(A) 
(B) 
BBMV-WC 
BBMV-SC 
BBMV-JMC 
BBMV-WC 
BBMV-SC 
BBMV-JMC 
Control 
GM 
Control 
GM 
Control 
G>1 
Control 
UN 
Control 
UN 
Control 
UN 
V 
max 
(|imoles/mg protein/h) 
250.00±12 
176.47±9* 
272.15±15 
166.66±9* 
500.00±20 
375.00±18* 
V 
max 
(|amoles/mg protein/h) 
250.00±12 
200.00±8* 
272.15±15 
214.30±11* 
500.00±20 
200.00±8* 
K^(xlO-3M) 
0.800±0.040 
0.760±0.040 
0.057±0.001 
0.055±0.001 
0.800±0.010 
0.880±0.050 
K_ (^x lO-^ M) 
0.800±0.040 
0.780±0.030 
0.057±0.001 
0.570±0.001 
0.800±0.010 
0.800±0.001 
Values are Mean ± SEM of five different preparations. 
Values are calculated from Lineweaver-Burk plots (Fig 16,23 and 24). 
* significantly different at p<0.01 from respective controls. 
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Table 17: Effect of (A) GM (10 days treatment) and (B) UN (5 days after treatment) on 
kinetic parameters of BBM-Maltase (Mtase) isolated from whole cortex 
(BBMV-WC), superficial cortex (BBMV-SC) and juxtamedullary cortex 
(BBMV-JMC). 
(A) 
(B) 
BBMV-WC 
BBMV-SC 
BBMV-JMC 
BBMV-WC 
BBMV-SC 
BBMV-JMC 
Control 
GM 
Control 
GM 
Control 
GM 
Control 
UN 
Control 
UN 
Control 
UN 
V 
max 
(|4molcs/mg protcin/h) 157.90±8 
98.70±4* 
358.85±15 
209.80±11* 
187.50±8 
150.01±7* 
V 
max 
(nmolcs/mg protcin/h) 
157.90±8 
112.80±6* 
358.85±15 
272.72±15* 
187.50±8 
93.75±4* 
K (x lO-^ M) 
m ^ ' 
20.00±1.0 
20.00±1.8 
10.00±0.5 
10.00±0.4 
13.33±0.5 
13.33±0.4 
K^(xlO-3M) 
20.00±1.0 
20.10±1.8 
10.00±0.5 
9.85i0.5 
13.33±0.5 
13.28±0.7 
Values are Mean ± SEM of five different preparations. 
Values are calculated from Lineweaver-Burk plots (Fig 17,25 and 26). 
* significantly different at p<0.01 from respective controls. 
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Table 18; Effect of (A) GM (10 days treatment) and (B) UN (5 days after treatment) on 
kinetic parameters of BBM-Leucineaminopeptidase (LAP) isolated from whole 
cortex (BBMV-WC), superficial cortex (BBMV-SC) and juxtamedullary 
cortex (BBMV-JMC). 
(A) 
(B) 
BBMV-WC 
BBMV-SC 
BBMV-JMC 
BBMV-WC 
BBMV-SC 
BBMV-JMC 
Control 
GM 
Control 
GM 
Control 
GM 
Control 
UN 
Control 
UN 
Control 
UN 
V 
max 
(l^ moles/mg protein/h) 18.75±1.3 
11.53±0.5* 
17.75±1.1 
10.03±0.5* 
38.46±2.0 
26.31±1.9* 
V 
max 
((imoles/mg protein/h) 18.75±1.3 
13.04±0.6* 
17.75±1.1 
12.93±0.6* 
38.46±2.0 
20.00±1.3* 
K^ixlO'M) 
0.40±0.020 
0.39±0.01 
0.40±0.018 
0.40±0.01 
0.26±0.020 
0.25±0.02 
K^(xlO-^M) 
0.40±0.020 
0.39±0.020 
0.40±0.018 
0.41±0.020 
0.26±0.020 
0.26±0.021 
Values are Mean± SEM of five different preparations. 
Values are calculated from Lineweaver-Burk plots (Fig 18,27 and 28). 
* significantly different at p<0.01 from respective controls. 
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Fig 19 : Specific activities of (A) Alkaline phosphatase (AlkPase) and (B) y-glutamyl 
transferase (GGtase) in BBMVs isolated from superficial cortex (SC) and 
juxtamedullary cortex (JMC) after 10 days of GM administration. 
Each bar represents results (Mean ± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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Fig 20 : Specific activities of (A) Maltase (Mtase) and (B) Leucineaminopeptidase (LAP) 
in BBMYs isolated from superficial cortex (SC) and juxtamedullary cortex (JMC) 
after 10 days of GM administration . 
Each bar represents results (MeaniSEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test, 
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Table 19 : Effect of 10 day GM treatment on the activities of (A) alkaline phosphatase 
(AlkPase) and (B) y-glutamyl transferase (GGtase) in BBMVs isolated from 
superficial cortex (BBMV-SC) and juxtamedullary cortex (BBMV-JMC). 
(A) 
Control 
GM 
BBMV-SC 
151.51±5.0 
53.05±4.0* 
(65%) 
BBMV-JMC 
126.33±3.0 
88.16±2.0* 
(30%) 
(B) 
BBMV-SC BBMV-JMC 
Control 
GM 
300.3±18 
150.6±10* 
(50%) 
600.5±22 
371.87±15* 
(38%) 
Results (specific activity expressed as |imoles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 from respective controls. 
Values in parenthesis represent percent decrease from respective controls. 
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Table 20; Eifect of 10 day GM treatment on the activities of (A) Maltase (Mtase) and 
(B) Leucineaminopeptidase (LAP) in BBMVs isolated from superficial cortex 
(BBMV-SC) and juxtamedullary cortex (BBMV-JMC). 
(A) 
Control 
GM 
BBMV-SC 
300±18 
120±8* 
(60%) 
BBMV-JMC 
201.5±12 
145.08±9* 
(28%) 
(B) 
Control 
GM 
BBMV-SC 
14.5±1 
7.75±0.5* 
(46.5%) 
BBMV-JMC 
37.0±3 
25.16±1.6* 
(32%) 
Results (specific activity expressed as j^inoles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 from respective controls. 
Values in parenthesis represent percent decrease from respective controls. 
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unchanged (Fig. 21-28). The activities of enzymes in SC-H as well as JMC-H were 
not found to be significantly different in treated or control rats (Table 14 and 21). 
When the activities of AlkPase, GGtase, Mtase and LAP were further analyzed, the 
activities of the membrane-bound enzymes both in SC-H as well as in JMC-H 
declined significantly in GM- and UN-treated rats compared to control rats. 
However, in supernatant (fi"ee or released enzymes) the activities were significantly 
enhanced in intoxicated rats as compared to control rats (Fig. 13 and 14). In GM-
treated rats the decline in membrane bound enzymes alongwith the increase in free 
enzymes was more pronounced in SC than JMC while in UN-treated rats the 
decrease in membrane bound and increase in free enzymes were greater in JMC than 
SC (Fig. 13 and 14). Results fi-om whole cortex, SC and JMC also indicate that GM 
affected AlkPase activity to a greater extent than GGtase activity while UN showed 
greater'effect on GGtase activity than AlkPase activity (Table 11 and 19), which may 
be due to different distribution of these enzymes along the nephron. These resuhs 
indicate that GM and UN, the two unrelated nephrotoxins cause differential damage 
to the proximal tubular membrane for diiferent populations of nephrons. 
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Fig. 2 1 : Kinetics of Allcpase in BBMV-SC from GM (10 day treatment), UN (5 day after 
treatment) .uid saline-treated control rats. (•)-control, (C))-GM, (A)-UN. 
Lines are drawn with the mean value of three separate experiments. 
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Fig. 22 : Kinetics of All<pase in BBMV-JMC from GM (10 day treatment), UN (5 day 
after treatment) and saline-treated control rats. (•)-control, (C))-GM, (A)-UN. 
Lines are drawn witli the mean value of three separate experiments. 
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Fig. 23: Kinetics of GGtase in BBMV-SC from GM (10 day treatment), UN (5 day after 
treatment) and saline-treated control rats. (•)-control, (O)-GM, (A)-IJN. 
Lines are drawn with the mean value of three separate experiments. 
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Fig. 24 : Kinetics of GGtase in BBMV-JMC from GM (10 day treatment), UN (5 day 
after treatment) and saline-treated control rats. (•)-control, ((D)-GM, (A)-UN. 
Lines are drawn with the mean value of three separate experiments. 
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Fig. 25: Kinetics of Maltase in BBMV-SC from GM (10 day treatment), UN (5 day after 
treatment) and saline-treated control rats. (•)-control, (O)-GM, (A)-UN. 
Lines are drawn with the mean value of three separate experiments. 
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Fig. 26: Kinetics of Maltase in BBMV-JMC from GM (10 day treatment), UN (5 day 
after treatment) and saline-treated control rats. (•)-control, (O)-GM, (A)-UN, 
Lines are drawn with the mean value of three separate experiments. 
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Fig. 27 : Kinetics of LAP in BBMV-SC fromGM (10 day treatment), UN (5 day after 
treatment) and saline-treated control rats. (•)-control, (O)-GM, (A)-IJN. 
Lines are drawn with the mean value of three separate experiments. 
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Fig. 28: Kinetics of LAP in BBMV-JMC from GM (10 day treatment), UN (5 day after 
treatment) and saline-treated control rats. (•)-control, (O)-GM, (A)-UN. 
Lines are drawn with the mean value of three separate experiments. 
108 
Table 21: Effect of 10 day GM treatment on the activities of AlkPase, GGtase, 
Maltase and LAP in the homogenates from superficial cortex (SC) and 
juxtamedullary cortex (JMC). 
Control 
GM 
Control 
GM 
AlkPase 
SC JMC 
15.2±1.0 13.1±1.1 
13.4±0.9 11.8±0.9 
Maltase 
SC JMC 
28.4±2.0 19.2±1.5 
23.2±2.0 17.8±1.2 
GGtase 
SC JMC 
29.4±2.0 55.4±3.0 
25.4±2.1 47.4±3.1 
LAP 
SC JMC 
1.5±0.10 3.5±0.21 
1.3±0.11 2.9±0.19 
Results (specific activity expressed as |imole/mg protein/hr) are Mean ± SEM for five 
different preparations. 
Each preparation includes kidneys from 5-6 rats in each group. 
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It is well established that loss of renal epithelial cell viability due to ischemic or 
toxic ARF results in the accumulation of cellular debris from injured tubule cells 
[93,238]. This leads to cell necrosis and death and renal excretory functions are 
altered [238]. The proximal tubular segment of the nephron was shown to be chief 
site of the damage due to ischemia or toxic insult [46,240,287,288]. Histological and 
morphological injury following GM administration occurs in the Si and S2 portions of 
the proximal tubules, whereas UN primarily affects the S3 portion. The kidney 
responds to toxic insult or ischemia with efifacement of the proximal tubular BBM as 
is evident by the decreased activities of marker enzymes associated with the 
membrane [46,47]. 
In the first part of this study, we undertook a series of experiments designed to 
better characterize the nephrotoxic effect of GM on PT cells after different durations 
of treatment. The activities of AlkPase, GGtase, Mtase and LAP in BBMVs isolated 
from whole cortex, declined markedly upto 10 days of GM treatment but with 
prolonged, 12 day and 15 day exposure, there was no further decrease in the 
activities of marker enzymes. Changes in the activities of carbohydrate metabolic 
enzyme (Result II), serum creatinine, BUN, proteinuria and enzymuria also showed 
the same pattern, with maximum change observed in 10 days of GM treatment and 
attenuation thereafter. These findings suggest that animals had become "resistant" or 
"tolerant" to a long-term continuous GM treatment. There is strong evidence in rat 
long-term gentamicin (LTG) model that after 10-14 days of GM treatment, 
regeneration of proximal tubular (PT) epithelium begins even with continued GM 
treatment. 
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Proximal tubular epithelium being selectively sensitive to GM undergoes necrosis 
and slough into the lumen of the nephron within a few days of treatment at toxic 
doses. It has been shown that if a sublethal but nephrotoxic dose of GM is 
administered, the mammalian kidney can repair the injured nephrons. The survivLig 
epithelial cells flatten, divide and migrate along the denuded basement membrane to 
reestablish the tubular epithelium. The process begins after several days following 
GM administration, with a regenerated epithelium present in the following weeks 
[133,134,289]. Regeneration however is limited to pre-existing nephrons [290]. 
Studies have shown that recovery of PT cells in long-term GM treatment as well as 
development of tolerance involves either tubular regeneration or a selective inhibition 
of GM uptake across the apical membrane or both [163,164,237,291]. 
The primary aim of the present study was to localize the effect of GM or UN 
treatment on the proximal tubular brush border membrane (BBM), the major 
fimctional site of nephron. BBM were isolated from superficial (SC) and deep (JMC) 
rat renal cortex after GM or UN treatment. The activities of BBM marker enzymes: 
AlkPase, Mtase, GGtase and LAP were determined to examine the structural and 
functional integrity of proximal tubules after toxic insult. The activities of AlkPase, 
Maltase, GGtase and LAP in BBMV isolated from SC and JMC, after GM treatment, 
declined markedly (Table 19 and 20). Further analysis of these marker enzymes, 
showed that the activities increased in supernatant with a corresponding decrease in 
the pellet of cortical homogenate (membrane bound enzymes) (Table 21). This 
suggests that BBM is severely damaged and may have been partially effaced during 
toxic insult. Due to effacing, the marker enzymes and other components might have 
111 
dissociated from the BBM into the supernatant. Tiiis niight also explain the increased 
activity of GGtase and AlkPase in urine after GM and UN treatment (Table 7 and 8) 
as also observed by Whiting [264], The activity pattern in BBMV(s) isolated from SC 
and JMC indicates that the activities of these marker enzymes decreased to a greater 
extent in BBMV-SC than in BBMV-JMC due to GM treatment while UN caused 
greater effect in BBMV-JMC than BBMV-SC. Similar to the observations in whole 
cortical homogenate, the activities of BBM marker enzymes AlkPase, GGtase, LAP 
and Mtase increased in the supernatant (free enzymes) and declined in the membrane 
bound fraction, from SC and JMC of UN- and GM-treated rats. The decrease in 
membrane bound enzymes and the simultaneous increase in the free enzymes was 
greater in SC than JMC in GM-treated rats. In UN-treated rats the effect was greater 
in JMC than SC. Since marker enzymes have different localization along the proximal 
tubule, they may possess different susceptibility to toxic insult. AlkPase and Maltase 
are considered to be the marker enzymes of renal SC zone or pars convoluta (Si and 
S2 subsegment) of the proximal tubule while GGtase alongwith LAP is considered to 
be the marker of JMC cortex or pars recta (S3 subsegment) of the proximal tubule 
(PT). The results show that activities of AlkPase and Maltase are more susceptible to 
GM while UN treatment causes greater effect on GGtase and LAP than AlkPase or 
Maltase activities. The results may suggest that BBM from deep PT subsegments is 
greatly damaged by UN while BBMVs of superficial PT region are greatly affected 
by GM. The data is in general agreement with the earlier morphological, histological 
and biochemical studies which show greater damage to the pars convoluta (Si and S2 
subsegments) by GM and to the pars recta (S3 subsegment) of proximal tubule by UN 
[43]. 
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Kinetic studies showed that the decline .in activities of the marker enzymes was 
largely due to decrease in Vmax with no or insignificant effect on Km values (Table IS-
IS). This indicates that the decrease in enzyme activity by GM and UN is mainly due 
to loss of active enzyme molecules per unit of BBM, 
The disappearance of brush border membrane is a prominent index of renal 
damage. Various nephrotoxins such as cephaloridine, mercuric chloride, puromycin 
aminonucleoside, vinblastine and potassium dichromate [66,292-296] result in loss 
of microvilli fi-om proximal tubular cells and the damage caused by drugs was greater 
and regeneration process required longer time. However, if the damage is not severe 
enough to cause cellular necrosis, the BBM may be reformed and the integrity of the 
proximal tubules can be restored as reported in long-term GM treatment [237]. 
Results of the present study show the attenuation of the effect of GM treatment after 
10 days of GM treatment, indicating that the regeneration of the damaged PT and 
hence restoration of its functions may have started thereafter. The studies also show 
that GM and UN act at different sites along the nephron. GM shows greater effect in 
superficial cortex pars convoluta (Si and S2 subsegments) while UN damages deep 
cortex pars recta (Si subsegment) to greater extent than superficial cortex. However, 
our results show that the effect of GM is not confined exclusively to superficial 
region as considerable damage is caused to deep cortex which is contrary to some of 
the earlier studies [100,135,297]. The reason for this disagreement may be the 
variability in dose or duration of treatment, sex or age of rats chosen for study and 
time of injection/administration of the drug, as these factors have been shown to play 
a significant role in GM nephrotoxicity [298,299]. 
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Effect of GM and UN on the activities of certain enzymes of carbohydrate 
metabolism: 
The jfunction of kidney i.e. the reabsorption of various ions and solutes depends 
on the continuous energy supply as ATP. The generation of ATP is the contribution 
of various metabolic pathways including glycolysis and oxidative metabolism. The 
relationship between the Oa-consumption and major function of kidney as transport 
of Na"^  is well documented. The acute renal failure produced by toxic insult results in 
the reduction of the Oi-consumption in the kidney tissue due to the mitochondrial 
damage which is apparent from the variations of different enzymes of various 
metabolic pathways especially those of glucose metabolism [300]. 
To determine the effect of GM or UN on the enzymes of various metabolic 
pathways, GM was injected for 5, 8, 10, 12 and 15 days and UN was injected as 
single bolus dose 5 days prior to sacrifice. After the sacrifice, kidneys were harvested, 
homogenized (see "Methods") and the activities of several enzymes eg, LDH 
(glycolysis), MDH, SDH, ICDH (TCA cycle), G6Pase and FBPase 
(gluconeogenesis), G6PDH (HMP-shunt pathways) and ME (an enzyme of 
biosynthetic importance) were determined in the homogenates of the cortex and 
medulla. The results are summarized in Fig. 29-43, Table 22-36. Five day treatment 
of GM caused an increase in LDH activity both in cortex (20%) and medulla (18%). 
Treatment of GM for 8 and/or 10 days showed further increase in LDH activity both 
in cortex (after 8 days: 34%, after 10 days: 43%) and in medulla (after 8 days: 30%, 
after 10 days: 39%). There was no further increase in LDH activity after 12 and 15 
days of GM treatment, however the activity was still higher as compared to 
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Fig 29 : Specific activity of Lactate deiiydrogenase (LDH) in the homogenates of kidney 
(A) cortex and (B) medulla from saline-treated control and GM-treated rats. 
Each bar represents results (Mean ± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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Fig 30 : Specific activities of (A) Lactate dehydrogenase (LDH) and (B) Succinate 
dehydrogenase (SDH) in the homogenates of Kidney Cortex, Medulla, superficial 
cortex (SC) and juxtameduUary cortex (JMC) from saline-treated control and 
UN-treated rats. 
Each bar represents results (Mean ± SEM) of five different preparations. 
* Significantly different fi-om saline-treated control at p<0.05 or higher degree by 
group t-test. 
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F i g J i : Specific activity of Malate dehydrogenase (MDH) in the homogenate of kidney 
(A) cortex and (B) medulla from saline-treated control and GM-treated rats. 
Each bar represents results (Mean ± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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Fig 32 : Specific activity of succinate dehydrogenase (SDH) in the homogenates of kidney 
(A) cortex and (B) medulla from saline-treated control and GM-treated rats. 
Each bar represents results (Mean± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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Fig 33: Specific activity of Isocitrate dehydrogenase (ICDH) in the homogenates of kidney 
(A) cortex and (B) medulla from saline-treated control and GM-treated rats. 
Each bar represents results (Mean ± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
119 
Qiitex Me^ luUa 
12-1 (B) • • Control 
vmm 
Cojtex Maiulla 
Fig 34 : Specific activities of (A) Malate dehydrogenase (MDH) and (B) Isocitrate 
dehydrogenase (ICDH) in the homogenates of Kidney Cortex, Medulla, superficial 
cortex (SC) and juxtamedullary cortex (JMC) from saline-treated control and 
UN-treated rats. 
Each bar represents results (Mean± SEM) of five different preparations. 
* Significantly diflFerent from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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Fig 35: Specific activity of Glucose-6 phosphatase (G6pase) in the homogenates of kidney 
(A) cortex and (B) medulla from saline-treated control and GM-treated rats. 
Each bar represents results (Mean± SEM) of five different preparations 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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Fig 36 : Specific activity of Fmctose-l,6-bisphosphatase (FBPase) in the homogenates of 
kidney (A) cortex and (B) medulla fi-om saline-treated control and GM-treated 
rats. 
Each bar represents results (Mean ± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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Fig 37: Specific activities of (A) Glucose-6 phosphatase (G6pase) and (B) Fructose-1,6 
bisphosphatase (FBPase) in the homogenates of Kidney cortex, medulla, 
superficial cortex (SC) and juxtameduUary cortex (JMC) from saline-treated 
control and UN-treated rats. 
Each bar represents results (Mean ± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test, 
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Fig 38 : Specific activity of Glucose-6 Phosphate dehydrogenase (G6DH) activity in the 
homogenates of kidney (A) cortex and (B) medulla from saline-treated control and 
GM-treated rats. 
Each bar represents results (Mean ± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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Fig 39 : Specific activities of (A) Glucose-6 Phosphate dehydrogenase (G6DH) and 
(B) Malic enzyme in the homogenates of Kidney Cortex, Medulla, superficial 
cortex (SC) and juxtamedullary cortex (JMC) from saline-treated control and 
UN-treated rats. 
Each bar represents results (Mean ± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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Fig 40 : Specific activity of Malic enzyme (ME) in the homogenate of kidney (A) cortex and 
(B) medulla from saline-treated control and GM-treated rats. 
Each bar represents results (Mean ± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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Fig 41 : Specific activity of Na'"-K''ATPase in the homogenates of kidney (A) cortex and 
(B) medulla from saline-treated control and GM-treated rats. 
Each bar represents results (Mean± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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Fig 42 : Specific activities of (A) Na '^-K^ATPase and (B) Acid Phosphatase (AcidPase) in 
the homogenates of Kidney cortex, Medulla, superficial cortex (SC) and 
juxtamedullary cortex (JMC) from saline-treated control and UN-treated rats. 
Each bar represents results (Mean ± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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Fig 43 : Activity of Acid Phosphatase (AcidPase) in the homogenates of kidney (A) cortex 
and (B) medulla from saline-treated control and GM-treated rats. 
Each bar represents results (Mean ± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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Table 22 : Effect of GM treatment on the activity of Lactate Dehydrogenase (LDH) in the 
homogenates of (A) whole cortex (WC) and (B) Medulla. 
(A) 
Duration of - , . . 
Treatment (days) 5 8 1 0 1 2 1 5 
Control 20.2±0.03 19.7±0.04 19.85±0.04 19.90±0.05 20.4±0.05 
GM 24.2±0.05* 26.4±0.06* 28.38±0.08* 27.06±0.06* 26.52±0.05* 
(20%) (34%) (43%) (36%) (30%) 
g) 
Duration of 
Treatment (days) 5 8 10 12 15 
Control 31.51±1.0 30±0.5 32.1±0.6 30.5±0.7 31.2±0.6 
GM 37.18±0.9* 39±1.0* 44.6±1.1* 40.26±1.0* 39.9±0.8* 
(18%) (30%) (39%) (32%) (28%) 
Results (specific activity expressed as (imoles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 firom respective controls. 
Values in parenthesis represent percent increase fi"om respective controls. 
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Table 23 : Effect of UN treatment on the activities of (A) Lactate Dehydrogenase (LDH) 
and (B) Succinate Dehydrogenase (SDH) in the homogenates of whole cortex 
(WC), medulla (M), superficial cortex (SC) and juxtamedullary cortex (JMC). 
(A) 
WC M SC JMC 
Control 22.0±0.5 30.0±0.6 21.4±0.4 29.85±0.6 
UN 25.96±0.4* 39.3±1.0* 25.68±0.6* 40.4±1.0* 
(18%) (31%) (20%) (36%) 
(B) 
WC M SC JMC 
Control 
UN 
12.21±0.5 
7.94±0.2* 
(35%) 
9.1±0.4 14.0±0.900 8.5±0.8 
5.46±0.3* 9.8±0.68* 4.6±0.2* 
(40%) (30%) (45%) 
Results (specific activity expressed as ^ moles/rngprotein/h for LDH and mEU/mg protein/h 
for SDH) are Mean± SEM of five different preparations. 
* significantly different at p<0.01 fi-om respective controls. 
Values in parenthesis represent percent change fi"om respective controls. 
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Table 24 : EfiFect of GM treatment on the activity of Malate Dehydrogenase (MDH) in the 
homogenates of (A) whole cortex (WC) and (B) Medulla. 
(A) 
Duration of 
Treatment (days) 
Control 
GM 
(B) 
Duration of 
Treatment (days) 
Control 
GM 
5 
109.31±3.0 
89.6±2.0* 
(19%) 
5 
102.2±2.0 
86.56±3.0* 
(15%) 
8 
110±4.0 
75.4±2.5* 
(31%) 
8 
100±3.0 
72.73±2.0'* 
(23%) 
10 
108±2.0 
67.7±2.0* 
(38%) 
10 
103±5.0 
• 70.2±2.0* 
(28%) 
12 
109±4.0 
85.25±3.0* 
(22%) 
12 
104±3.0 
84.78±3.0* 
(17%) 
15 
110±3.0 
89.48±3.0* 
(18%) 
15 
105±4.0 
88.43±2.0* 
(13%) 
Results (specific activity expressed as jimoles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 fi-om respective controls. 
Values in parenthesis represent percent decrease fi-om respective controls. 
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Table 25 : Effect of GM treatment on the activity of Succinate Dehydrogenase (SDH) in 
the homogenates of (A) whole cortex (WC) and (B) Medulla. 
(A) 
Duration of 
Treatment (days) 5 8 10 12 15 
Control 
GM 
12.1±0.42 
7.8±0.29* 
(36%) 
11.9±0.38 11.95±0.41 11.93J:0.37 12.21±0.35 
7.1±0.24* 6.1±0.22* 6.4±0.25* 7.0±0.28* 
(40%) (50%) (44%) (42%) 
(B) 
Duration of 
Treatment (days) 5 8 10 12 15 
Control 
GM 
9.1±0.36 
7.3±0.3* 
(20%) 
8.9±0.38 9.3±0.41 9.25±0.33 9.18±0.35 
6.67±0.29* 6.31±0.31* 6.75±0.35* 6.97±0.28* 
(25%) (32%) (27%) (26%) 
Results (expressed as mEU/mg protein/h) are Mean± SEM of five different preparations. 
* significantly different at p<0.01 fi*om respective controls. 
Values in parenthesis represent percent decrease fi-om respective controls. 
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Table 26 : Effect of GM treatment on the activity of Isocitrate Dehydrogenase (ICDH) in 
the homogenates of (A) whole cortex (WC) and (B) Medulla. 
( ^ 
Duration of . 
Treatment (days) 
5 8 10 12 15 
8.3±0.34 8.3±0.31 8.2±0.33 8.0±0.28 
5.8±0.21* 5.0±0.17* 5.3±0.17* 4.7±0.19* 
Control 
GM 
8.1±0.32 
6.1±0.19* 
(24%) (30%) (4 %) (35%) (28%) 
(B) 
Duration of 
Treatment (days) 5 8 10 12 15 
Control 6.2±0.10 6.0±0.11 6.4±0.10 6.1±0.11 6.3±0.1 
GM 4.96±0.09* 4.5±0.08* 4.5±0.07* 4.27±0.08* 4.75±0.05* 
(20%) (25%) (30%) (28%) (24%) 
Results (specific activity expressed as jimoles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 from respective controls. 
Values in parenthesis represent percent dcrease from respective controls. 
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Table 27; EflFect of UN treatment on the activities of (A) Malate Dehydrogenase (MDH) 
and (B) Isocitrate Dehydrogenase (ICDH) in the homogenates from whole 
cortex (WC), medulla (M), superficial cortex (SC) and juxtameduUary cortex 
(JMC). 
(Ai 
(B) 
Control 
UN 
'
Control 
UN 
WC 
112.4±3.0 
99.8±2.0* 
(11%) 
WC 
8.5±0.3 
6.29±0.25* 
(26%) 
M 
100.0±2.0 
74.0±1.5* 
(26%) 
M 
6.2±0.2 
3.8±0.12* 
(38%) 
SC 
107.0±5.0 
94.2±3.0* 
(12%) 
SC 
9.5±0.12 
7.1 ±0.3* 
(25%) 
JMC 
100.3±3.0 
73.6±2.0* 
(27%) 
JMC 
6.0±0.15 
3.6±0.2* 
(40%) 
Results (specific activity expressed as |j,moles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 from respective controls. 
Values in parenthesis represent percent decrease from respective controls. 
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Table 28; Effect of GM treatment on the activity of Glucose-6-Phosphatase (G6Pase) in 
the homogenates of (A) whole cortex (WC) and (B) Medulla. 
( ^ 
Duration of 
Treatment (days) 5 8 10 12 15 
Control 0.30±0.012 0.28±0.011 0.31±0.011 0.29±0.010 0.30±0.011 
GM 0.25±0.010* 0.24±0.012* 0.20±0.008* 0.21±0.008* 0.23±0.009* 
(17%) (20%) (33%) (30%) (23%) 
(B) 
Duration of 
Treatment (days) 5 8 10 12 15 
Control 0.20±0.006 0.20±0.007 0.188±0.007 0.198±0.009 0.20±0.010 
G M 0.18±0.006 0.17±0.005* 0.158±0.005* 0.16±0.007* 0.16±0.007* 
(10%) (15%) (21%) (20%) (19%) 
Results (specific activity expressed as |inioles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 fi-om respective controls. 
Values in parenthesis represent percent decrease fi-om respective controls. 
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Table 29; EflFect of GM treatment on the activity of Fructose 1,6 bisPhosphatase (FBPase) 
in the homogenates of (A) whole cortex (WC) and (B) Medulla. 
( ^ 
Duration of c o i rv i ' ) i c 
Treatment (days) '' ° ^ " ^'^ ^-' 
Control 0.86±0.08 0.87±0.078 0.86±0.081 0.84±0.075 0.85±0.079 
G M 0.688±0.052* 0.65±0.053* 0.62±0.05* 0.67±0.054* 0.68±0.051* 
(20%) (24%) (28%) (22%) (20%) 
m 
Duration of 
Treatment (days) 5 8 10 12 15 
Control 0.74±0.054 0.72±0.051 0.74±0.049 0.73±0.053 0.75±0.052 
GM 0.62±0.055* 0.60±0.051* 0.58±0.059*0.60±0.058=^ 0.61±0.062* 
(16%) (19%) (21%) (19%) (17%) 
Results (specific activity expressed as |j,moles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 fi'om respective controls. 
Values in parenthesis represent percent decrease fi'om respective controls. 
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Table 30; Effect of UN treatment on the activities of (A) Glucose-6-Phosphatase (G6Pase) 
and (B) Fructosel,6 bisPhosphatase (FBPase) in the homogenates of whole 
cortex (WC), medulla (M), superficial cortex (SC) and juxtamedullary cortex 
(JMC). 
(A) 
WC M SC JMC 
Control 0.32±0.01 0.19±0.01 0.35±0.02 0.255±0,01 
UN 0.23±0.009* 0.13±0.006* 0.225±0.01* 0.15±0.001* 
(27%) (32%) (35%) (42%) 
(B) 
WC M SC JMC 
Control 0.87±0.07 0.75±0.07 0.86±0.08 0.75±0.05 
UN 0.6±0.03* 0.4±0.023* 0.58±0.05* 0.48±0.04* 
(31%) (46%) (32%) (36%) 
Results (specific activity expressed as (amoles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 fi-om respective controls. 
Values in parenthesis represent percent decrease fi-om respective controls. 
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Table 31 : EflFect of GM treatment on the activity of Glucose-6-Phosphate Dehydrogenase 
(G6PDH) in the homogenates of (A) whole cortex (WC) and (B) MeduUa. 
(A) 
Duration of 
Treatment (days) 5 8 10 12 15 
1.3±0.06 1.31±0.04 1.29±0.03 1.27±0.04 
1.62±0.06* 1.68±0.06* 1.5±0.04* 1.45±0.05* 
(25%) (31%) (18%) (13%) 
Control 
GM 
1.28±0.05 
1.54±0.07* 
(20%) 
(B) 
Duration of 
Treatment (days) 5 8 10 12 15 
Control 0.94±0.03 0.941±0.03 0.943±0.04 0.944±0.02 0.94±0.04 
GM 0.98±0.04 1.08±0.05* 1.18±0.06* 1.15±0.04* 1.14±0.05 
(4%) (15%) (25%) (13%) 
Results (specific activity expressed as |imoles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 fi-om respective controls. 
Values in parenthesis represent percent increase from respective controls. 
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Table 32 : Effect of UN treatment on the activities of (A) Glucose-6-Phosphate 
Dehydrogenase (G6PDH) and (B) Malic Enzyme (ME) in the homogenates of 
whole cortex (WC), medulla (M), superficial cortex (SC) and juxtameduUary 
cortex (JMC). 
(A) 
WC M SC JMC 
Control 1.3±0.06 0.95±0.04 1.32±0.04 0.93±0.03 
UN 0.83±0.04* 0.55±0.02* 0.86±0.04* 0.5±0.02* 
(36%) (42%) (35%) (46%) 
(B) 
WC M SC JMC 
Control 
UN 
13.08±0.4 
17.0±0.6* 
(30%) 
9.2±0.3 
12.9±0.4* 
(40%) 
13.4±0.33 
17.7±0.6* 
(31%) 
9.2±0.31 
13.06±0.4* 
(40%) 
Results (specific activity expressed as fxmoles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 fi-om respective controls. 
Values in parenthesis represent percent change fi-om respective controls. 
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Table 33 : Effect of GM treatment on the activity of Malic Enzyme (ME) in the 
homogenates of (A) whole cortex (WC) and (B) Medulla. 
(A) 
Duration of 
Treatment (days) 
Control 
GM 
(B) 
Duration of 
Treatment (days) 
5 
12.9±0.51 
9.1±0.38* 
(29%) 
5 
8 
12.7±0.48 
8.7±0.35* 
(31%) 
8 
10 
13.1±0.55 
8.2±0.32* 
(37%) 
10 
12 
12.8±0.52 
8.4±0.35* 
(34%) 
12 
15 
12.98±0.55 
8.68±0.36* 
(33%) 
15 
Control 9.2±0.22 9.4±0.21 9.5±0.31 8.9±0.3 9.1±0.32 
GM 7.82±0.12* 7.7±0.18* 6.84±0.13* 6.76±0.14* 7.28±0.11* 
(15%) (18%) (28%) (24%) (20%) 
Results (specific activity expressed as nmoles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 fi-om respective controls. 
Values in parenthesis represent percent decrease fi^om respective controls. 
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Table 34 : Effect of GM treatment on the activity ofNa^-K^ATPase in the homogenates of 
(A) whole cortex (WC) and (B) Medulla. 
(A) 
Duration of 
Treatment (days) 
Control 
GM 
(B) 
Duration of 
Treatment (days) 
5 
5.01±.19 
4.21±.18* 
(16%) 
5 
8 
5.09±.17 
3.1±.13* 
(39%) 
8 
10 
5.06±.16 
2.85±.12* 
(44%) 
10 
12 
4.98±.15 
2.95±.12* 
(40%) 
12 
15 
4.94±.17 
3.4±.15* 
(30%) 
15 
Control 4.3±0.09 4.1±0.07 4.5±0.1 4.4±0.09 4.0±0.08 
GM 3.87±0.05* 3.36±0.06* 3.2±0.06* 3.38±0.06* 3.62±0.08* 
(10%) (18%) (28%) (23%) (20%) 
Results (specific activity expressed as |j,moles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 fi-om respective controls. 
Values in parenthesis represent percent decrease from respective controls. 
142 
Table 35; Efiect of UN treatment on the activities of (A) Na^-K'-ATPase and (B) Acid 
Phosphatase (AcidPase) in the homogenates of whole cortex (WC), medulla 
(M), superficial cortex (SC) and juxtamedullary cortex (JMC). 
(A2 
WC M SC JMC 
Control 5.06±0.3 4.4±0.2 5.3±0.25 4.89±0.4 
UN 3.84±0.2* 2.86±0.1* 3.71±0.3* 2.9±0.12* 
(24%) (35%) (30%) (40%) 
(B) 
WC M SC JMC 
Control 10.27±0.4 6.15±0.3 10.5±0.4 7.2±0.29 
UN 12.22±0.46* 7.62±0.28* 12.7±0.45* 8.9±0.22* 
(19%) (24%) (21%) (24%) 
Results (specific activity expressed as ^imoles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 fi-om respective controls. 
Values in parenthesis represent percent change fi-om respective controls. 
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Table 36; Effect of GM treatment on the activity of Acid Phosphatase (AcidPase) in the 
homogenates of (A) whole cortex (WC) and (B) Medulla. 
( ^ 
Duration of ^ 
Treatment (days) -' ° ^ ^ ^ ^ *-' 
10.5±0.35 10.3±0.42 10.6±0.42 10.4±0.35 
7.4±0.25* 7.21±0.23* 8.73±0.24* 8.95±0.22* 
(28%) (30%) (15%) (13%) 
Control 
GM 
10.3±0.4 
7.68±0.2* 
(25%) 
(B) 
°"^^'°"°' 5 8 10 12 15 Treatment (days) 
Control 6.2±0.3 6.2±0.21 6.5±0.22 6.3±0.21 6.0±0.23 
GM 4.88±0.15* 4.75±0.14* 4.62±0.16* 5.30±0.18* 5.40±0.17 
(21%) (23%) (25%) (14%) (12%) 
Results (specific activity expressed as ^moles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 from respective controls. 
Values in parenthesis represent percent decrease fi-om respective controls. 
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respective saline-treated controls (Table 22). Similarly in medulla the LDH activity 
increased upto 10 days but did not show further increase on prolonged treatment 
after 12 and 15 days of GM administration. Intergroup comparison showed the 
maximum increase in LDH activity both in cortex and medulla after 10 days of GM 
treatment (Fig. 29). UN treatment also caused significant increase in LDH activity in 
cortex (18%) as well as in medulla (31%). Effect of GM on the activities of cortical 
and medullary ICDH and MDH, the two important enzymes of tricarboxylic acid 
(TCA) cycle, and on SDH, the marker enzyme for mitochondria (also a TCA cycle 
enzyme), are shown in Fig. 31-33, Table 24-26. The activities of MDH, ICDH and 
SDH in cortex were markedly reduced, amounting to 38%, 40% and 50% reduction 
respectively, after 10 day GM treatment. The decrease in activities at other time 
points: 5, 12, 15 day was less compared to that after 10 days treatment. However, 
the effect of GM on SDH activity was more profound as compared to MDH and 
ICDH. The activities were also found to decrease in medulla in a time-dependent 
manner till 10 day treatment, however, to a lesser extent as compared to cortex. The 
decrease in activity of MDH, ICDH and SDH in medulla amounted to 28%, 30% and 
32% respectively, after day 10 of GM treatment. The decrease after 12 and 15 day 
GM treatment was less profound compared to 10 day GM treatment, however, the 
activities of all the three enzymes were significantly lowered compared to their 
respective saline-treated controls. The activities of MDH, ICDH and SDH were also 
altered by UN treatment both in cortex and medulla (Fig. 30 and 34, Table 23 and 
27). The activities of MDH, ICDH and SDH markedly declined in cortex, amounting 
to 11%, 26% and 35% respectively. Similar to GM, the effect of UN was more 
pronounced on the activity of SDH as compared to MDH and ICDH. The activities 
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of SDH, ICDH and MDH were also decreased in medulla in UN-treated rats. 
However, the decline in the activity was greater for SDH (40%) than MDH (26%) 
and ICDH (38%). 
The effect of GM and UN was also determined on the activities of G6Pase and 
FBPase; representative enzymes of gluconeogenesis (Fig. 35-37, Table 28-30). The 
activity of both G6Pase and FBPase decreased in cortex as well as in medulla in GM-
treated rats. After 5 days of GM treatment, the cortical activity of G6Pase showed 
17% decline while that of FBPase showed 20%) decline, as compared to control 
values. Further, the activities of cortical G6Pase and FBPase were markedly and 
time-dependently reduced, amounting to 20%, 24%, and 33%, 28%> by day 8 and day 
10, respectively. However, there was no further decline in activities of these enzymes 
in day 12 and day 15 groups compared to day 10 group. Figure 35B and 36B depict 
the effect of GM on the activities of medullary G6Pase and FBPase. Short-term 
treatment of GM had significant effect on the activities of both the enzymes in 
medulla. The decrease in activity of FBPase (16%)) was greater than G6Pase (10%)) 
after 5 day treatment. The activities of G6Pase and FBPase were markedly reduced at 
other time points namely 8 day (15%, 19%)); 10 day (21%, 21%); 12 day (20%, 19%) 
and 15 day (19%, 17%)). The comparison of cortical and medullary G6Pase and 
FBPase shows that the activities of gluconeogenic enzyme were affected to greater 
extent in cortex than in medulla by GM treatment. In UN-treated group, the activities 
of cortical G6Pase and FBPase were reduced significantly, amounting to about 27%) 
and 31%) reduction, respectively. The activities of G6Pase and FBPase were also 
decreased in medulla fi-om UN-treated rats. However, UN showed differential effects 
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on the activity of FBPase witli a more pronounced decline in medulla (46%) than in 
cortex (31%). 
The effect of GM and UN was also determined on the activities of G6PDH (an 
enzyme of HMP-Shunt pathway) and ME (an enzyme of biosynthetic importance 
which together with G6PDH, is responsible for the supply of NADPH). Results 
summarized in Table 31 show that the activity of cortical G6PDH was significantly 
and dose-dependently increased at least upto day 10 GM treatment (31%). The other 
time duration of treatment: 5 day, (20%); 8 day (25%); 12 day (18%) and 15 day 
(13%) also had significant effect on the activity of G6PDH. Figure 38B depicts the 
effect of GM on the activity of medullary G6PDH. As in cortex, G6PDH activity in 
medulla increased maximally after 10 days of GM treatment, however, the activity 
was also high at other time points of GM treatment compared to respective controls. 
In contrast, in UN-treated rats, the G6PDH activity decreased both in cortex as well 
as in medulla (Fig. 39A, Table 32A). The activity was greatly decreased in medulla 
(42%) compared to cortex (36%). However, the activity of ME decreased both in 
cortex and medulla on GM treatment, the decrease being greater in cortex compared 
to medulla (Fig. 40, Table 33). The activity of cortical ME decreased significantly 
with the increased duration of treatment amounting to 37% reduction after 10 day 
GM treatment. The decrease in activity at other time points: 5 day (29%); 8 day 
(31%); 12 day (34%) and 15 day (33%) was also significant compared to control 
rats. The activity of medullary ME also decreased maximally after 10 days GM 
treatment. In contrast, in UN-treated rats the ME activity increased both in cortex 
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and medulla, however, the increase was more profound in medulla (40%) compared 
to cortex (30%) (Fig. 39B, Table 32B). 
The activity of Na''-K''ATPase, a basolateral membrane (BLM) enzyme was 
significantly reduced by GM in cortex as well as in medulla; the decrease in activity 
being greater in cortex than in the medulla (Fig. 41, Table 34). The activity of cortical 
Na^-K^ATPase decreased significantly and duration dependently after 5 day (16%), 8 
day (39%) and 10 day (44%) of GM treatment. However there was no fiirther 
decline on long term GM treatment for 12 days and 15 days. The medullary Na""-
K^ATPase also decreased, however, to lesser extent at all time durations of GM 
treatment compared to the respective saline-treated controls. UN administration 
caused significant decline in Na'^ -K'^ ATPase activity both in cortex and medulla. 
However, the decrease in the activity of Na^-K^ATPase in medulla (35%) was 
greater than in cortex (24%) (Fig. 42A, Table 35A). 
The activity of lysosomal enzyme AcidPase was also determined after UN and 
GM treatment (Table 35B and 36). In GM-treated rats the activity of cortical 
AcidPase decreased at all time points: 5 day (25%); 8 day (28%); 10 day (30%); 12 
day (15%) and 15 day (13%), with maximum decline at 10 days of GM treatment 
(Fig. 43A, Table 36). Similarly, in medulla AcidPase activity was markedly and 
dose/duration-dependently reduced upto 10 days of GM treatment (Fig. 43B). 
However, the effect of GM on AcidPase activity was greater in cortex than in 
medulla. In contrast, in UN-treated rats the activity of AcidPase increased both in 
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cortex and in medulla (Fig. 42B, Table 35B). The effect apparently being more in 
medulla than cortex. 
The activities of the above metabolic enzymes were also determined in the kidney 
tissue homogenates from the outer cortex (superficial cortex) and from the deep 
cortex plus outer stripe of outer medulla (JMC). As the above results depict that 10 
days GM treatment show maximum affect without recovery or desensitization, 
therefore this time point was chosen for subsequent studies in SC and JMC 
homogenates. Dose of UN and duration of its treatment was kept the same as in our 
earlier studies. It is believed that the SC-tissue predominantly contains the early 
proximal convoluted tubule (SI and S2-subsegments) together with distal convoluted 
tubule (DCT) and cortical collecting tubule (CCT) while the JMC-tissue contains 
predominantly the late proximal tubule (S3-subsegment) together with deep PCT, 
MAL, MCT and LH. Results summarized in Table 23A and 37A show the effect of 
UN and GM on LDH activity in SC and JMC homogenates. The LDH activity 
increased both in SC-H and JMC-H from GM-treated as well as from UN-treated 
rats, however, the increase in activity was greater in SC-H (45%) than JMC-H (33%) 
in GM-treated groups while in UN-treated groups the increase in LDH activity was 
greater in JMC-H (36%) than SC-H (20%) (Fig 30A and 44A, Table 23A and 37A). 
MDH, SDH and ICDH activities were markedly reduced amounting to about 38%, 
52% and 45%, respectively, in SC-H and 27%, 35% and 32% respectively, in JMC-H 
due to GM treatment (Fig. 44B and 45, Table 37B and 38). Similarly in UN-treated 
rats, the activities of MDH, SDH and ICDH declined both in SC-H and JMC-H, 
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Table 37; Effect of 10 day GM treatment on the activity of (A) Lactate Deliydrogenase 
(LDH) and (B) Succinate Dehydrogenase (SDH) in the homogenates of 
superficial cortex (SC) and juxtamedullary cortex (JMC). 
(A) 
Control 
GM 
3) 
Control 
GM 
SC 
21.4±0.4 
31.03±0.8* 
(45%) 
SC 
14±0.9 
6.72±0.86* 
(52%) 
JMC 
29.85±0.6 
39.70±1.0* 
(33%) 
JMC 
8.52±0.89 
5.52±0.68* 
(35%) 
Results (specific activity expressed as ^ moles/tngprotein/h for LDH and mEU/mgprotein/h 
for SDH) are Mean± SEM of five different preparations. 
* significantly different at p<0.01 fi-om respective controls. 
Values in parenthesis represent percent change fi*om respective controls. 
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Fig 44: Specific activities of (A) Lactate dehydrogenase (LDH) and (B) Succinate 
dehydrogenase (SDH) in the homogenates of superficial cortex (SC) and 
juxtamedullary cortex (JMC) from saline-treated control and GM-treated rats. 
Each bar represents results (Mean ± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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(B) Control 
Gentamicin 
Fig 45 : Specific activities of (A) Malate dehydrogenase (MDH) and (B) Isocitrate 
dehydrogenase (ICDH) in the homogenates of superficial cortex (SC) and 
juxtamedullary cortex (JMC) from saline-treated control and GM-treated rats. 
Each bar represents results (Mean ± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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Table 38 : Effect of 10 day GM treatment on the activities of (A) Malate Dehydrogenase 
(MDH) and (B) Isocitrate Dehydrogenase (ICDH) in the homogenates of 
superficial cortex (SC) and juxtamedullary cortex (JMC). 
(A) 
Control 
GM 
B) 
Control 
GM 
SC 
107.31±5.0 
66.5±2.0* 
(38%) 
SC 
9.5±.12 
5.22±.085* 
(45%) 
JMC 
100.03±3.0 
72.96±2.0* 
(27%) 
JMC 
6.0±.09 
4.08±.072* 
(32%) 
Results (specific activity expressed as |j.moles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 fi-om respective controls. 
Values in parenthesis represent percent decrease firom respective controls. 
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however, the decline was more prominent in JMC-H (Fig. 30B and 34, Table 23B 
and 27). 
GM treatment showed significant affect on gluconeogenic enzymes G6Pase and 
FBPase in SC and JMC (Table 39). The activities of both the enzymes were lowered 
in SC as well as in JMC homogenates (Fig. 46). However, the decrease in activity 
was more in SC-H (G6Pase: 37%, FBPase: 36%) than JMC-H (G6Pase: 28%, 
FBPase: 26%) in GM-treated rats, while in UN-treated rats activities of both the 
enzymes were lowered to greater extent in JMC-H (G6Pase: 42%, FBPase: 36%) 
than SC-H (G6Pase: 35%, FBPase: 32%) (Fig. 37, Table 30). GM treatment caused 
an increase in the activHy of G6PDH both in SC-H and JMC-H (Table 40A). 
However, the extent of increase was higher in SC-H (35%) than in JMC-H (25%) as 
compared to respective saline-treated controls. In contrast in UN-treated rats the 
activity of G6PDH decreased both in SC-H as well as in JMC-H as compared to the 
respective controls (Fig. 39A), The decrease was greater in JMC-H (46%) than SC-H 
(35%). As compared to G6PDH a reverse effect was observed on the activity of ME 
by GM and UN treatment. ME enzyme activity was decreased in GM-treated rats 
(Fig. 473, Table 403), the decrease being greater in SC-H (42%) than JMC-H 
(30%), while UN caused an increase in the ME activity both in SC and JMC 
homogenates (Fig. 39B, Table 32B). However, the increase in ME activity was 
significantly higher in JMC-H (40%) than SC-H (31%). 
Effect of UN and GM on the activity of Na'"-K''ATPase in homogenates fi-om SC 
and JMC is simimarized in Table 35A and 41A. Na'^ -K'^ ATPase decreased markedly 
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Table 39; Effect of 10 day GM treatment on the activities of (A) Glucose-6-Phosphatase 
(G6Pase) and (B) Fructosel ,6-bisPhosphatase (FBPase) in the homogenates 
of superficial cortex (SC) and juxtamedullary cortex (JMC). 
(A) 
Control 
GM 
SC 
0.35±0.017 
0.22±0.013* 
(37%) 
JMC 
0.255±0.011 
0.18±0.011* 
(28%) 
(B) 
Control 
GM 
SC 
0.86±0.087 
0.56±0.043* 
(36%) 
JMC 
0.745±0.075 
0.55±0.040* 
(26%) 
Results (specific activity expressed as |imoles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 fi-om respective controls. 
Values in parenthesis represent percent decrease fi"om respective controls. 
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Fig 46 : Specific activities of (A) Glucose-6 phosphatase (G6pase) and (B) Fmctose-1,6 
bisphcsphatase (FBPase) in the homogenates of superficial cortex (SC) and 
juxtamedullary cortex (JMC) from saline-treated control and GM-treated rats. 
Each bar represents results (Mean ± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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Table 40 : Efifect of 10 day GM treatment on the activities of (A) Glucose-6-Phosphate 
Dehydrogenase (G6PDH) and (B) Malic Enzyme (ME) in the homogenates of 
superficial cortex (SC) and juxtamedullary cortex (JMC). 
(A) 
Control 
GM 
J) 
Control 
GM 
SC 
1 32±0.03 
1.78±0.04* 
(35%) 
SC 
13.4±0.33 
7.8±0.11* 
(42%) 
JMC 
0.924±0.06 
1.16±0.02* 
(25%) 
JMC 
9.2±0.31 
6.44±0.13* 
(30%) 
Results (specific activity expressed as |imoles/mg protein/h) are Mean ± SEM of five 
different preparations. 
* significantly different at p<0.01 fi-om respective controls. 
Values in parenthesis represent percent change fi-om respective controls. 
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Fig 47 : Specific activities of (A) Glucose-6 Phosphate dehydrogenase (G6DH) and 
(B) Malic enzyme in the homogenates of superficial cortex (SC) and 
juxtameduUary cortex (JMC) from saline-treated control and GM-treated rats. 
Each bar represents results (Mean ± SEM) of five different preparations. 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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Table 4 1 : Effect of 10 day GM treatment on the activities of (A) Na'^ -K'^ ATPase and 
(B) Acid Phosphatase (AcidPase) in the homogenates of superficial cortex (SC) 
and juxtamedullaiy cortex (JMC). 
(A) 
Control 
GM 
SC 
5.3±0.25 
2.33±0.2* 
(56%) 
JMC 
4.89±0.4 
3.27±0.4* 
(33%) 
(B) 
Control 
GM 
SC 
10.5±0.4 
7.39±0.31* 
(26%) 
JMC 
7.2±0.3 
5.56±0.21* 
(22%) 
Results (specific activity expressed as jiimoles/mg protein/h) are Mean ± SEM of five 
difierent preparations. 
* significantly difiFerent at p<0.01 fi-om respective controls. 
Values in parenthesis represent percent decrease fi-om respective controls. 
159 
in SC-H as well as JMC-H after GM treatment (Fig. 48A). The decrease in activity 
was more pronounced in SC-H (56%) than JMC-H (33%). UN treatment also 
showed significant effect on Na -^K^ATPase activity in SC-H (30%), however a more 
marked decrease was observed in JMC-H (40%). Activity of AcidPase was found to 
decline due to GM treatment (Fig. 48B, Table 4IB), both in SC-H as well as in JMC-
H. In contrast AcidPase activity was significantly high in the homogenates of SC and 
JMC from UN-treated rats compared to control rats (Fig. 420, Table 35B). 
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JMC 
SC JMC 
F i p 4 8 : Specific activities of (A) Na'^-K"'ATPase and (B) Acid Phosphatase (AcidPase) in 
thehomogenates of superficial cortex (SC) and juxtamedullary cortex (JMC) from 
saline-treated control and GM-treated rats 
Each bar represents results (Mean ± SEM) of five different preparations 
* Significantly different from saline-treated control at p<0.05 or higher degree by 
group t-test. 
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The structure and iunction of the kidney and its various components in animals 
and humans have been greatly characterized both in physiological and 
pathophysiological conditions [2,38,301,302]. The kidney consists of different tissue 
zones such as cortex, outer and inner medulla, which themselves behave as individual 
organs [1]. Further, "nephron", the structural unit of the kidney, also comprises of 
various subsegments of distinct structures with specific functions. Intra- and Inter-
nephron heterogeneity is also very well understood [303]. The reabsorption of Na^ is 
considered to be the major function of the kidney [3-5], because the transport of 
water, ions and various solutes depends, directly or indirectly, on Na^ reabsorption 
[5]. The proximal tubule of the renal cortex has been shown to be the major nephron 
site where majority of ions and solutes including Na^ are reabsorbed across the 
luminal BBM, mostly by active transport processes [36,37,304,305]. The energy 
required for these transport processes is usually provided by the hydrolysis of ATP 
supplied by various metabolic activities of the cell [2]. A direct relation between the 
transport of Na^ and energy yielding metabolic reactions (eg. glycolysis and TCA 
cycle) concomitant with oxygen-tensions (PO2) or its utilization in various kidney 
tissue zones or cells has been demonstrated [8-12]. Various solutes whose transport 
is dependent upon Na"" reabsorption are also regulated at the BBM site under various 
physiological, pathophysiological and pharmacological conditions [37,38,305-
308,318-321]. 
The existence of the major biosynthetic and catabolic pathways of intermediary 
metabolism especially for carbohydrates in the adult mammalian kidney have been 
reported long time back [8,10]. However, the activities of enzymes of above 
162 
pathways were not studied in detail during toxic ARF. It is known that glycolysis 
preferably occurs in the medulla [1,309-311] while oxidative metabolism (eg. TCA 
cycle) is more prevalent in the renal cortex [68,71]. In the present study the activities 
of certain metabolic en2ymes were simultaneously determined in the homogenates of 
cortex and outer medulla and/or of superficial (SC) and juxtameduUary cortex (JMC) 
isolated from rats subjected to toxic (GM or UN) insult. As described in the 
"Results", administration of GM or UN to rats caused a profoimd increase in LDH 
activity both in cortex and medulla (Table 22 and 23), however, the increase being 
significantly greater in cortex than medulla. In contrast, the activities of TCA cycle 
enzymes MDH, ICDH and SDH were significantly decreased by GM as well as UN 
administration. GM treatment caused time dependent decrease in the activities with 
maximum decline after 10 days of treatment. The markedly inhibited activity of MDH 
would probably reduce the production of oxaloacetate fi"om malate, which is required 
for the continuation of TCA cycle. These observations are in agreement with the 
results of the earlier studies in which the activities of MDH and ICDH were found to 
be lowered by toxic or ischemic injury [300]. Other studies have demonstrated a 
decrease in the contents of a-KG, pyruvate, OAA, Lactate and glutamate, substrates 
for TCA cycle enzymes, after toxic or ischemic insult [312], indicating an overall 
decline in the TCA cycle pathway. Although the actual rate of glycolysis was not 
determined, the increased activity of LDH along with simultaneous decline in MDH, 
ICDH and SDH activities may suggest the shift of oxidative metaboUsm to glycolysis 
to meet the energy need of cells after toxic insult as most neptrotoxins are known to 
cause mitochondrial dysfiinction. Thus, the increase in LDH activity appears to be an 
adaptive change to compensate the decreased rate of TCA cycle. It has been shown 
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that GM-induced nephrotoxicity did not alter liver functions or apparent histology of 
the hepatocytes [301]. These observations together with the present observation 
guardedly suggest that in GM- or UN-induced injury, oxidative metabolism is 
affected to limit the production of ATP mainly due to mitochondrial dysflmction. 
Simmons et al. [145] reported that gentamicin inhibits the oxidative phosphorylation 
in isolated renal cortex and decreases the ATP content of rat kidney. TCA cycle 
enzymes were affected to a greater extent in renal cortex than in medulla as it is the 
main site where glucose is oxidatively metabolized. These studies suggest that GM-
induced toxicity may primarily be produced by impairment of renal mitochondrial 
fiinctions. 
Results summarized in Table 28-30 clearly indicate that activities of both G6Pase 
and FBPase; the enzymes involved in the synthesis of glucose were always much 
higher in cortical homogenates than medullary homogenates in control as well as in 
GM- or UN-treated rats. The activities of FBPase and G6Pase were significantly 
decreased similar to TCA cycle enzymes by both GM and UN treatment in cortical 
and medullary homogenates. However, the decrease in gluconeogenic enzymes in 
GM-treated rats was more promment in cortex unlike UN-treated rats where the 
effect was greater in medulla. The reduced activity of MDH may have reduced the 
production of oxaloacetate from malate which is required for the continuation of 
TCA cycle as well as for gluconeogenesis. These results are in agreement with the 
findings of several authors who have reported impairment of glucose metabolism in 
tissues isolated from uraemic animals. Michalik et al. [313] have demonstrated the 
inhibition of glucose formation from pyruvate or lactate in the rabbit renal cortex 
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when incubated with various aminoglycosides including GM or other nephrotoxins 
[301]. Malate dehydrogenase (MDH) and Aspartate transaminases (AST) activities 
have been shown to be markedly depressed in GM-treated rats [300]. This would 
affect the gluconeogenesis in renal cortex since AST and MDH are the enzymes 
involved in the malate-aspartate shuttle. The reduced activities of these enzymes 
would diminish the flux of the reducing equivalents and gluconeogenic intermediates 
across the mitochondrial barrier. Ross et al. [314] demonstrated the inhibition of 
gluconeogenesis in isolated rat kidney by addition of inhibitors of transaminases and 
malate dehydrogenase. 
GM and UN treatment caused a mixed effect on the activities of G6PDH and 
ME, both involved in the production of NADPH required for many biosyntheiic 
pathways. A significant, time-dependent activation (with maximum activation at 10 
days treatment) of G6PDH was found after GM administration. However, UN-
treated groups showed significant decrease in the activity of G6PDH. The enhanced 
activity of G6PDH in GM-treated rats could possibly be due to the depressed rate of 
glucose oxidation and the diversion of cellular glucose-6 phosphate for the pentose 
phosphate pathway or possibly due to the increased utilization of the reduced form of 
pyridine co-enzymes (NADPH) in the detoxification of hydroxyl fi-ee radicals known 
to be generated in GM nephrotoxicity [315] and in the drug detoxification by 
cytochrome P450 linked enzymes [316]. The utilization of NADPH leads to 
increased NADP/NADPH ratio, a condition known to activate G6PDH. In 
comparison to G6PDH, a reverse effect was observed on the activity of malic enzyme 
by GM or UN treatment. ME activity decreased in GM-treated groups but increased 
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significantly in UN-treated rats particularly in medullary homogenate. Since GM has 
been shown to inhibit the activity of AST and MDH [300], the enzymes involved in 
the malate-aspartate shuttle, the decreased activity of ME could possibly be due to 
the inadequate supply of substrates especially malate. However, NADPH required for 
biosynthetic pathways in UN-treated rats seems to be provided by an enhanced ME 
activity rather than G6PDH. 
A significant decline in cortical and medullary AcidPase was observed aflier GM 
administration. The decreased activity of AcidPase in GM-treated rats may be 
ascribed to the "lysosomotropic" nature of GM i.e. GM uptake in lysosomes either by 
pinocytosis or by any other mechanism [154]. GM may stay within the lysosomes and 
may act either by altering the lysosomal content or the lysosomal ability to degrade 
engulfed substances, thus inducing lysosomal storage disorders. Morphologically, 
these changes are translated into the formation of myeloid bodies [124,128-130]. In 
addition, as summarized by Feldman et al. [124] (Fig. 3), it appears that within the 
lysosomes, aminoglycosides might interfere with the catabolism of the membrane 
receptor by directly inhibiting phospholipase C, by modifying substrate-enzyme 
affinity, or by increasing the intralysosomal pH above the range of the enzyme. 
Unlike GM treatment, UN administration caused significant increase in AcidPase 
activity in homogenates from both renal cortex and medulla. The increased activity of 
AcidPase may be attributed to the altered properties of the lysosomal membranes, 
thus inducing an increase in its permeability towards exogenous substrates or even 
lysosomal enzymes, which may exhibit increased cytosolic activity by escaping the 
organelle. However, the effect of UN on AcidPase observed in the present study is 
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also supported by several morphological studies which have shown the increased size 
and number of lysosomes in PT epithelial cells in UN-induced ARF [176,317]. 
The activities of above metabolic en2ymes were also determined in the SC and 
JMC after GM and UN administration; the activities of these enzymes were 
differentially affected in SC and JMC tissues. In this study only outermost half part of 
cortex was taken as SC-tissue while JMC included the lower half of the cortex 
together with the outer-stripe of outer medulla (See "Methods" for details). It is well 
known that various nephronal subsegments are differentially distributed both in SC 
and JMC tissues [25]. It has been demonstrated both by morphologic and 
biochemical studies that SC tissue contains predominantly the early proximal 
convoluted tubule (SI and S2-subsegments) together with distal nephronal 
subsegments such as DCT and CCT, while JMC tissue is enriched with proximal 
straight tubule (PST, pars recta, S3-subsegments) of both superficial and deep 
nephrons together with deep PCT and other distal nephronal subsegments such as 
MCT, MAL and thin segments of LH [245,309]. The activities of various metabolic 
enzymes have been determined and were found to be differentially distributed in these 
nephron/ nephronal subsegments [309]. In view of the above findings, effect of GM 
or UN was also observed in SC and JMC tissues. The activities of MDH, SDH and 
ICDH decreased significantly and more markedly in SC-H compared to JMC-H, 
however, the activity of LDH increased to greater extent in SC-H than JMC-H in 
GM-treated rats while in UN-treated rats changes in the activities of these enzymes 
were more profound in JMC-H than SC-H. 
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The change in the activities of above enzymes was found to be much greater than 
that observed in the cortex or medulla and it was more profound in the SC than JMC 
in GM-treated rats. This correlates with the fact that 02-tension and consumption is 
certainly higher in the superficial cortex than in the deep cortex [19-22]. In superficial 
region PCT and DCT showed a higher oxidative metabolic activity. The 
mitochondrial dysfiinction might have resulted in depleted 02-consumption and 
decreased activities of TCA cycle enzymes (MDH, ICDH, SDH). As a result ATP 
will not be produced in sufficient amount resulting in the decreased kidney fimctions. 
It appears that, to compensate the reduced oxidative phosphorylation, the rate of 
glycolysis may have increased leading to increased LDH activity. The activities of 
TCA cycle enzymes were decreased significantly in SC-H than in JMC-H after GM 
treatment, similarly, LDH activity also increased to greater extent in SC-H than JMC-
H. Thus depression of TCA cycle is paralleled by increased glycolytic activity. As 
results indicate (Table 23 and 27), the UN administration caused a reverse effect as 
that of GM in different renal tissue (SC and .IMC). The reason for this may be the 
difference in site and mode of action for the two different nephrotoxins. 
The activities of FBPase and G6pase decreased significantly both in SC-H as well 
as JMC-H after GM or UN intoxication. Kidney utilizes intermediate products of the 
citric acid cycle for gluconeogenesis besides acetate, lactate, pyruvate, proline and 
some other metabolites; thus decreased activities of gluconeogenic enzymes may be 
due to depleted TCA cycle intermediates and low level of mitochondrial energy 
production as both GM and UN reduced the activities of TCA cycle enzymes: SDH, 
ICDH and MDH significantly. However, both GM and UN significantly affected the 
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FBPase and G6Pase activities in SC-H than JMC-H. The suppression of G6pase and 
FBPase seems to be due to mitochondrial dysfunction paralleled by decrease of O2 
consumption. 
Similar to the whole cortex homogenate (WC-H) and medullary homogenate (M-
H), the activity of G6PDH was found to increase in SC-H and JMC-H in GM-treated 
rats. However, GM administration caused a greater increase in G6PDH enzyme in SC 
than JMC while UN intoxication lead to decrease in G6PDH but caused significant 
increase in ME activity. The activity of ME was however differentially affected by 
UN intoxication, showing greater increase in JMC than SC. Both ME and G6PDH 
are of immense importance in metabolism because major supply of cellular NADPH, 
which is required for many biosynthetic pathways, is dependent on these two 
eruzymes. It appears that enhanced G6PDH activity provides NADPH required in 
GM-treated rats, while increased ME activity meets the cellular NADPH requirement 
in UN-treated rats. Differential activation of G6PDH and ME by GM and UN may 
possibly be due to the increased utilization of NADPH in the detoxification of 
hydroxyl fi-ee radicals [315] or in the drug detoxification [316] resulting in an 
increased NADP/NADPH ratio, which might be activating the enzymes. 
A direct relation between transport of sodium and energy yielding metabolic 
reactions or dependence of transport of various solutes on sodium transport 
prompted the examination of the possible effect of GM and UN on the activity of 
Na'^ -K'^ ATPase. It was found that in GM-treated rats, the decrease in Na"^ -K'"ATPase 
activity was greater in cortex and SC as compared to medulla and JMC, respectively, 
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while in UN-treated rats, the loss of activity appeared to be higher in homogenates 
from medulla and JMC. The decline in Na'"-K'^ ATPase activity in intoxicated rats may 
be attributed to the limited supply of ATP because of mitochondrial dysfunction 
[315] and depleted substrate level of TCA cycle. The decrease of Na '^-K'^ ATPase may 
also be related to renal parenchymal dysfunction, an explanation supported by the 
decrease in Mg-ATPase and the renal histologic findings [318]. 
In summary, our studies indicate that the derangement in glucose metabolism 
accompanies the GM-induced nephrotoxicity or UN intoxication as is evidenced by 
altered activities of enzymes involved in glucose metabolism. An increase in LDH 
activity may indicate diminished oxidation of pyruvate via the TCA cycle. The 
depression of SDH, ICDH and MDH activities seems to indicate a low level of 
mitochondrial energy production paralleled by a decrease in O2 consumption. The 
high activity of LDH may suggest that in toxin-induced tubular lesions, the 
metabolism is changed from oxidative to glycolytic energy production. The markedly 
inhibited activities of SDH and ICDH alongwith suppressed activity of MDH, an 
enzyme also involved in the malate-aspartate shuttle, may explain the diminished 
gluconeogenesis specifically in the renal cortex of GM- or UN-induced nephrotic 
rats. 
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enzyme also involved in the malate-aspartate shuttle, may explain the diminished 
gluconeogenesis specifically in the renal cortex of GM- or UN-induced nephrotic 
rats. 
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Effect of GM and UN on the Pi transport: 
It is well known that toxic insult causes alterations in the renal fimctions mainly 
by affecting cellular metabolism of the PT and the structural integrity of its BBM. 
However, to date, the effect of GM or UN on the BBM transport of Pi has not been 
studied in detail. The Pi is the chief contender to be involved in the restoration of the 
energy required for transports across the BBMV in the proximal tubules. In the 
present studies, transport of Pi was determined under (i) normal conditions (ii) GM 
cell injury (iii) UN cell injury (iv) protection or prevention by certain dietary and 
hormonal stimuli. It has been observed from previous studies that ischemia or toxic 
ARF causes alterations in the membrane fluidity due to changes in the lipid 
composition [256,319-323] but the changes in membrane fluidity due to GM or UN 
have remained a matter of conflict. In the present study GM and UN brought about 
considerable changes in BBM CL and PL content as shown in Table 42. 
Transport properties of renal PT-BBMV under normal and toxic conditions: 
As described in the "Methods", separate group of rats were treated with either 
saline (control) or GMAJN. To study the effect of GM or UN on Pi uptake across 
BBM, the kidney from control (saline) and treated (GM or UN) rats were harvested 
and BBMVs were prepared from whole cortex by Mg^ precipitation as described in 
"Methods". The transport of Pi was determined by microfiltration technique using 
^^ Pi as radiotracer (see "Methods" for detail). The results summarized in Fig. 49A 
(Table 43A) show a typical time course pattern of ^^ Pi uptake in the presence of Na"^ -
gradient in BBMV-WC of control, GM-treated and UN-treated rats. The initial 
uptake of ^^ Pi increased proportionally with respect to the elapsed time of incubation 
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Table 42: Efifect of GM (10 day treatment) and UN (5 days after treatment) on 
phospholipids, cholesterol and cholesterol/phospholipids (C/P) ratio of 
BBMVs isolated fi-om whole cortex. 
Groups 
Control 
GM 
UN 
Phospholipids 
0.182±0.021 
0.241 *±0.012 
0.232*±0.020 
Cholesterol 
0.100±0.003 
0.089±0.002 
0.094±0.003 
C/P 
0.55±0.022 
0.37*±0.023 
0.40*±0.025 
Values are Mean ± SEM of five different BBMV preparations. Each preparation 
includes kidneys fi*om 5-6 rats in each group. 
*significantly different fi'om control at p<0.05 by group t-test. 
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Fig 49; Time course of Na^ gradient dependent ^^ Pi uptake by BBMVs isolated from 
(A) whole cortex, (B) superficial cortex and ( Q juxtamedullary cortex from control 
( • ) , GM treated (A) and UN treated (•) rats. 
Values are represented as Mean± SEM fi)r five different preparations. 
*significantly different from control at p<0.05 or higher degree by group t-test. 
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Table 43; Effect of GM (10 day treatment) and UN (5 days after treatment) on Na"" 
gradient-dependent ^^ Pi uptake by BBMVs isolated from (A) whole cortex, 
(B) superficial cortex and ( Q jvixtamedullary cortex. 
(A) 
Control 
GM 
UN 
(B) 
5sec 
950±30 
712.5*±35 
760*±30 
lOsec 
1283±45 
936.5*±40 
988*±35 
20sec 
1941±72 
1167*±50 
(40%) 
1355*±40 
(29.2%) 
120min 
260±12 
265±18 
275±15 
Control 
GM 
UN 
5sec 
1100±40 
702*±30 
769*±28 
lOsec 
1668±55 
1100.88*±40 
1310.2*±52 
20sec 
2425±85 
1333.75*±55 
(45%) 
1770.7*±60 
(27%) 
120min 
320±15 
340±16 
330±48 
( Q 
Control 
GM 
UN 
5sec 
570±29 
402*±18 
290*±14 
lOsec 
950±40 
650*±25 
510*±24 
20sec 
1285±58 
892*±38 
(30.6%) 
639*±25 
(50.21%) 
120min 
225±11 
240±12 
245±11 
Results (uptake expressed as pmole/mg protein) are Mean ± SEM for five diSerent 
BBMVs preparations. 
*significantly different fi"om control at p<0.05 or greater degree by group t-test. 
Values in parenthesis are percent decrease from respective saline-treated-controls. 
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(5-20s) and then declined towards equilibrium when determined after 120 min. of 
incubation. However, the Na'^-gradient dependent (Nao>Na,) concentrative uphill 
transport of Pi was quite low in both GM- and UN-treated rats; determined at early 
time points (eg. 5s, 10s, 20s) compared to saline treated control rats. However, the 
uptake of ^^ Pi was not significantly affected by toxic insult after equilibration (at 
120 min.). 
Since it has been shown that nephrotoxins or ischemia cause much damage to the 
proximal tubular epithelia including the microvillar membrane and that the epithelia 
becomes leaky, the uptake of Pi was also determined in the absence of a Na^-gradient 
[NaCl replaced by KCl (Ko>K,) in the incubation medium]. The uptake of ^^ Pi in the 
absence of Na'^ -gradient was significantly increased in BBMV fi-om both GM or UN 
treated rats compared to their respective saline-treated controls (Table 44A). This 
indicates that GM or UN may have caused alterations in the BBMVs to increase 
diffiisional uptake capacity. Due to these discrepancies, net Na^-gradient uptake 
[(uptake in the presence of Na'^-gradient) - (uptake in the absence of Na^-gradient)] 
at 20s was also calculated as summarized in Table 45A. The result indicates that both 
GM and UN cause a significant decline in the net Na^-dependent uptake of ^^Pi. To 
fiirther characterize the decrease of ^^ Pi transport due to GM or UN administration, 
the uptake was determined at various ^^ Pi concentrations in the incubation medium. 
Kinetic analysis by double-reciprocal plots of the Na"'-dependent Pi uptake at 20s 
revealed a high correlation of data with a straight line (Fig. 50), indicating the BBM 
transport process in all groups obeyed Michaelis-Menten kinetics. The data 
confirmed that BBM transport of Pi in the normal rat exceeded that in the GM- or 
175 
Table 44: Effect of GM (10 day treatment) and UN (5 days after treatment) on ^ P^i 
uptake by BBMVs isolated from (A) whole cortex, (B) superficial cortex 
and (Q juxtamedullary cortex in presence of Na"^  gradient (NaCl) and in 
absence of Na^ gradient (NaCl replaced by KCl). 
(A) 
Group 
Control 
GM 
UN 
Na"^  gradient dependent 
20 sec 120 min 
1941.3±70 300.0±11 
1200.4*±45 320.0±14 
(38%) 
1360.4*±48 310.0±12 
(22%) 
Na^ gradient independent 
20 sec 120 min 
80.2±3 230.0±10 
140.1*±7 260.0±14 
(75%) 
120.8*±6 248.8±12 
(51%) 
(B) 
Group 
Control 
GM 
UN 
Na"*^  gradient 
20 sec 
2400.8±101 
1298.8*±41 
(46%) 
1780.4*±53 
(27%) 
dependent 
120 min 
340.1±15 
360.2±18 
348.4±14 
Na"*" gradient 
20 sec 
89.4±4 
173.2*±8 
(95%) 
120.2*±6 
(35%) 
independent 
120 min 
280.4±15 
307.4±16 
298.3±12 
(O 
Group 
Control 
GM 
UN 
Na^ gradient dependent 
20 sec 120 min 
1260.4±49 265.4±12 
890.2*±29 280.4±15 
(29%) 
640.8*±41 285.3±14 
(49%) 
Na"*^  gradient independent 
20 sec 120 min 
60.4±3 182.4±8 
84.56*±4 302.1±10 
(40%) 
126.4*±6 3110.1±14 
(110%) 
Results (uptake expressed as pmole/mg protein) are Mean ± SEM of five different 
BBMV preparations. 
*significantly different from control at p<0.05 or greater degree by group t-test. 
Values in parenthesis represent percent change from respective saline-treated controls. 
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Table 45; Effect of GM (10 day treatment) and UN (5 days after treatment) on net 
Na^ gradient dependent ^^ Pi uptake by BBMVs isolated from (A) whole 
cortex, (B) superficial cortex and (Q juxtamedullary cortex at 20 sec 
incubation. 
(A) 
Group 
Control 
GM 
UN 
NaCl 
(lOOmM) 
1941.3±70 
1200.4*±45 
(38%) 
1360.4*±48 
(22%) 
KCl 
(lOOmM) 
80.2±3 
140.1*±7 
(75%) 
120.8*±6 
(51%) 
Net uptake 
(Na-K) 
1860.8±78 
1060.4*±39 
(43%) 
1239.6*±52 
(33.38%) 
(B) 
Group 
Control 
GM 
UN 
NaCl 
(lOOmM) 
2400.8±101 
1298.8*±41 
(46%) 
1780.4*±53 
(27%) 
KCl 
(lOOmM) 
89.4±4 
173.2*±8 
(95%) 
120.2*±6 
(35%) 
Net uptake 
(Na-K) 
2311.4±108 
1125.6*±48 
(51%) 
1660.3*±69 
(28%) 
(Q 
Group 
Control 
GM 
UN 
NaCl 
(lOOmM) 
1260.4±49 
890.2*±29 
(29%) 
640.8*±41 
(49%) 
KCl 
(lOOmM) 
60.4±3 
84.56*±4 
(40%) 
126.4*±6 
(110%) 
Net uptake 
(Na-K) 
1199.9±56 
805.7*±34 
(33%) 
514.4*±21 
(57%) 
Results (uptake expressed as pmole/mg protein/20 sec) are Mean ± SEM of three 
different BBMV preparations. 
•significantly different from control at p<0.05 or greater degree by group t-test. 
Values in parenthesis represent percent change from respective saline-treated controls. 
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Fig. 50: Na '^-gradient dependent ^^ Pi uptake as a function of phosphate concentration by 
BBMV-WC from GM (10 day treatment), UN (5 day after treatment) and 
saline-treated control rats. (•)-control, (CD)-GM, (A)-IJN. 
Lines are drawn with the mean value of three separate experiments. 
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UN-treated rats over a wide range of Pi concentrations (0.05nun-0.4nim) in the 
incubation medium. The results (Fig. 50, Table 46A) also indicate that marked 
reduction due to GM or UN treatment in Na'^-dependent ^^ Pi transport were due to 
decrease in the maximum rate of transport (Vmax). However, there was no significant 
difference in the affinity (Km) of ^^ Pi after GM/UN treatment as compared to control 
groups. 
To localize the effect of GM and UN on the ^^ Pi transport, the BBMV were 
isolated fi-om superficial (BBMV-SC) and juxtamedullary (BBMV-JMC) cortex of 
saline treated control and GM or UN treated rats as described in the "Methods" and 
the transport of ^^ Pi was determined in the presence of Na^ concentration gradient. 
As summarized in Fig. 49B-C and Table 43B-C, results show a typical time course 
pattern of ^^ Pi uptake both in BBMV-SC and BBMV-JMC fi-om control and treated 
rats. Although the pattern of ^^ Pi uptake in the early "uphill" concentrative phase was 
analogous in both BBM\^-SC and BBMV-JMC in control and treated rats but the 
uptake was higher in BBMV-SC than in BBMV-JMC in all groups of rats as 
previously reported [324]. Moreover, the uptake of ^^ Pi at equilibrium phase (at 
120 min.) was also higher in BBMV-SC compared with BBMV-JMC. As shown in 
Fig, 49B-C and Table 43B-C, the uptake was decreased in both BBMV-SC and 
BBMV-JMC fi-om GM-treated rats, however, the decrease in ^^ Pi uptake was much 
greater in BBMV-SC than BBMV-JMC. In UN-treated rats, the uptake also 
decreased both in BBMV-SC and BBMV-JMC but unlike GM treatment, the 
decrease was more prominent in BBMV-JMC than BBMV-SC. Apparent K^ and 
Vmax values were determined graphically from double-reciprocal plot of ^^ Pi uptake 
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Table 46: Effect of GM (10 day treatment) and UN (5 days after treatment) on the 
kinetic parameters of Na'*"-dependent ^^ Pi uptake by BBMVs isolated from 
(A) whole cortex, (B) superficial cortex and (C) juxtamedullary cortex. 
(A) 
(B) 
(Q 
Group 
Control 
GM 
UN 
Group 
Control 
GM 
UN 
Group 
Control 
GM 
UN 
' m a x 
(pmol/mg protein/20 sec) 
2020.2±100 
1388.8*±48 
1778.4*±68 
' m a x 
(pmol/mg protein/20 sec) 
2560.41±120 
1587.50*±70 
1960.04*±89 
' m a x 
(pmol/mg protein/20 sec) 
1403.30±58 
1081.08*±39 
769.20*±30 
Km(XlO-^M) 
0.1±0.003 
0.1±0.028 
0.097±0.003 
Km(XlO-^ M) 
0.100±0.002 
0.106±0.003 
0,108±0.021 
Km(XlO-^M) 
0.081±0.001 
0.080±0.002 
0.083±0.001 
Values are Mean ± SEM of three different BBMV preparations. 
Values are calculated from Lineweaver-Burk plot (Fig 50). 
*significantly different from control at p<0.05 or greater degree by group t-test. 
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by BBMV-SC and BBMV-JMC from control and treated rats measured in the 
presence of a Na'^-gradient (Nao>Na,) (Fig. 51 and 52). The experiments were done 
in such a way that the BBMV preparations from the control and treated (GM or UN) 
rats were always tested in one experimental day under identical conditions. Our data 
show that Vmax (expressed as pmole ^^Pi/mg protein/20s) was significantly higher in 
control rats compared with GM- or UN-treated rats. The apparent Km value for 
control BBMV was slightly lower than GM- or UN-treated rats. The kinetic studies 
showed that the decrease in ^^ Pi transport is due to decrease in Vmax as the difference 
in Km is insignificant (Table 46B-C). 
To fiirther investigate whether GM or UN alter the properties of ^^ Pi transport 
with respect to Na* concentrations, the transport of ^^ Pi was determined at various 
extravesicular Na^ concentrations (Nao = 20, 40, 60 and lOOmM in incubation 
media). The total osmolality, and molar concentrations of CV in the media were held 
constant (300mosm and lOOmM) by appropriate addition of choline chloride as 
reported by Szczepanska Konkel et al. [275]. As shown in Table 47, the rate of ^^ Pi 
transport in BBMV-WC increased steadily with increased extravesicular Na^ 
concentrations in incubation media in control (saline treated) as well as in treated 
rats. However, at all concentration gradients of Na^ (Nao>Nai), the uptake of ^^ Pi was 
less in GM- and UN-treated rats as compared to control rats. The graphic analysis of 
relationship between ^^ Pi uptake and [NaJ showed sigmoidal curves in GM- and UN-
treated as well as in control rats (Fig. 53). It is apparent from the curves that 
variations were mainly due to alterations in the Vn^ x. A Hill plot transformation of the 
data yielded a straight line (Fig.53) and the calculated [S]o.5 were 35.5, 25.1 and 31.6 
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CS3mM 
Fig. 51: Na -^gradient dependent ^ P^i uptake as a function of phosphate concentration by 
BBMV-SC from GM (10 day treatment), UN (5 day after treatment) and 
saline-treated control rats. (•)-control, (O)-GM, (A)-UN. 
Lines are drawn with the mean value of three separate experiments. 
182 
Fig. 52: Na'^ -gradient dependent ^ P^i uptake as a fimction of phospliate concentration by 
BBMV-JMC from GM (10 day treatment), UN (5 day after treatment) and 
saline-treated control rats. (•)-control, (O)-GM, (A)-UN. 
Lines are drawn with the mean value of three separate experiments. 
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Table 47: Effect of different extravesicular [Na^J gradient on ^^ Pi uptake by BBMVs 
isolated from renal whole cortex from control, GM-treated and UN-treated 
rats. 
Group 
Control 
GM 
UN 
20mM 
260±12 
169*±7 
(35%) 
187.2*±8 
(28%) 
40mM 60mM 
350±15 588±25 
192.5*±9 270.5*±13 
(45%) (54%) 
213.5*±10 305*±14 
(39%) (48%) 
80mM 
666.6±25 
306.6*±15 
(53%) 
360*±18 
(46%) 
lOOmM 
688±30 
342*±15 
(50%) 
385.3*±15 
(44%) 
Results (uptake expressed as pmole/mg protein/20 sec) are Mean ± SEM for three 
different BBMV preparations, 
*significantly different from control at p<0.05 or greater degree by group t-test. 
Values in parenthesis represent percent decrease from control. 
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Figure 53; Na^-dependent ^^ Pi uptake as a function of external Na^ concentration [Na^ J by BBMVs 
from whole cortex of (A) control (saline-treated), (B) GM-treated and (C) UN-treated rats. 
Insets illustrate Hill's plot of the data. 
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for (A) control, (B) GM-treated and (C) UN-treated rats, respectively. The values of 
n were 0.2, 1.66 and 1.72, respectively, for the above curves. It appears from this 
data that about two Na"^  were involved in the transport of one ^^ Pi in control rats. 
However, in case of GM- and UN-treated rats less than two Na^ but definitely 
greater than one Na"" appear to be involved for the transport of one Pi (Table 48). 
This data suggests that the properties of Pi-carrier with respect to [NaJ may have 
altered or modified during GM- and UN-induced cellular injury. 
Effect of T3 and/or LPD on "Pi transport after GM and/or UN treatment: 
The results of the present studies thus far indicate that toxic insult causes specific 
alterations in the structure and fiinction of the proximal tubules which are manifested 
by: (a) decrease in the activity of BBM marker enzymes, (b) changes in the activities 
of enzymes belonging to various metabolic pathways, and, (c) decrease in the 
transport of Pi across BBMV isolated from the renal proximal tubules. Some of the 
above GM-induced alterations were shown to be partially restored on long-term 
treatment with GM but were severe in case of short-term treatment with UN as well 
as GM (Results I and II). Thyroid hormone (Thyroxine), generally referred to as 
metabolic hormone, shows beneficial effects on the recovery of nephrotoxic ARF 
[43,63,222]. It has been generalized that these beneficial effects are mainly due to 
restoration of Na^-K^ATPase and cell volume regulation by thyroxine, which- were 
affected due to nephrotoxic ARF. Thyroid hormone (T3) and feeding of a low 
phosphate diet (LPD) have been shown to specifically increase BBMV Na"^ -
dependent transport of Pi by different mechanisms [228,325-327]. Considering the 
important involvement of Pi in energy-related processes, the following experiment 
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Table 48; Effect of GM (10 day treatment) and UN (5 days after treatment) on kinetic 
parameters of ^^ Pi uptake at various [Na'^ o] by BBMVs isolated from 
whole cortex. 
Group 
Control 
GM 
UN 
n 
2 
1.66 
1.72 
[S]o.5mM 
35.48 
25.1 
31.62 
Values are mean of three different BBMV preparations. 
Values are calculated from Hill's plot (Fig. 53). 
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was designed and carried out to determine whether the treatment of T3 and/or the 
feeding of LPD can protect against GM- or UN-induced damage or can cause the 
recovery of the Pi transport in the proximal tubules. The animals were first stabilized 
on NPD/standard pellet diet for 10 days. After 10 days, the animals were divided into 
different groups (see "Methods") and the allocation of animals was adjusted so that 
at this time the groups did not differ in body wt., food intake and/or urinaiy Pi 
excretion. 
The experiments were done in such a way that the BBMV preparations fi-om all 
comparable groups were always tested in one experimental day under identical 
conditions. The whole cortex studies from rats fed standard pellet rat diet and treated 
with GM (GM+V) or UN (UN+V) showed significant decrease in ^^ Pi uptake as 
compared to control rats (S+V). When intoxicated rats were treated with T3 for 15 
days prior to and alongwith GM or UN administration, the ^^Pi uptake returned to 
control values (Fig. 54A, Table 49). Animals treated with T3 without toxic insult 
showed the highest ^^ Pi uptake (Table 49) at the initial uphill phase (5 s, 20 s) 
compared to any other group. In NPD-fed rats, UN and GM treatment reduced the 
^^ Pi uptake significantly (Fig. 54B) compared to NPD-fed control rats. Feeding of 
LPD diet for 15 days prior to and alongwith GM or UN administration resisted any 
decrease in ^^ Pi uptake. Intergroup comparison showed that rats fed with LPD diet 
without any toxic insuh had highest ^^ Pi uptake compared to other groups (Table 50). 
In the earlier studies we observed that BBMV prepared from the superficial 
cortex (BBM-SC) and those prepared from the juxtamedullary renal tissue zone i.e. a 
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Fig. 54; (A) Effect ofGM (10 day treatment) and UN (5 days after treatment) on Na^-
dependent ^^ Pi uptake by BBMVs isolated from whole cortex of T^-treated 
rats. 
Each bar represents results (Mean ± SEM) of five different BBMV 
preparations. 
* significantly different at p<0.01 from control (V+S). 
^ significantly different at p<0.01 from V+GM. 
* significantly different at p<0.01 from V+UN. 
(B) Effect of GM (10 day treatment) and UN (5 days after treatment) on Na+-
dependent ^^ Pi uptake by BBMVs isolated from whole cortex c^LPD-fed 
rats. 
Each bar represents results (Mean ± SEM) of five different BBMV 
preparations. 
* significantly different at p<0.01 from control (NPD+S). 
^ significantly different at p<0.01 fromNPI>KjM. 
* significantly different at p<0.01 fromNPD+UN. 
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Table 49: Effect of GM (10 day treatment) and UN (5 days after treatment) on 
Na'^ -dependent '^ P^i uptake by BBMVs isolated from whole cortex of T3-
treated rats. 
v+s 
T+S 
V+GM 
T+GM 
V+UN 
T+UN 
5 sec 
1015±40 
1725±52 
710±32 
1435±60 
793±39 
1501±65 
20sec 
2340±65 
3510±103*(50%)^ 
1450±48*(38%)^ 
2405±90^(63%)^ 
1638±78*(30%)^ 
2615±102^(65%)^ 
120 min 
310±10 
295±9 
320±20 
308±12 
315±16 
306±13 
Results (uptake expressed as pmole/mg protein) are Mean ± SEM of five different 
BBMV preparations, 
* significantly different from control group (V+S) at p<0.05 (V+S) by group t-test. 
^ significantly different from control group (V+GM) at p<0.05 by group t-test. 
^ significantly different from control group (V+UN) at p<0.05 by group t-test. 
values in parenthesis represent percent change from control group (V+S). 
value in parenthesis represents percent increase from group V+GM. 
value in parenthesis represents percent increase from group V+TJN. 
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Table 50; Effect of GM (10 day treatment) and UN (5 days after treatment) on Na""-
dependent ^^ Pi uptake by BBMVs isolated from whole cortex of LPD-fed 
rats. 
NPD+S 
LPD+S 
• NPD+GM 
LPD+GM 
NPD+UN 
LPD+UN 
5 sec 
1104±72 
1615±82 
715±35 
1395±82 
798±40 
1465±78 
20 sec 
2390±55 
3827±115*(60%)^ 
1465±52* (39%)^^ 
2535±120^(59%)^ 
1695±80* (29%)" 
2500±118^(47%)'^ 
120 min 
319±18 
295±10 
320±20 
295±16 
320±19 
290±19 
Results (uptake expressed as pmole/mg protein) are Mean ± SEM of five different 
BBMV preparations. 
* significantly different from control group (NPD+S) at p<0.05 by group t-test. 
''' significantly different from group NPD+GM at p<0.05 by group t-test. 
* significantly different from group NPD+UN at p<0.05 by group t-test. 
values in parenthesis represent percent change from control group (NPD+S). 
value in parenthesis represents percent increase from group NPD+GM. 
value in parenthesis represents percent increase from group NPD+UN. 
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tissue consisting of juxtamedullary cortex and outer stripe of outer medulla of rat 
kidney (BBMV-JMC), differ in some basic parameters, such as specific activities of 
BBM enzymes, en2ymes of carbohydrate metabolism and ^^ Pi uptake. BBMV-SC 
and BBMV-JMC have also been shown to differ with regard to the regulation of their 
reabsorptive properties due to various stimuli [328,250]. Hence BBMV were 
prepared from kidney tissues taken from the outer cortex (SC) and from the deep 
cortex plus outer stripe of outer medulla (SMC) to study the hormonal (T3) and 
dietary (LPD, NPD) affect on Na'^ -coupled co-transport of ^^ Pi under normal as well 
as imder nephrotoxic conditions. ^^ Pi uptake in BBMV-SC and BBMV-JMC was 
significantly decreased in GM+V and UN+V groups as compared to control (S+V) 
group. UN+T3 and GM+T3 groups of rats were treated with T3 for 15 days prior to 
and along with UN and GM administration, respectively. As shown in Results, T3 
treatment (for 15 days prior to and along with GM and UN administration: GM+T, 
UN+T) to intoxicated rats completely reversed the decline in the ''^ Pi uptake caused 
by GM or UN intoxication in GM+V or UN+V groups, both in BBMV-SC and in 
BBMV-JMC. However, the protective effect of T3 was more prominent in BBMV-
JMC than BBMV-SC (Fig. 55, Table 51). LPD treatment for 15 days prior to and 
alongwith GM or UN treatment successfiilly prevented the damage caused by GM or 
UN on the transport of Pi both in BBMV-SC and BBMV-JMC (Fig. 56). The uptake 
values in LPD+GM and LPD+UN groups were restored to the corresponding control 
values (NPD+S) or an additional increase in the uptake was observed with respect to 
the control values. The observed protective effect of LPD was greater in BBMV-SC 
than BBMV-JMC (Table 52) However, both in T3 and LPD fed rats, the inter group 
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Fig 55; Effect of GM (10 day treatment) and UN (5 days after treatment) on 
Na'^ -dependent ^^ Pi uptake by BBMVs isolated from (A) superficial cortex and 
(B) juxtamedullary cortex of T3-treated rats. 
Each bar represents results (Mean ± SEM) of five different BBMV preparations. 
* significantly different at p<0.01 from control (V+S). 
^ significantly different at p<0.01 from V+GM. 
* significantly different at p<0.01 from V+UN. 
193 
Table 51: Effect of GM (10 day treatment) and UN (5 days after treatment) on 
Na^-dependent ^^ Pi uptake by BBMVs isolated from (A) superficial cortex 
and (B) juxtamedullary cortex of Ts-treated rats. 
(A) 
(B) 
v+s 
T+S 
V+GM 
T+GM 
V+UN 
T+UN 
V+S 
T+S 
V+GM 
T+GM 
V+UN 
T+UN 
5 sec 
109U50 
1309±55 
698±30 
1097±48 
761±35 
1115+45 
5 sec 
560+30 
840+41 
408+10 
720+31 
280+10 
540+15 
20sec 
2405+100 
2910±80*(21%)^ 
1298±50*(46%)^ 
2450+93^(87%)'' 
1684+56* (30%)^ 
2350+97^(45%)"^ 
20sec 
1285+61 
2172+70*(69%)^ 
890±35*(30%)^ 
1320+40^(33%)^ 
640±20*(50%)'' 
1241+43^(94%)^ 
120min 
310+20 
330+20 
320+15 
310+15 
316+14 
320+14 
120min 
260+10 
252+12 
265+11 
255+11 
268+10 
250+12 
Results (uptake expressed as pmole/mg protein) are Mean + SEM of five different 
BBMV preparations. 
* significantly different from control group (V+S) at p<0.05 (V+S) by group t-test. 
^ significantly different from control group (V+GM) at p<0.05 by group t-test. 
^ significantly different from control group (V+UN) at p<0.05 by group t-test. 
values in parenthesis represent percent change from control group (V+S). 
value in parenthesis represents percent increase from group V+GM. 
value in parenthesis represents percent increase from group V+UN. 
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Fig 56: Effect, of GM (10 day treatment) and UN (5 days after treatment) on 
Na^-dependent ^^ Pi uptake by BBMVs isolated from whole cortex of LPD-fed 
rats. 
Each bar represents results (Mean ± SEM) of five different BBMV preparations. 
* significantly different at p<0.01 from control (NPD+S). 
^ significantly different at p<0.01 fi-omNPD+GM. 
* significantly different at p<0,01 from NPD+UN. 
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Table 52; Effect of GM (10 day treatment) and UN (5 days after treatment) on 
Na^-dependent ^^ Pi uptake by BBMVs isolated from (A) superficial cortex 
and (B) juxtameduUary cortex of LPD-fed rats. 
(A) 
(B) 
NPD+S 
LPD+S 
NPD+GM 
LPD+GM 
NPD+UN 
LPD+UN 
NPD+S 
LPD+S 
NPD+GM 
LPD+GM 
NPD+UN 
LPD+UN 
5 sec 
980±40 
1372±41 
590±25 
1005±50 
702±20 
1100±40 
5sec 
502+40 
610+35 
311+23 
504+32 
240+28 
460+23 
20sec 
2160+81 
3350±90*(55%)^ 
1298+32* (40%)^ 
2250+80^(73%)'' 
1576+51*(27%)'* 
2370+78^(50%)*^ 
20sec 
1100+61 
1320±65*(20%)^ 
780+44*(29%)^ 
1115+55 (^43%)*^ 
485±28*(56%)^ 
950+3 8^ (96%)*^  
120sec 
320+18 
315+13 
330+15 
320+11 
332+17 
328+14 
120sec 
280+15 
285+18 
282+11 
287+11 
285+9 
278+12 
Results (uptake expressed as pmole/mg protein) are Mean + SEM of five different 
BBMV preparations. ^ 
* significantly different from control group (NPD+S) at p<0.05 by group t-test. 
^ significantly different from group NPD+GM at p<0.05 by group t-test. 
* significantly different from group NPD+UN at p<0.05 by group t-test. 
values in parenthesis represent percent change from control group (NPD+S). 
value in parenthesis represents percent increase from group NPD+GM. 
value in parenthesis represents percent increase from group NPD+UN. 
196 
differences in ^^ Pi uptake were observed only in the initial uphill phase (5 s and 20 s), 
while uptake at equilibrium (120 min.) was not changed (Table 49-52). 
To explain the effect of T3 and LPD on kinetic parameters of ^^ Pi uptake, the 
Na'^ -gradient dependent ^¥i uptake by BBMVs from WC, SC and JMC were 
examined using wide range of ''^ Pi concentrations. The graphical analysis by 
Lineweaver-Burk double reciprocal plot shows that increase in Na*-gradient 
dependent uptake of ^^ Pi by BBMV from both Ts-treated rats and LPD-fed rats 
(Fig. 57-62) were due to the increased Vmax with no change in apparent Km values. 
Moreover, the protective effect due to T3 and LPD on GM- or UN-treated rats also 
appeared to be due to alterations in Vmax rather than K^ (Table 53-56). 
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CSDmM 
Fig. 57 : Effect of T3 on kinetic parameters of Na'-gradient dependent "Pi uptake as a 
function of phosphate concentration by BBMV-WC from GM (10 day 
treatment), UN (5 day after treatment) and saline-treated control rats. 
Lines are drawn with the mean value of three separate experiments. 
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Fig. 58: Effect of LPD on kinetic parameters of Na'^ -gradient dependent ^^ Pi uptake as a 
function of phosphate concentration by BBMV-WC from GM (10 day 
treatment), UN (5 day ai^ er treatment) and saline-treated control rats. 
Lines are drawn with the mean value of three separate experiments. 
199 
.0024 
Fig. 59 : Effect of T3 on kinetic parameters of Na'-gradient dependent "Pi uptake as a 
fimction of phosphate concentration by BBMV-SC from GM (10 day treatment), 
UN (5 day after treatment) and saline-treated control rats. 
Lines are drawn with the mean value of three separate experiments. 
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Fig. 60: Effect of Tj on kinetic parameters of Na'^ -gradient dependent ^^ Pi uptake as a 
function of phosphate concentration by BBMV-JMC from GM (10 day treat-
ment), UN (5 day after treatment) and saline-treated control rats. 
Lines are drawn with the mean value of three separate experiments. 
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Fig. 6 1 : Elfect of LPD on kinetic parameters of Na'^ -gradient dependent ^ P^i uptalce as a 
fijnction of phosphate concentration by BBMV-SC from GM (10 day treatment), 
UN (5 day after treatment) and saline-treated control rats. 
Lines are drawn with the mean value of three separate experiments. 
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Fig. 62: Effect of LPD on kinetic parameters ofNa^-gradient dependent ^^ Pi uptake as a 
function of phosphate concentration by BBMV-JMC from GM (10 day 
treatment), UN (5 day after treatment) and saline-treated control rats. 
Lines are drawn with the mean value of three separate experiments. 
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Table 53; Effect of GM (10 day treatment) and UN (5 days after treatment) on the 
kinetic parameters of Na^-dependent •'^ Pi uptake by BBMVs isolated from 
whole cortex of Ts-treated rats. 
Group 
V+S 
T+S 
V+GM 
T+GM 
V+UN 
T+UN 
' m a x 
(pmol/mg protein/20 sec) 
2150.43±93 
3225.42'±150 
1498.30*±72 
2367.31 ^ ±91 
1612.50'±82 
2457.40*±94 
K,„(X1()"^ M) 
0.089±0.002 
0.088±0.004 
0.087±0.003 
0.091 ±0.003 
0.090±0.004 
0.088±0.003 
Values are Mean ± SEM of three different BBMV preparations. 
Values are calculated from Lineweaver-Burk plot (Fig 57). 
significantly different from control group (V+S) at p<0.05 or greater degree by 
group t-test. 
^ significantly different from group V+GM at p<0.05 or greater degree by group t-test. 
^ significantly different from group V+UN at p<0.05 or greater degree by group t-test. 
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Table 54; Effect of GM (10 day treatment) and UN (5 days after treatment) on the 
kinetic parameters of Na^-dependent ^^ Pi uptake by BBMVs isolated from 
whole cortex of LPD-fed rats. 
Group 
NPD+S 
LPD+S 
NPD+GM 
LPD+GM 
NPD+UN 
LPD+UN 
' m a x 
(pmol/mg protciny20 
2200.1 ±89 
3300.0*±120 
1430.3*±42 
2310.0^±92 
1650.0*±65 
2500.0*±83 
Km(X10"-*M) 
sec) 
0.088±0.002 
0.088±0.003 
0.086±0.002 
0.086±0.002 
0.086±0.003 
0.089±0.004 
Values are Mean ± SEM of three different BBMV preparations. 
Values are calculated from Lineweaver-Burk plot (Fig 58). 
significantly different from control group (NPD+S) at p<0.05 or greater degree by 
group t-test. 
•' significantly different from group NPD+GM at p<0.05 or greater degree by group t-
test. 
^ significantly different from group NPD+UN at p<0.05 or greater degree by group t-
test. 
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Table 55: Effect of GM (10 day treatment) and UN (5 days after treatment) on the 
kinetic parameters of Na"^ -dependent ^^ Pi uptake by BBMVs isolated from 
(A) superficial cortex and (B) juxtamedullary cortex of Ts-treated rats. 
(A) 
(B) 
Group 
V+S 
T+S 
V+GM 
T+GM 
V+UN 
T+UN 
Vmax 
(pmol/mg protein/20 sec) 
2440.00±101 
3000.20'±118 
1635.10*±72 
2593.02^±82 
1878.80*±82 
2615.20*±92 
Km(XlO-^ M) 
0.088±0.003 
0.086±0.005 
0.088±0.002 
0.086±0,003 
0.089±0.003 
0.085±0.003 
Group 
V+S 
T+S 
V+GM 
T+GM 
V+UN 
T+UN 
'max 
(pmol/mg proteln/20 sec) 
1300.20+42 
2041.10*±74 
975.40'±35 
1365.40^+45 
680.60*±30 
1152.50^+52 
KmCXlo'-^ 
0.083+0.004 
0.084+0.003 
0.080+0.004 
0.079+0.002 
0.084+0.004 
0.084+0.003 
Values are Mean + SEM of three different BBMV preparations. 
Values are calculated from Lineweaver-Burk plots (Fig 59 and 60). 
significantly different from control group (V+S) at p<0.05 or greater degree by 
group t-test. 
significantly different from group V+GM at p<0.05 or greater degree by group t-test. 
* significantly different from group V+UN at p<0.05 or greater degree by group t-test. 
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Table 56; Effect of GM (10 day treatment) and UN (5 days after treatment) on the 
kinetic parameters of Na^-dependent ^^ Pi uptake by BBMVs isolated from 
(A) superficial cortex and (B) juxtamedullary cortex of LPD-fed rats, 
(A) 
(B) 
Group 
NPD+S 
LPD+S 
NPD+GM 
LPD+GM 
NPD+UN 
LPD+UN 
Vmax 
(pmol/mg protein/20 sec) 
2200.0±82 
3256.0*±120 
1320.0*±52 
2394.0^±101 
1672.0*±65 
2458.0^±118 
KmCXlO '^M) 
0.104±0.004 
0.100±0.004 
0.103±0.005 
0.108±0.004 
0.098±0.002 
0.100±0.003 
Group 
NPD+S 
LPD+S 
NPD+GM 
LPD+GM 
NPD+UN 
LPD+UN 
'max 
(pmol/mg protein/20 sec) 
1205.4+45 
1386.0*±60 
964.0*±35 
1291.1^+52 
626.6*±30 
1140.0^+52 
Km(XlO-^ M) 
0.080+0.004 
0.080+0.003 
0.081+0.002 
0.083+0.003 
0.084+0.004 
0.081+0.003 
Values are Mean ± SEM of three different BBMV preparations. 
Values are calculated from Lineweaver-Burk plots (Fig 61 and 62). 
* 
significantly different from control group (NPD+S) at p<0.05 or greater degree by 
group t-test. 
^ significantly different from group NPD+GM at p<0.05 or greater degree by group 
t-test. 
* significantly different from group NPD+UN at p<0.05 or greater degree by group 
t-test. 
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Renal ischemia or toxic insult stands as a major cause of acute renal failure [46-
48,329,330]. Morphologic studies have shown that the proximal tubule particularly 
its BBM is an earliest and most prominent site of morphological damage in toxic 
injury. In other cellular and/or biochemical studies, toxic insult, especially GM-
induced, was shown to alter cellular energy metabolism mainly by decreasing the O2 
consumption besides other factors which resulted in decreased ATP level. The 
surface BBM, which is damaged due to toxic insult or ischemia, resulted in 
widespread BBM alterations affecting its structural integrity [46-48,331-334]. 
Surface polarity, membrane fluidity, marker enzyme activities are some of the 
changes induced by UN or GM eventually leading to the loss of reabsorptive renal 
functions [256,322,323,333,334]. Although renal toxic injury is reported to markedly 
reduce proximal tubule fluid, sodium, glucose and organic cation reabsorption [335-
338]. The mechanism for such reductions is not yet fully understood. The transport 
of Pi during the toxic insult has not so far been studied, which is especially required 
for the maintenance of energy yielding reactions as well as in the generation of the 
currency of energy i.e. ATP. Failure of cells to maintain ATP levels is the hallmark of 
toxic insult. 
The present studies are designed to carefully examine the effect of GM or UN on 
the transport of Pi in the isolated BBMVs. The effect of GM and UN on the transport 
properties of Pi were further characterized to understand the mechanism of the toxic 
effects. Some stimulators of Pi transport such as T3 and LPD were used to examine 
whether the effect of GM and UN on Pi transport can be ameliorated. 
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The results of the present study have indicated that GM as well as UN cause a 
marked reduction in the transport of ^^ Pi. As described in "Results", Na^-gradient 
dependent (Nao>Nai) transport of Pi was markedly reduced by both GM and UN in 
the initial uphill phase (5-20s) (Fig. 49). However, the uptake of ^^ Pi after 
equilibration for 120 min. was not affected (Table 43). The effect of GM or UN on 
''^ Pi transport was observed only when an inward Na^-gradient (Nao>Na,) was 
present, while in the absence of Na'^ -gradient (when NaCl in the incubation media 
was replaced by KCl) the uptake of ^^ Pi at 20s was even higher in GM- or UN-
treated groups of rats as compared to control rats indicating that GM and UN may 
have caused an increase in diffusional uptake capacity of BBM. Similar uptakes of 
^^ Pi at 120 min. both in the presence and absence of sodium gradient suggest an equal 
intra-vesicular volume of BBMVs isolated from control as well as GM- or UN-
treated rats. To fijrther characterize the decrease in ^ P^i transport due to GM and UN 
treatment, the uptake was determined at various ^^ Pi concentrations in the incubation 
medium. The results indicate that marked reduction in Na^-dependent ^^ Pi transport 
due to toxic insult was due to decrease in the maximum rate of transport (Vmax). 
However, alterations in the affinities were also apparent but only to a lesser degree 
than Vmax changes. These studies revealed that the effect of GM and UN on ^^ Pi 
uptake was possibly due to the change in the number of active transporters. 
As previous morphological, biochemical, histological studies and our present 
studies on BBM marker enzymes and carbohydrate metabolic enzymes showed the 
different sites of action for GM and UN along the nephron, the affect of GM and UN 
on Pi transport was also studied in BBMVs isolated from superficial cortex 
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(BBMV-SC) and deep cortex (BBMV-JMC). The GM showed maximum effect on 
^^ Pi uptake in BBMV-SC while UN showed greater effect in BBMV-JMC than in 
BBMV-SC thus confirming the different sites of action. The kinetic studies irom 
these two different subpopulations showed that the decrease in ^^ Pi uptake may be 
due to loss of active transporters as the change in affinity is insignificant. However, 
this loss appears to be more prominent in BBMV-SC than BBMV-JMC fi-om GM-
treated rats but in BBMV-JMC fi-om UN-treated rats. 
The detailed mechanism of toxic injury is not clearly understood. However, 
several lines of evidence indicate that nephrotoxins cause alterations in BBM, as 
documented by morphological studies [44,318]. It has been reported that the BBM is 
both lost into the lumen and internalized within the cell. The extent of membrane loss 
or duration of time required for regeneration is dependent upon the degree of toxic 
injury. Biochemical evidence also indicates an alteration in the BBM lipid 
composition [256,322,323]. These changes may result in the alterations of membrane 
fluidity as well as polarity as suggested by Molitoris in ischemic ARF [319], Synthesis 
and turn over of some other cell organelles may also be affected by variation in the 
lipid composition. Changes in serum as well as BBM phospholipids and cholesterol 
were observed in the present studies (Table 42). These can be regarded as 
biochemical aberrations responsible for altered structural and fianctional integrity of 
proximal tubule and/or its BBM [333]. Inadequate oxygen consumption due to 
mitochondrial damage and lack of necessary metabolite due to impaired carbohydiate 
metabolism may result in the decreased ATP levels required for active transports of 
Na"^  and other Na^-dependent transport. Reduced ATP level with decreased Na'^ -K^ 
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ATPase activity may have also caused decrease in ^^ Pi transport. Alterations in the 
intrinsic properties of transporter molecules due to toxic injury may also be one of 
the cause to reduced ^^ Pi transport as is suggested for ischemic ARP [49,50]. 
Reduced phlorizin binding was demonstrated when Na-dependent glucose transport 
was lowered by ischemia indicating reductions in the number of glucose transporters 
[50]. The present studies also addressed the question whether GM or UN 
intoxication somehow modifies the Pi transporter which may have caused decrease in 
the uptake. The properties of ^^ Pi transporter with respect to [Na^ ,*^ ] during GM and 
UN intoxication were studied. At different extra-vesicular [Nao*], the transport of 
^^ Pi increased steadily with increasing Na concentrations ([Naj,']=20 to lOOmM) in 
control as well as in GM- or UN-treated rats. However, at all sodium gradients 
studied, the uptake of''^Pi was lower in GM- or UN-treated rats compared to control 
group (Table 47). It has been suggested that sodium serves both as a driving force in 
terms of gradient (Nao^>Na,"^ for the translocation across BBM and also as a factor 
modulating the interaction of Pi with the Na"^ - Pi co-transporter in the BBM [37,339-
341], The allosteric modulatory component of Nao"*^  action likely accounts for 
sigmoidal dependence of Pi transporter on [Nao^]. A transformed Hill plot of the data 
yielded a straight line (Fig. 53) and the calculated [S]o5 varied among different 
groups. It was lowest (25.1) in GM-treated groups where Pi transporter was 
maximally affected. 
The calculated 'n' values which indicate the number(s) of Na^ interacting with 
one Pi for transporting it were 2.0, 1,66 and 1.72 for control, GM- and UN-treated 
rats respectively. It is apparent that about two sodiimi ions were interacting with one 
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Pi in control while less than two but greater than one sodium were involved in 
intoxicated groups. The data can guardedly suggest that interactions between Pi 
transporter and sodium might have modified during toxic insult. 
Many hormonal and non-hormonal factors controlling Pi homoeostasis have been 
shown to modulate the rate of BBM Na^-Pi co-transport [36-38,227,228,250]. In 
general most in vivo maneuvers stimulate PT-Pi reabsorption, so that the effect is 
retained at the level of isolated membranes. Thyroid hormone (T3) and dietary Pi 
deprivation (by feeding LPD) are most thoroughly investigated tools which stimulate 
BBM Na-Pi co-transport by Vmax effect, nevertheless by differential mechanism. 
Whether T3 and LPD modulate the "Pi transport during toxic insult especially during 
GM and UN intoxication has not been studied so far. In view of this, the preliminary 
experiments were performed to demonstrate whether the decrease in ^^ Pi transport 
due to toxic insult can be prevented by using the known stimulators (T3 and LPD) of 
Pi transport. T3 treatment or LPD feeding alone resulted in a significant increase in Pi 
transport in the uphill phase and not at equilibriimi as shown in Table 49 and 50 as 
also reported earlier [228,286]. The results show that GM or UN treatment 
significantly decreased Pi transport in NPD-fed or vehicle-treated control rats. 
However, in GM or UN intoxicated rats when T3 treatment or LPD feeding was done 
prior to and alongwith GM or UN treatment, the transport of Pi was almost equal to 
or even higher than the respective vehicle-treated or NPD-fed control rats. These 
results successfully demonstrate that T3 and LPD can prevent the GM- or UN-
induced lowering of ^^ Pi transport. It is apparent fi-om the kinetic studies that the 
decrease in ^^ Pi transport by GM or UN treatment and recovery by T3 treatment or 
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LPD feeding were largely due to alterations in Vmax while Km values were unaffected 
(Table 53 and 54). The enhanced Vmax in Ts-treated and LPD fed rats may probably 
be due to increased number of active enzyme molecules as it has been reported that 
T3 enhances Pi transport, by increasing the activity of Na'"-K^ ATPase and by 
synthesizing more transporters while LPD enhances Pi transport by increasing the 
rate of translocation of transporter due to altered BBM fluidity. 
Earlier studies have shown that T3 and LPD affect BBMV-SC and BBMV-JMC 
differently [250,328,342]. Since ^^ Pi uptake was decreased to greater extent in 
superficial cortex (pars convoluta and S2) by GM and in deep cortex (pars recta, S1) 
by UN, the effect of T3 and LPD were also studied on BBMV isolated fi"om these 
different sub-populations of proximal tubules. As shown in results, T3 enhanced the 
^^ Pi transport to greater extent in BBMV-JMC while LPD enhanced the ^^ Pi uptake 
to greater extent in BBMV-SC as also reported earlier [250,328]. GM or UN 
administration to NPD- or vehicle-treated control rats significantly decreased Pi 
transport. The effect of GM was greater in BBMV-SC while UN showed greater 
effect in BBMV-JMC as also observed in our earlier experiments. However, when 
GM or UN intoxicated rats were simultaneously treated with T3 or fed with LPD 
prior to and alongwith GM or UN treatment, the Pi transport in BBMV-SC and 
BBMV-JMC was foimd to be almost equal to or even higher than the respective 
vehicle-treated or NPD-fed control rats. The recovery in ^^ Pi transport due to T3 
treatment appeared to be greater in UN-treated rats while recovery due to LPD 
feeding was more pronounced in GM-treated rats. Thus our results successfully 
demonstrate that T3 can be more effective in ameliorating UN-induced decrease in 
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•'^ Pi uptake while LPD can effectively ameliorate GM-induced lowering of ^^ Pi 
transport. Thus T3 and LPD have differential effects on the recovery of GM- or UN-
induced injury. However the protective effects of LPD and T3 on BBM-SC as well as 
on BBMV-JMC were mainly due to Vmax effect may be by different mechanism. How 
T3 and LPD modulated the transport during toxic insult remains to be seen and a 
subject of future studies. 
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There is no better example of "better living through chemistry" than the benefits 
derived from the modem technology of the pharmaceutical industry. However, in 
relation for these spectacularly effective means of treating disease, come the 
additional risks of drug related adverse side effects. Such risks are brought into sharp 
focus by the increased frequency with which drug induced nephrotoxicity is being 
recognized. Despite the availability of increasing sophisticated investigative 
techniques, a review of contemporary scientific literature seems to suggest increasing 
controversy regarding experimental ARF. A variety of experimental models have 
been used to study ARF but with limited success. It is apparent that there is no 
consensus of fact or opinion concerning the primary mechanism responsible for the 
pathophysiologic manifestations of acute renal failure. While some of the controversy 
may be related to the lack of a single experimental model or a single pathophysiologic 
mechanism, there are additional dimensions which must be considered. Many 
investigators, regardless of model or mechanism, have neglected to consider either 
the severity of the model studied or at what time point in the course of acute renal 
failure studies were being performed. 
"Acute renal failure" is a process in which both kidneys stop their excretory 
fimctions. The major causes of ARF have been identified as either toxic insult or 
ischemia, which is manifested by oligoxiria, and increased blood urea nitrogen and 
creatinine. Classical concepts regarding the cause of the loss of renal ftmction after 
toxic injury or ischemia include: tubular leakage across the damaged epithelium, 
tubular obstruction by cast fonnation and decreased RBF and GFR [52]. It is now 
believed that the mechanism of ARF is located at the tubular level rather than at the 
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vascular level [45]. The proximal tubule along the length of the nephron is now 
unequivocally considered to be the principal site of damage caused by drug or 
ischemia induced ARF. It is believed that obstruction material originates largely from 
damaged proximal tubular epithelium. During the early phase of ARF, exfoliated 
microvillar brush border membrane (BBM) is sloughed into lumen which might be 
narrowed down by cell swelling [46]. The cast formation causes tubular obstruction 
which ultimately leads to tubular necrosis and kidney dysilinctioning [40], Both 
proximal convoluted as well as straight tubules are greatly but differentially affected 
in ARF [343]. 
Aminoglycoside antibiotics are the most frequent instigators of antibiotic-
associated acute renal failure. Two models of direct cellular injury seem to be 
prevalent, one involves intracellular accumulation of the drug followed by cytolysis 
mediated by interference- with mitochondrial energy production while the other 
involves membrane interaction leading to altered permeability and cellular 
dysfiinction and/or destruction. Gentamicin results in profound alterations in the 
morphology, structural integrity, metabolism and fimctions of the proximal tubules. 
Brush border membrane, which is the major functional site in the proximal tubule, is 
badly damaged by gentamicin exposure [44,300,333,338]. 
In GM-induced biochemical aberrations, inadequate oxygen consumption due to 
mitochondrial damage/dysfunction causes depletion of essential metabolites, severely 
depleted ATP level and altered Ca"^ homeostasis in the renal cortex 
[145,315,344,345]. Both aerobic and anaerobic cellular metabolic activities are 
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modulated which were manifested by increased glycogen and decreased TCA cycle 
[300]. As a result BBM degenerates and BBM transport functions are impaired 
[336,337,338]. The activities of some BBM marker enzymes also decrease in the 
membranes while such enzymes appear in the urine [346]. 
It is not clear whether the vulnerability of renal proximal tubules to 
aminoglycosides is a consequence of their retention by tubules or from disruption of 
specific metabolic processes intrinsic to proximal tubules, or due to a synergistic 
combination of gentamicin toxicity with other common renal injuries. Gentamicin 
inhibits the function of membrane-bound transporters and disrupts the ion gradient 
across the plasmalemma [335,338]. The fall of the ion gradient is aggravated in all 
probabilities by inhibition of the Na* pump, occurring in conjunction with impaired 
renal mitochondrial function and inhibition of protein synthesis [145,315,333]. 
Gentamicin also affects tubular lysosomes, reducing the activity of lysosomal 
enzymes to the point causing severe cellular phospholipidosis [257]. One possible 
interpretation of the diverse data is that gentamicin is an exceedingly toxic chemical 
capable of acting independently at multiple cellular sites. However, this explanation is 
not consistent with the relative tissue selectivity of gentamicin, which for the most 
part is a nephrotoxic and ototoxic compound [204]. 
UN administi-ation has been widely used as an experimental model of nephrotoxic 
ARF. In studies of these models extending over many years, the origins of renal 
injury are traced to diverse cellular and biochemical lesions, the later encompasses 
impaired mitochondrial function, decreased oxidative phosphorylation, calcium 
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dependent cell injury, impaired mitochondrial sequestration of calcium, primary 
arrangements in the cytoskeleton, dearrangement of membrane phospholipids, 
complexation of critical thiol groups present in protein and consumption of low 
molecular weight cellular thiols [46,165,170,241,331,347]. This is in contrast with 
GM which appears to primarily affect the structure and function of membrane 
phospholipids [348]. However, despite extensive study by conventional bioanalytical 
procedures, the mechanism of UN-induced renal dysfunction and biochemical 
sequelae of UN exposure remains poorly understood. 
Structural and functional tubular changes accompany the development of ARF in 
experimental animals. While the change associated with nephrotoxic models induced 
by mercuric chloride and cisplatin, have been described in detail, the change 
associated with sub-lethal cell injury induced by uranium compounds are little known. 
However, in common with other ARF models the most frequent pathological lesion 
observed in the kidney as a result of UN administration is acute necrosis [176,347]. 
Earlier studies have shown that the pathophysiologic manifestations of UN-induced 
ARF parallel with those observed in clinical ARF. In view of this to gain an insight 
into the mechanism underlying drug-induced nephrotoxicity, we have studied in 
parallel the ARF induced by known chemical nephrotoxins namely, uranyl nitrate 
(UN) and gentamicin (GM), an aminoglycoside antibiotic. The following studies were 
performed and the effect of GM or UN was determined: 
(1) On natural history of animals, ion-excretion (Pi, Ca, Mg, Na, K), glucosuria, 
proteinuria, enzymuria (GGtase, LAP, AcidPase and LDH) and serum 
parameters (creatinine, cholesterol, urea nitrogen and phospholipids). 
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(2) On the activities of marker enzymes of tubular BBM isolated from renal 
cortex and from superficial and juxtamedullary cortex. 
(3) On the activities of metabolic enzymes especially of carbohydrate metabolism 
in different kidney tissue zones eg. whole cortex/superficial and 
juxtamedullary cortex and medulla. 
(4) On the activity of lysosomal and BLM marker enzymes. 
(5) On the transport of ^^ Pi in BBMYs isolated from whole cortex, superficial 
cortex and juxtamedullary cortex. 
(6) On the transport of ^ P^i in BBMVs isolated from rats either treated with T3 or 
fed LPD prior to and alongwith GM and UN intoxication. 
1 (a) The results show that food intake and body weight remained unchanged in GM 
and UN-treated rats. However, GM as well as UN caused significant polyuria, 
proteinuria, glycosuria and enzymuria along with marked ion wasting, 
(b) GFR as estimated by creatinine clearance was significantly reduced by GM as 
well as UN. In GM-treated rats maximum GFR decline was observed after day 
10. GM and UN administration caused significant increase in the BUN, serum 
phospholipid and cholesterol while Pi was markedly decreased. 
2 (a) The activities of BBM marker enzymes: AlkPase, GGtase, Mtase and LAP in 
the BBMVs isolated from whole cortex were affected by GM and UN 
administration, however differentially. The activities were declined in a diu-ation 
dependent manner by GM treatment with maximum decline after 10 days of 
GM administration. The prolonged GM treatment showed no fiirther decline in 
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enzyme activities. UN administration also caused significant decline in the 
marker enzymes activities. However, the effect of GM and UN was different as 
GM reduced AlkPase and Mtase to a greater extent while UN showed greater 
effect on the activities of GGtase and LAP. 
(b) Since the activities of marker enzymes in the cortical homogenates were not 
different between control and GM or UN-treated rats, further analysis indicated 
that affected enzymes were disassociated from the membrane and became the 
part of supernatant. The activities were decreased in the particle bound fraction 
while increased in the supernatant in both GM or UN-intoxicated rats. 
(c) Since superficial cortex is known to be severely damaged by GM while UN 
causes greater damage to deep cortex, BBMVs were isolated from these tissues 
from control and GM/UN-treated rats. The activities of marker enzymes: 
AlkPase, GGtase, Mtase and LAP decreased both in BBMV-SC and BBMV-
JMC from GM/UN-treated rats. However, the decrease in enzyme activities 
was greater in BBMV-SC than BBMV-JMC in GM-treated rats, while UN 
administration caused greater decrease in the enzyme activities in BBMV-JMC. 
Again, membrane bound enzymes were decreased both in superficial and 
juxtamedullary cortex and appeared in the supernatant due to GM or UN 
treatment. 
(d) Kinetics studies in BBMVs from whole cortex, superficial cortex and 
juxtamedullary cortex revealed that activities were altered mainly due to Vmax 
effect as the changes in Km were not significant. 
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3 (a) The activities of the enzymes belonging to various metabolic pathways of 
glucose metabolism for eg. glycolysis, TCA cycle, HMP shunt pathway and 
gluconeogenesis were differently affected by GM or UN. The activity of LDH 
increased significantly both in cortex as well as medulla by GM or UN-
treatment. The activities of MDH, ICDH and SDH were decreased by GM or 
UN both in cortex and medulla. However, the effect of GM was more profound 
in cortex while the effect of UN was more pronounced in medullary region. The 
activities of both G6pase and FBPase (gluconeogenic enzymes) were lowered 
by both GM as well as UN-treatment in cortical and medullary homogenates. 
However, GM and UN-treatment showed differential effects on the activity of 
G6PDH and ME. The GM-treatment increased the G6PDH activity at all the 
time durations of treatment while the activity of malic enzyme was decreased. 
The pattern of the effect of GM-treatment for various time durations on the 
activities of all the above mentioned metabolic enzymes was similar, with 
maximum effect observed after 10 days of drug administration. However, UN 
administration showed the reverse effect on the activities of G6PDH and ME 
than that of GM causing decline in G6PDH activity while an increase in ME 
activity. 
(b) The activity of BLM marker enzyme Na-K ATPase was also decreased by GM 
and UN both in cortex as well as in medulla. However, GM administration 
caused greater decrease in activity compared to UN, particularly in cortex. 
(c) AcidPase, the marker enzyme of lysosomes was affected differently by GM or 
UN. While GM administration decreased the AcidPase activity both in cortex 
and medulla, UN administration significantly enhanced the activity. 
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(d) The activities of above metabolic enzymes were also studied in the homogenates 
prepared from superficial and juxtamedullary cortex after GM or UN 
administration. The pattern of the effect of GM or UN on enzyme activities was 
same as observed for cortical and medullary homogenates. However, the eftect 
of GM on enzyme activities was more pronounced in SC-H, while UN caused 
greater alterations in deep cortex/JMC. 
4 Since renal proximal tubule in general and its brush border membrane in particular 
is reported to be damaged by toxic insult, the transport properties of "Pi in 
BBMVs were determined under normal as well as under pathological conditions 
induced by GM or UN-administration, 
(a) The resuhs indicate that the transport of ''^ Pi was decreased significantly by GM 
as well as UN. Na-gradient dependent (Nao>Na,) uptake of •'^ Pi in GM- or UN-
treated group declined sharply at all time points (5s, 10s and 20s) except at 
equilibrium (120min.). Na-independent (Ko>Ki) initial uptake of ^^ Pi (at 20s) 
was found to be even higher in GM- or UN-treated rats compared to respective 
control rats. However, net Na-gradient dependent uptake of''^ Pi (Na-dependent 
minus Na-independent) was declined significantly both in GM- and UN-treated 
rats as compared to control rats. 
To localize the effect of GM and UN on the ^^ Pi transport, the BBMVs were 
isolated from superficial (BBMV-SC) and juxtamedullary (BBMV-JMC) cortex 
of saline-treated control and GM or UN-treated rats. The results showed that 
the ^^ Pi uptake was decreased both in BBMV-SC and BBMV-JMC from GM-
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treated rats, however, the decrease in ^^ Pi uptake was much greater in BBMV-
SC than BBMV-JMC. In UN-treated rats, the uptake also decreased both in 
BBMV-SC and BBMV-JMC but unlike GM treatment, the decrease was more 
prominent in BBMV-JMC than BBMV-SC. 
(b) Kinetic studies revealed that decrease in ^^ Pi transport by toxic insult (GM or 
UN administration) in BBMV-WC, BBMV-SC and BBMV-JMC was due to 
Vmax alterations as Km remained unchanged. 
(c) The Na-gradient dependent transport of ^^ Pi determined at different extra-
vesicular Na concentrations ([Nao]=20 to lOOmM) showed a sigmoidal 
relationship between the rate of ^^ Pi uptake and [Nao] in control rats. The shape 
of the curves were modified during toxic insult (GM or UN administration). 
The effect was more pronounced on V a^x values. A Hill plot transformation of 
the data yielded straight lines and calculated [S] 0.5 were 35.5, 25.1 and 31.62 
for control, GM-treated and UN-treated rats respectively. The calculated 'n ' 
values were 2.0, 1.66 and 1.72 for the above respective groups. The data 
revealed a deviation in the interaction of Na^ with Pi from 2:1 in control to less 
than 2 Na"^  for each Pi during GM or UN Intoxication. Thus it appears that 
some intrinsic properties of ^^ Pi transporters in addition to other factors may 
have altered due to GM or UN intoxication. 
(d) The effect of T3 and LPD was determined on ^^ Pi transport in control and 
GM/UN-treated rats. It appears from the results that both T3 treatment or LPD 
feeding mitigated the severity of toxic damage to ^^ Pi transport due to GM or 
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UN intoxication. Kinetic analysis revealed that recovery due to T3 treatment or 
LPD feeding was mainly due to increased Vmax as K^ remained unaltered, 
(e) The effect of T3 or LPD was also determined on ^^ Pi transport in BBMVs 
isolated from SC and JMC from control and GM or UN-treated rats. The 
results showed that GM or UN administration to NPD-fed or vehicle-treated 
control rats caused significant decline in ^^ Pi transport. While GM caused 
greater decline in •'^ Pi transport in BBMV-SC, UN produced greater decline 
BBMV-JMC. When GM or UN-intoxicated rats were treated with T.i or fed 
with LPD, prior to and alongwith GM or UN treatment, ^^ Pi transport was 
found to be recovered completely, and was almost equal to or even higher than 
that observed in the respective vehicle-treated or NPD-fed controls. However, 
T3 caused greater recovery of ^^ Pi transport in UN-treated rats while LPD 
caused a more profound recovery in GM-treated rats. The resuhs show that T3 
effectively ameliorates UN-induced effects on ^^ Pi transport while LPD is more 
effective in ameliorating GM-induced damage. 
In conclusion, the resuhs of the present study evidently show that GM or UN 
intoxication markedly damage the structural integrity and may alter metabolic and 
other functional aspects of PT. The activities of certain enzymes of carbohydrate 
metabolism were however altered differently by GM and UN in different kidney 
tissue zones. It appears that reduced Pi transport and mitochondrial dysfunction may 
cause decline in ATP levels in the renal tissue. The above factors along with reduced 
Na -K ATPase cause damage to surface membrane and its subsequent loss in the 
lumen. The marker enzyme components may either be inactivated or disassociated 
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from the membrane as the results show decline in marker enzyme activities in 
membranes with simultaneous increase in urinary enzyme activity. The membrane 
fluidity may have been also affected as a result of changed lipid composition. Finally 
the transport properties of BBMVs were altered accordingly. The GM and UN 
affected the different structural and fimctional components differentially as evidenced 
from the results. T3 treatment or LPD feeding proved beneficial in preventing the 
severity of toxic damage and in restoration of normal renal transport functions. LPD 
was foimd to be more effective in checking the severity of GM-induced damage to Pi 
transport while T3 was more effective in ameliorating UN-induced effects on Pi 
transport. 
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